UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________________________________________________________
FORM 10-K
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
________________________________________________________________________________________________________
For the fiscal year ended December 31, 2020
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______________ to ______________.
Commission File Number 001-37998
________________________________________________________________________________________________________
JOUNCE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
________________________________________________________________________________________________________
Delaware
(State or other jurisdiction of
incorporation or organization)
780 Memorial Drive
Cambridge,
Massachusetts
(Address of principal executive offices)
45-4870634
(I.R.S. Employer
Identification No.)
02139
(Zip Code)
Registrant’s telephone number, including area code: (857) 259‑3840
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common Stock, $0.001 par value per share
Trading Symbol(s)
JNCE
Name of each exchange on which registered
Nasdaq Global Select Market
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No x
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S‑T (§ 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of
“large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.
Large accelerated filer
Non‑accelerated filer
☐
☐
Accelerated filer
Smaller reporting company
Emerging growth company
☒
☒
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of
the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Act). Yes ☐ No ☒
As of June 30, 2020, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s Common Stock held by non-affiliates of the registrant
was approximately $117,863,213, based upon the closing price of the registrant’s Common Stock on June 30, 2020.
As of February 19, 2021, there were 45,393,561 shares of common stock, $0.001 par value per share, outstanding.
Portions of the registrant’s Definitive Proxy Statement on Schedule 14A relating to its 2021 Annual Meeting of Stockholders to be filed within 120 days of the end of the registrant’s fiscal year ended
December 31, 2020 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.
Documents Incorporated by Reference
Table of Contents
PART I
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
PART II
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
PART III
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
PART IV
Item 15.
Item 16.
EXHIBIT INDEX
SIGNATURES
Table of Contents
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures above Market Risk
Financial Statements and Supplementary Data
Change in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
Exhibits and Financial Statement Schedules
Form 10-K Summary
Page
4
22
52
52
52
52
53
53
54
63
63
63
63
64
65
67
67
67
68
69
69
Table of Contents
References to Jounce
Throughout this Annual Report on Form 10-K, the “Company,” “Jounce,” “Jounce Therapeutics,” “we,” “us,” and “our,” except where the context requires
otherwise, refers to Jounce Therapeutics, Inc. and its consolidated subsidiary, and “our board of directors” refers to the board of directors of Jounce
Therapeutics, Inc.
Cautionary Note Regarding Forward-Looking Statements and Industry Data
This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements other than
statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These
statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to
be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
The words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“target,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these
identifying words. These forward-looking statements include, among other things, statements about:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
the timing, progress, and results of preclinical studies and clinical trials for our current and future product candidates, including statements
regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials
will become available, and our research and development programs;
our plans and expectations in light of the COVID-19 pandemic and its impacts on our operations and global healthcare systems;
the timing, scope, or likelihood of regulatory filings and approvals, including, as applicable, timing of our investigational new drug applications
for, biologics license application filing for, and final Food and Drug Administration approval of our current and future product candidates;
our ability to use our Translational Science Platform to identify targets for future product candidates and to match immunotherapies to select
patient subsets;
our ability to identify, develop and advance future product candidates into, and successfully complete, clinical studies;
our ability to develop combination therapies, whether on our own or in collaboration with third parties, for our current and future product
candidates;
our expectations regarding the size of the patient populations for our product candidates, if approved for commercial use, and any product
candidates we may develop;
our commercialization and marketing capabilities and strategy;
the pricing and reimbursement of our current and future product candidates, if approved;
the implementation of our business model and our strategic plans for our business, our current and future product candidates, and our technology;
our ability to develop and commercialize a companion diagnostic or complementary diagnostic for our current and future product candidates;
the rate and degree of market acceptance and clinical utility of our current and future product candidates;
the potential benefits of our exclusive license of JTX-1811 to Gilead Sciences, Inc.;
our ability to establish or maintain future collaborations or strategic relationships or obtain additional funding;
our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;
our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering
our current and future product candidates, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property
rights;
our competitive position, and developments and projections relating to our competitors and our industry;
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and
1
Table of Contents
•
the impact of laws and regulations.
There are a number of important risks and uncertainties that could cause our actual results to differ materially from those indicated by forward-looking
statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue
reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the
forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K,
particularly in the section entitled “Risk Factors” in Part I, Item 1A that could cause actual results or events to differ materially from the forward-looking
statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures
or investments that we may make.
You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and
with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this
Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K, and we do not assume any obligation to update any forward-
looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
This Annual Report on Form 10-K may include industry and market data, which we may obtain from our own internal estimates and research, as well as
from industry and general publications and research, surveys, and studies conducted by third parties. Industry publications, studies, and surveys generally
state that they have been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.
While we believe that such studies and publications are reliable, we have not independently verified market and industry data from third‑party sources.
Summary of Risk Factors
Below is a summary of the principal risk factors that make an investment in our common stock speculative or risky. This summary does not address all of
the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the
heading “Risk Factors” and should be carefully considered, together with other information in this Form 10-K and our other filings with the SEC, before
making an investment decision regarding our common stock.
•
•
•
•
•
•
•
•
•
•
•
The ongoing COVID-19 pandemic has adversely affected, and may continue to adversely affect, our business, including our clinical trials, supply
chain and preclinical studies.
We are early in our development efforts. If we are unable to advance our product candidates through clinical development, advance future product
candidates to clinical development or obtain marketing approval and ultimately commercialize any product candidates, our business will be
materially harmed.
Clinical product development involves a lengthy and expensive process, with an uncertain outcome. We will incur additional costs in connection
with, and may experience delays, in completing, or ultimately be unable to complete, the development and commercialization of our product
candidates.
If we encounter difficulties enrolling or retaining patients in our clinical trials, our clinical development activities could be delayed or otherwise be
adversely affected.
Because we rely on third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development
materials may become limited or interrupted or may not be of satisfactory quantity or quality.
We rely and expect to continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their
contractual duties, comply with regulatory requirements or meet expected deadlines, our business could be substantially harmed.
We face significant competition. If our competitors develop and market products that are more effective, safer or less expensive than any of our
product candidates, our commercial opportunities will be negatively impacted.
We rely on our Translational Science Platform to identify and develop product candidates. Our competitive position could be materially harmed if
our competitors develop a platform similar to our Translational Science Platform and develop rival product candidates.
We will depend on Gilead to develop, manufacture and commercialize JTX-1811 and may depend on additional third parties for the development
and commercialization of our other product candidate programs.
We may develop companion diagnostics and/or complementary diagnostics for our product candidates. If we are unable to successfully develop
such companion diagnostics or complementary diagnostics, or experience significant delays in doing so, we may not realize the full commercial
potential of our current or future product candidates.
We have accumulated significant losses since our inception and anticipate that we will continue to incur substantial net losses in the foreseeable
future.
2
Table of Contents
•
•
•
•
•
We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to
delay, limit, reduce or terminate our product development or commercialization efforts.
If we are unable to obtain, maintain and protect our intellectual property rights for our product candidates or if our intellectual property rights are
inadequate, our competitive position could be harmed.
If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be
adversely affected.
We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we
may not be able to successfully implement our business strategy.
The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common
stock.
Website and Social Media Disclosure
From time to time, we may use our website (www.jouncetx.com), investor and media relations website (http://ir.jouncetx.com), Facebook page
(https://www.facebook.com/jouncetx), LinkedIn page (https://www.linkedin.com/company/3494537/) and Twitter feed (https://twitter.com/JounceTx) as
channels for the distribution of information. The information we post through these channels may be deemed material. Accordingly, investors should
monitor these channels, in addition to following our press releases, Securities and Exchange Commission filings and public conference calls and webcasts.
The contents of our website and social media channels are not, however, a part of this report.
3
Table of Contents
Item 1. Business
Overview
PART I
We are a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system
to attack tumors and provide long-lasting benefits to patients. Our strategy is to use a biomarker-driven approach from discovery through clinical
development. We have developed a suite of integrated technologies that comprise our Translational Science Platform, enabling us to comprehensively
interrogate the cellular and molecular composition of tumors. By focusing on specific cell types, both immune and non-immune, within tumors, we can
prioritize targets and then identify related biomarkers designed to match the right therapy to the right patient. Our pipeline is focused on product candidates
to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors, which represent significant opportunities requiring different biological
approaches. We aim to develop product candidates that address the unmet medical need of patients in both of these populations.
Our highest priority program, JTX-8064, is being developed for patients with either PD-(L)1-inhibitor resistant or PD-(L)1 inhibitor sensitive tumors. JTX-
8064 is the first tumor-associated macrophage candidate to emerge from our Translational Science Platform. JTX-8064 is an antibody that binds to
Leukocyte Immunoglobulin Like Receptor B2, or LILRB2 (also known as ILT4), which is a cell surface receptor expressed on macrophages. In January
2021, we began enrollment in the INNATE trial, our Phase 1 dose-escalation clinical trial of JTX-8064 as a monotherapy and in combination with either
our PD-1 inhibitor, JTX-4014, or pembrolizumab in patients with advanced solid tumors. Our goal is to advance this program rapidly, and, as a result,
INNATE is a proof-of-concept trial that includes indication-specific expansion cohorts.
Vopratelimab is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, or ICOS, a protein on the surface of
certain T cells commonly found in many solid tumors. We are currently enrolling patients in the SELECT trial, which is evaluating vopratelimab in
combination with JTX-4014, our anti-PD-1 antibody, compared to JTX-4014 alone in biomarker-selected, immunotherapy-naive second-line non-small cell
lung cancer, or NSCLC, patients. We identify patients for SELECT using TIS
, an 18 gene signature that includes genes relevant to both CD8 and CD4
T cell biology. TIS
has been optimized to predict for emergence of ICOS hi CD4 T cells in the peripheral blood, which have been associated with
clinical benefit in patients treated with vopratelimab alone or in combination with nivolumab. SELECT is a randomized Phase 2 clinical trial outside the
United States, and we dosed the first patient in October 2020. Due to COVID-19-related delays, we now expect to report clinical data from SELECT in
2022.
vopra
vopra
JTX-4014 is a clinical-stage anti-PD-1 antibody that we are developing primarily for potential use in combination with our product candidates, as we
believe that combination therapy has the potential to be a mainstay of cancer immunotherapy. We presented safety and preliminary efficacy data from a
Phase 1 clinical trial of JTX-4014 monotherapy in 2019. Based on the results of that clinical trial, we are using JTX-4014 in combination with
vopratelimab in SELECT, and we plan to use JTX-4014 in combination with JTX-8064 in INNATE.
JTX-1811 is the most recent product candidate to emerge from our Translational Science Platform, and in August 2020, we entered into an agreement to
exclusively license JTX-1811 to Gilead Sciences, Inc., or Gilead. JTX-1811 is a monoclonal antibody that is designed to selectively deplete T regulatory
cells in the tumor microenvironment, or TME, by targeting a receptor called CCR8, which is preferentially expressed on intra-tumoral T regulatory cells.
With our biomarker-driven approach, we leverage our Translational Science Platform to interrogate cell types within the human TME and to identify and
prioritize targets across a broad spectrum of immune and non-immune cell types. In addition, early in the development process, we use our Translational
Science Platform to identify potential predictive biomarkers to enable us to enrich our clinical trials for patient populations that may be more likely to
respond to a particular immunotherapy. Once clinical data is available for a product candidate, we then use a reverse translational approach to interrogate
tumor and blood samples from patients with known outcomes. By using these reverse translational findings, we believe we are better able to design clinical
trials and more efficiently develop cancer immunotherapies that potentially provide greater benefit to patients. We believe that the biomarker results,
coordinated to clinical response, will assist with determining the utility of proceeding to the use of a companion diagnostic and/or complementary
diagnostic for a given therapy.
Our Strategy
We aim to build a multi-product company that discovers, develops and commercializes first-in-class and/or best in class novel therapeutics and
combination approaches for patients who are less likely to respond, or who have experienced limited or no response, to currently-approved therapies. Key
elements of our strategy include:
•
Aggressively develop our product candidates, and potential future product candidates, using a biomarker-driven approach and reverse translational
analysis aimed at bringing the right immunotherapy to the right patients;
4
Table of Contents
•
•
•
Continue investment in our Translational Science Platform to enhance our understanding of the TME, as we look to broaden the benefit of
immunotherapy through targeting additional cell types;
Address the unmet need of cancer patients with tumors unresponsive to T effector cell-directed therapies by focusing our discovery efforts on
other cell types within the TME; and
Expand our pipeline by leveraging our internal discovery platform and/or in-licensing new technologies, product candidates and methodologies.
Immuno-Oncology Overview
Historically, cancer treatments have focused on either killing or arresting the proliferation of the tumor cells themselves. However, fundamental work
pioneered by one of our founders, Dr. James Allison, led to the discovery of one of the first immune cell checkpoint therapies. In 2018, Dr. Allison was
awarded the Nobel Prize in Physiology or Medicine for his work related to the discovery of cancer therapy by inhibition of negative immune regulation.
Immune checkpoint inhibitors show promise in treating various cancers, including immunotherapies that bind to the PD-1 or PD-L1 receptor on certain T
cells, and are approved in multiple cancer types and across different lines of therapy.
Even with the success of these antibodies that bind to PD-1 or PD-L1, known as PD-1 checkpoint inhibitors, there is still a significant unmet medical need
for patients who fail to respond to or respond and later relapse on these therapies. The interplay between the immune system and cancer is dynamic and as
more patients, in an expanded set of indications, are being exposed to cancer immunotherapies we are learning about the factors that may contribute to a
lack of response or a failed response. Biological approaches—beyond those focused on CD8 biology—may be needed to address the unmet medical need
of cancer patients who do respond to and relapse after receiving PD-1 checkpoint inhibitors. Reasons for resistance to immunotherapy may include a lack
of appropriate immune cells in the TME, such as the absence of T effector cells, or the presence of immunosuppressive cells, such as T regulatory cells or
tumor associated macrophages. Additionally, a tumor may initially respond to a PD-1 checkpoint inhibitor, but other immune checkpoints may emerge or
an acquired resistance to the particular immunotherapy may occur, for example through genetic alterations in key T cell signaling pathways. In these cases,
therapeutic approaches that utilize new mechanisms and target cell types other than T effector cells within the TME may restore or broaden the
applicability of cancer immunotherapies. We believe LILRB2 may function as an immune checkpoint for macrophages, and its activation, through ligand
binding, may suppress anti-tumor immune responses. We believe that by inhibiting LILRB2’s interaction with its ligands, our lead macrophage program,
JTX-8064, may have the potential to restore the activity of PD-1 checkpoint inhibitors in otherwise resistant settings. For patients who have benefited from
cancer immunotherapies, data emerging from clinical studies with PD-1 checkpoint inhibitors suggests the importance of a biomarker-driven patient-
enrichment strategy, like that used for pembrolizumab, in first-line NSCLC patients and in second line microsatellite-instability-high, or MSI-H, cancer
patient populations. Additional highlights of the evolving immunotherapy landscape include longer-lasting responses as compared to chemotherapy and
that these longer-lasting responses can be improved with combination therapy.
Our Translational Science Platform enables both the identification and prioritization of targets across a broad spectrum of immune and non-immune cell
types and the identification of potential biomarkers to inform our clinical development strategy. We believe this platform may position us to address
multiple pathways and indications, including those that may be important in colder tumors, and to identify the most appropriate indications and most
responsive patient populations for our new immunotherapies. By taking this dual approach, we believe we may be able to address areas of unmet need,
particularly in the combination setting.
The promise of long-lasting benefit to cancer patients has led to heightened enthusiasm for these types of immunotherapy products and the rapid expansion
of the market opportunity. The current market for PD-1/PD-L1 therapies is estimated to be $33 billion, and the overall market for immunotherapy is
expected to expand over the next five years, with a 2026 market size estimated to be $63 billion across solid and blood-based tumors according to market
reports.
5
Table of Contents
Our Product Pipeline
We are developing a pipeline of immunotherapies that we believe will provide a meaningful and long-lasting benefit to cancer patients. We plan to develop
each of these as a single agent and/or in combination with other therapies, as applicable. The following table depicts our current pipeline:
Development Programs
JTX-8064: An Anti-LILRB2 (ILT4) Monoclonal Antibody Designed to Reprogram Macrophages
JTX-8064 is a humanized IgG4, anti-LILRB2 monoclonal antibody designed to reprogram macrophages. Specifically, it binds to Leukocyte
Immunoglobulin Like Receptor B2 (LILRB2/ILT4) and block interactions with its ligands. We are currently assessing JTX-8064 in INNATE, a Phase 1
clinical study of JTX-8064 as a monotherapy and in combination with either JTX-4014 or pembrolizumab. We began enrolling patients in INNATE in
January 2021, and indication-specific expansion cohorts are planned in this proof-of-concept trial. INNATE will assess pharmacodynamic and potential
predictive biomarkers with the aim of informing the future clinical development of JTX-8064.
JTX-8064 is the first tumor-associated macrophage candidate developed from our Translational Science Platform. When LILRB2 binds to HLA molecules,
including HLA-G, on cancer cells and macrophages, it induces an immunosuppressive state in the macrophages. In preclinical studies, JTX-8064 inhibited
this immunosuppressive interaction, reprogramming the macrophages to a more immuno-stimulatory state. We believe therapies targeting these innate
immune cells may have the potential to benefit patients with tumors that are less likely to respond to existing T cell-focused approaches.
Vopratelimab: An Anti-ICOS Monoclonal Antibody Immunotherapy
Vopratelimab is a clinical-stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells. We believe that
vopratelimab’s mechanism of action engages CD4 T cells and enables a different element of the immune response than PD-1 checkpoint inhibitors, which
act primarily on CD8 T cells. The design of our ongoing Phase 2 SELECT clinical trial was informed by data suggesting that high expression of ICOS per
T cell is necessary for vopratelimab to drive the activation of T effector cells. SELECT aims to determine whether vopratelimab can enhance the
therapeutic benefit of PD-1 inhibitors in TIS
biomarker-selected patients.
vopra
We initiated SELECT in October 2020 to assess vopratelimab in combination with JTX-4014 compared to JTX-4014 alone. SELECT is a randomized trial
biomarker is a baseline tumor
outside the United States with TIS
RNA signature with a threshold optimized for the emergence of
biomarker-selected, immunotherapy-naive second-line NSCLC patients. The TIS
vopra
vopra
6
Table of Contents
vopra
vopra
peripheral ICOS hi CD4 T cells, a vopratelimab pharmacodynamic biomarker associated with clinical benefit and not associated with PD-1 inhibitor
through a reverse translational analysis of tumor biopsies in a subset of patients in our ICONIC Phase 1/2 clinical trial, in
therapy. We identified TIS
vopra
whom CD4 T cell populations were analyzed for ICOS levels. This indicated an association between the emergence of ICOS hi CD4 T cells and TIS
.
was applied retrospectively to clinical outcomes, it also appeared predictive of improved response rate, six- and nine-month progression free
When TIS
has the potential to identify patients who may be more responsive to
survival and overall survival. We believe selecting patients by using TIS
vopra
vopratelimab, and those who may be more responsive to JTX-4014. Although both trial arms may benefit from TIS
patient selection, the SELECT trial
is powered to demonstrate the statistical superiority of vopratelimab plus JTX-4014 compared to JTX-4014 alone. Due to delays attributable to the
COVID-19 pandemic, we now expect to report clinical data from SELECT in 2022.
vopra
We also assessed vopratelimab in two Phase 2 trials, EMERGE and ICONIC. Although neither EMERGE nor ICONIC met pre-specified criteria for
continuation of enrollment in the patient populations studied, this clinical data informed the biomarker approach we are using in SELECT. We intend to
follow the EMERGE patients still on study and complete the analysis of biomarker data. In ICONIC, all responders remained on study for more than one
year, including three responders to vopratelimab plus nivolumab who have remained on study for more than three years. These responses were
accompanied by persistence of high levels of ICOS hi CD4 T cells in the blood. Response rate, progression free survival, and overall survival were
improved in patients with on-treatment emergence of ICOS hi CD4 T cells, whom we refer to as ICOS hi, compared with those patients without the cells,
whom we refer to as ICOS lo, and with the overall study population. Furthermore, in a separate analysis of blood samples from responding and non-
responding patients who received PD-1 checkpoint inhibitor monotherapy treatment, no emergence of ICOS hi CD4 T cells was observed, suggesting that
the emergence of this cell population is attributable to activity of vopratelimab. Vopratelimab demonstrated an acceptable safety profile in these trials.
JTX-4014: An Anti-PD-1 Antibody for Combination Therapy
Combination therapy aimed at multiple targets has become an important element of immunotherapy development efforts with the goal of creating
improved, long-lasting responses. PD-1 checkpoint inhibitors are anticipated to play a key role in combination therapies. For this reason, we are developing
our own anti-PD-1 antibody, JTX-4014, primarily for use in combination with future product candidates. We believe this will give us greater flexibility to
develop our pipeline of therapies. For example, in SELECT, our goal is to evaluate the efficacy of JTX-4014 alone and in combination with vopratelimab in
a biomarker-selected patient population. Additionally, we plan to use JTX-4014 in combination with JTX-8064 in INNATE.
At the November 2019 meeting of the Society for Immunotherapy of Cancer, we reported safety and preliminary efficacy data from our Phase 1 clinical
trial of JTX-4014. JTX-4014 demonstrated an acceptable safety profile based on a 6-cohort dose-escalation trial. Response Evaluation Criteria in Solid
Tumors, or RECIST, responses were observed in three of 18 patients, including one complete response and two partial responses.
JTX-1811: An Anti-CCR8 Monoclonal Antibody Designed to Deplete Tumor T regulatory Cells
JTX-1811 is the most recent product candidate to emerge from our Translational Science Platform, and, in October 2020, we entered into an agreement to
exclusively license JTX-1811 to Gilead Sciences, Inc., or Gilead. JTX-1811 is an anti-CCR8 monoclonal antibody designed to selectively deplete intra-
tumoral T regulatory cells in the TME. T regulatory cells suppress anti-tumor immune responses, and by depleting these immunosuppressive cells, we aim
to foster more productive immune responses within the tumor microenvironment. Therapies targeting T regulatory cells may play an important role in
addressing the growing unmet need in cancer patients who do not respond to currently-approved immunotherapies and these T regulatory cell therapies
may have the potential to complement existing approaches that focus on T effector cells. We are currently conducting IND-enabling activities for JTX-
1811, with the goal of filing an investigational new drug application, or IND, in the first half of 2021. Under the terms of our agreement, we will advance
JTX-1811 until the clearance of an IND application or an earlier date specified by Gilead, at which time the program will be transitioned to Gilead.
Discovery Programs
With our focus on bringing the right immunotherapy to the right patients, we continue to invest in our Translational Science Platform as we believe that the
systematic interrogation of the immune make-up of human tumors gives us the ability to target different cell types within the TME beyond the T effector
cells that are the focus of currently-approved therapies. We can also use our Translational Science Platform and biomarker efforts to inform our clinical
strategy by identifying specific patient populations within or across different types of cancer. This may enable us to fully exploit the promise of
immunotherapy in cancer by allowing us to pursue tumor types not currently served by therapies that target the T effector arm of the adaptive immune
system, as well as potentially convert the TME from an immunosuppressive environment to an immune activating environment and tailor our approach to
both PD-(L)1-inhibitor resistant and PD-(L)1-inhibitor sensitive tumors.
7
Table of Contents
Analysis of The Cancer Genome Atlas using our proprietary gene signatures, which represent various immune cells, shows that the immune cell
composition of tumors is diverse, both across and within indications. This analysis suggests that a significant number of tumors, including cold tumors in
particular, may not benefit from the current T cell focused immunotherapies, such as PD-1 checkpoint inhibitors.
We are leveraging our Translational Science Platform to systematically and comprehensively interrogate cell types within the TME, including myeloid cells
such as macrophages, T regulatory cells and non-immune cells, such as stromal cells, with the goal of enabling us to develop therapies for patients who
have yet to benefit from immunotherapies.
License Agreements
Gilead License Agreement
On August 31, 2020, we entered into an exclusive license agreement with Gilead, or the Gilead License Agreement, granting Gilead a worldwide and
exclusive license to develop, manufacture and commercialize JTX-1811 and certain derivatives thereof, as well as backup antibodies defined within the
agreement. Concurrently with the license agreement, we entered into a stock purchase agreement with Gilead, or the Stock Purchase Agreement, and a
registration rights agreement. The agreements with Gilead were subject to review under the Hart-Scott Rodino Antitrust Improvements Act of 1976 and
other customary closing conditions, and became effective on October 16, 2020, the closing date of the transaction.
Under the terms of the Gilead License Agreement and Stock Purchase Agreement, Gilead paid us a one-time, non-refundable upfront payment of
$85.0 million and $35.0 million for an equity investment. Under the terms of our agreement, we will advance JTX-1811 until the clearance of an IND
application or an earlier date specified by Gilead, at which time the program will be transitioned to Gilead. We are entitled to receive payments from Gilead
upon the achievement of specified clinical, regulatory and sales milestones, including potential clinical development and regulatory milestone payments up
to an aggregate total of $510.0 million and potential sales milestone payments up to an aggregate total of $175.0 million. We are also eligible to receive
tiered royalty payments based on a percentage of annual worldwide net sales ranging from the high-single digits to mid-teens, based on future annual net
sales of licensed products, on a licensed product-by-licensed product and country-by-country basis.
Unless terminated earlier in accordance with its terms, the Gilead License Agreement provides that it will expire (i) on a licensed product-by-licensed
product and country-by-country basis on the date of the expiration of the royalty term with respect to such licensed product in such country and (ii) in its
entirety upon the expiration of all applicable royalty terms with respect to the licensed products in all countries, following which the applicable licenses
under the Gilead License Agreement will become fully paid-up, perpetual, irrevocable and royalty-free. Gilead may terminate the Gilead License
Agreement for convenience, in its sole discretion, in its entirety or on a product-by-product or region-by-region basis, at any time with prior written notice
to us.
Celgene License Agreement
On July 22, 2019, we entered into an exclusive license agreement with Celgene, or the Celgene License Agreement, granting Celgene a worldwide and
exclusive license to develop, manufacture and commercialize JTX-8064 and certain derivatives thereof, as well as any antibody or other biologic controlled
by us that is specifically directed to the LILRB2 receptor. Under the terms of the Celgene License Agreement, Celgene paid us a one-time, non-refundable
upfront payment of $50.0 million.
Celgene was subsequently acquired by Bristol Myers Squibb, or BMS, in November 2019. As part of its Celgene integration process, BMS streamlined its
pipeline to address areas of overlap. As a result, Celgene terminated the Celgene License Agreement effective June 3, 2020, or the Celgene License
Agreement Termination Date. As of the Celgene License Agreement Termination Date, we have sole worldwide rights to JTX-8064, and all of our
intellectual property rights pertaining to JTX-8064 were reacquired by us.
Manufacturing
We rely on and will continue to rely on our contract manufacturing organizations, or CMOs, for both drug substance and drug product. While we do not
plan to develop our own full-scale manufacturing capabilities, we may consider establishing a small, flexible approach for supporting preclinical IND-
enabling studies and early clinical trials. As of now, all of our manufacturing is outsourced to well-established third-party manufacturers. We have entered
into long-term contracts with CMOs for drug supply of JTX-8064, vopratelimab and JTX-4014.
8
Table of Contents
Competition
The biotechnology and pharmaceutical industries, and the immunotherapy subsector, are characterized by rapid evolution of technologies, fierce
competition and strong defense of intellectual property. While we believe that our product candidates, discovery programs, technology, knowledge,
experience, and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology
companies, academic institutions, governmental agencies and public and private research institutions, among others.
Any product candidates that we successfully develop and commercialize will compete with currently-approved therapies and new therapies that may
become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety
and convenience of our products and the ease of use and effectiveness of any companion diagnostics and/or complementary diagnostics. Potentially
competitive therapies fall primarily into the following groups of treatment:
•
•
•
•
•
•
•
•
traditional cancer therapies, including chemotherapy and targeted therapies;
a clinical-stage anti-ILT4 (LILRB2) antibody program, MK-4830, in clinical trials being developed by Merck & Co., Inc., or Merck;
three clinical-stage anti-ICOS agonist antibody programs in clinical trials, being developed by BMS, GlaxoSmithKline plc and Kymab Group
Ltd.;
a bispecific anti-ICOS and anti-PD-1 antibody program in clinical development being developed by Xencor, Inc.;
approved immunotherapy antibodies, including an approved anti-CTLA 4 antibody (Yervoy , marketed by BMS) and approved anti-PD-1/anti-
PD-L1 antibodies (Bavencio , Keytruda , Libtayo , Opdivo , Tecentriq , and Imfinzi , marketed by Merck KGaA and Pfizer, Inc., Merck,
Regeneron Pharmaceuticals, Inc., BMS, Genentech, Inc. and AstraZeneca PLC, respectively);
®
®
®
®
®
®
®
anti-PD-1/anti-PD-L1 immunotherapy antibodies in clinical development;
other agonist immunotherapy antibodies in clinical development; and
antibody-drug conjugates and therapies targeting T regulatory cells and B cells, macrophages and other immune cell types that are in clinical
development.
The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our
products. In addition, our competitors may obtain Food and Drug Administration, or FDA, or other regulatory approval for their products more rapidly than
we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.
Many of the companies against which we may compete, either alone or with their strategic partners, have significantly greater financial resources and
expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved
products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing
clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
Intellectual Property
Our intellectual property is critical to our business and we strive to protect it, including by obtaining and maintaining patent protection in the United States
and internationally for our product candidates, novel biological discoveries, including new targets and applications, and other inventions that are important
to our business. For our product candidates, generally we intend to first pursue patent protection covering both compositions of matter and methods of use.
As we continue the development of our product candidates, we intend to identify additional means of obtaining patent protection that would potentially
enhance commercial success, including through additional methods of use and biomarker and companion diagnostic and/or complementary diagnostic
related claims.
The patent positions of biotechnology companies like ours are generally uncertain and involve complex legal, scientific and factual questions. In addition,
the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance.
Consequently, we may not obtain or maintain adequate patent protection for any of our product candidates. As of February 19, 2021, with respect to JTX-
8064 patent rights, we own one pending U.S. non-provisional application, twenty-one pending foreign patents and patent applications within one patent
family that covers compositions of matter and methods of use, and we own one issued U.S. patent that covers methods of use. As of February 19, 2021,
with respect to vopratelimab patent rights, we own three pending U.S. provisional patent applications, five pending U.S. non-provisional applications,
twenty-seven pending foreign patents and patent applications, and five pending
9
Table of Contents
Patent Cooperation Treaty, or PCT, patent applications within ten patent families that cover compositions of matter and methods of use and ICOS-related
biomarkers, and we own two issued U.S. patents and five issued foreign patents that cover compositions of matter and methods of use. As of February 19,
2021, with respect to JTX-4014 patent rights, we own one pending U.S. non-provisional application, seventeen pending foreign patent applications, and
one pending PCT application within two patent families that cover compositions of matter and methods of use, and we own one issued U.S. patent and one
issued foreign patent that covers compositions of matter and methods of use.
We cannot predict whether the patent applications we pursue will issue as patents in any particular jurisdiction or whether the claims of any issued patents
will provide any proprietary protection from competitors. Even if our pending patent applications are granted as issued patents, those patents, as well as any
patents we license from third parties, may be challenged, circumvented or invalidated by third parties.
In addition, we exclusively in-licensed a patent portfolio from Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center and
Memorial Hospital for Cancer, or MSK, and University of Texas MD Anderson Cancer Center, or MD Anderson, consisting of four issued U.S. patents,
one issued Australian patent, one issued Japanese patent, one issued Canadian patent, two issued Chinese patents, one issued European patent that has been
validated in thirteen European jurisdictions, one pending U.S. patent application, and two pending foreign patent applications. This licensed patent
portfolio covers methods related to the use of an ICOS agonist in combination with blocking agents of certain T cell inhibitory receptors. The issued
patents and the pending patent applications (if issued) licensed from MSK and MD Anderson, if the appropriate maintenance, renewal, annuity or other
governmental fees are paid, are expected to expire in 2030, excluding any additional term for patent term adjustments or patent term extensions.
The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file,
the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, the patent term that covers an FDA-
approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the
FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. The length
of the patent term extension is related to the length of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a
patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions
are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products
receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of
our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the
United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.
We also rely on unpatented know-how, inventions and other proprietary information relating to JTX-8064, vopratelimab, JTX-4014, JTX-1811, our future
product candidates and our Translational Science Platform. We seek to protect and maintain the confidentiality of proprietary information to protect aspects
of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary
information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop
substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not
be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored
researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These
agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the
course of the individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements
with employees also provide that all inventions conceived by the employee in the course of employment with us or from the employee’s use of our
confidential information are our exclusive property. However, such confidentiality agreements and invention assignment agreements can be breached, and
we may not have adequate remedies for any such breach. For a more comprehensive discussion of the risks related to our intellectual property, please see
“Risk Factors—Risks Related to Intellectual Property.”
Exclusive License Agreement with Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, and Memorial Hospital
for Cancer and Allied Diseases
In September 2015, we amended and restated an exclusive license agreement from December 2013 with MSK. Pursuant to this amended and restated
license agreement, MSK and MD Anderson granted to us a worldwide exclusive license under certain patents to manufacture, develop and commercialize
certain products and services, including those products for which the use in combination with another product for the treatment of any disease is covered by
such patents (including, potentially, vopratelimab), and to practice certain methods covered by the patents. Under the license agreement, we are obligated to
use
10
Table of Contents
commercially reasonable efforts to commercialize at least one licensed product or licensed service as defined in the license agreement.
In connection with the license agreement, we issued to MSK and MD Anderson an aggregate of 60,974 shares of our common stock. We also paid an
upfront license fee of $30,000 to MSK and MD Anderson. Commencing on the third anniversary of the effective date of the license agreement, we must
pay an annual maintenance fee ranging in the mid-four figures to the mid-five figures. The annual maintenance fee is fully credited against the royalty
payments for the same year or any subsequent year or any other amount due under the license agreement. We are obligated to pay MSK milestone
payments of up to $3,475,000 for the first and second licensed products to achieve certain development and marketing approval milestones, including up to
$2,725,000 for the first licensed product to achieve such developmental and marketing approval milestones. On a country-by-country basis and licensed
product-by-licensed product or licensed service-by-licensed service basis, we are also obligated to pay MSK a low single-digit percentage royalty on net
sales of licensed products or licensed services, to the extent used in combination with another product for the treatment of any disease covered by the
applicable patents, until the earlier of the expiration of the last valid patent claim covering such licensed product or licensed service in such country or
twelve years after the first commercial sale of such licensed product or licensed service in such country. If we sublicense our rights under our license
agreement with MSK, we would be obligated to pay MSK a low double-digit percentage royalty of the total gross proceeds we receive in consideration of
the grant of the sublicense, excluding royalties, research and development funding, payments for equity or debt securities and certain other expenses we
have incurred that are reimbursed by the sublicensee.
Unless terminated earlier, the license agreement expires on the date that we no longer have any royalty payment obligations under the license agreement.
We may terminate the license agreement for convenience in its entirety upon 30 days’ prior written notice to MSK and MD Anderson. Either party may
terminate the license agreement in its entirety in the event of an uncured material breach or the bankruptcy, insolvency, dissolution or winding up of the
other party which is not dismissed or cured within a set period of time. If we terminate the license agreement because of MSK’s and MD Anderson’s
uncured breach or insolvency, we will retain a non-exclusive, perpetual, irrevocable, fully paid-up, royalty-free worldwide license to the licensed patents.
Upon expiration of our obligation to pay royalties for a licensed product or service in a country, our license to the licensed patents for such licensed product
or service will become exclusive, perpetual, irrevocable, fully paid-up and royalty-free in such country.
Government Regulation
Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research,
development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, sales, pricing,
reimbursement, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products, such as JTX-8064,
vopratelimab, JTX-4014, JTX-1811 and future product candidates. Generally, before a new drug or biologic can be marketed, considerable data
demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and
approved by the regulatory authority.
U.S. Drug Development
In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations and regulates
biologics under the FDCA, the Public Health Service Act, or PHSA, and their implementing regulations. Both drugs and biologics also are subject to other
federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal,
state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. The failure to comply with the
applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to
administrative or judicial sanctions. These sanctions could include, among other actions, the FDA’s refusal to approve pending applications, withdrawal of
an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or
distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial
enforcement action could have a material adverse effect on us.
JTX-8064, vopratelimab, JTX-4014, JTX-1811 and future product candidates must be approved by the FDA through either a New Drug Application, or
NDA, or Biologics License Application, or BLA, process before they may be legally marketed in the United States. We expect JTX-8064, vopratelimab,
JTX-4014, JTX-1811 and future product candidates to be regulated by the FDA as biologics and require the submission of a BLA prior be being marketed
in the United States. The process generally involves the following:
•
completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good
laboratory practice, or GLP, requirements;
11
Table of Contents
•
•
•
•
•
•
•
•
•
submission to the FDA of an IND application, which must become effective before human clinical trials may begin;
approval by an independent institutional review board, or IRB, or ethics committee at each clinical trial site before each trial may be initiated;
performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice, or GCP,
requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed
indication;
submission to the FDA of an NDA or BLA;
determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the filing for review;
satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug or biologic will be produced
to assess compliance with current good manufacturing practices, or cGMP, requirements to assure that the facilities, methods and controls are
adequate to preserve the drug or biologic’s identity, strength, quality and purity;
potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA or BLA;
FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee, prior to any commercial
marketing or sale of the drug or biologic in the United States; and
compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or
REMS, and the potential requirement to conduct post-approval studies.
Preclinical Studies and IND
The preclinical developmental stage generally involves laboratory evaluations of product chemistry, formulation and stability, as well as in vitro and animal
studies to evaluate toxicity, assess the potential for adverse events and, in some cases, establish a rationale for therapeutic use. The conduct of preclinical
studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results
of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among
other things, to the FDA as part of an IND. An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in
interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans.
Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An
IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more
proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the
clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.
Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. Clinical holds are
imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments in clinical, non-clinical,
and/or chemistry, manufacturing, and controls. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to
suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a
specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. Following issuance of a clinical hold or partial clinical
hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on
information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.
Clinical Trials
The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of
qualified investigators in accordance with GCP requirements, including the requirement that all research subjects provide their informed consent. Clinical
trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion
criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be
submitted to the FDA as part of the IND. Furthermore, an IRB for each institution at which the clinical trial will be conducted must review and approve the
protocol before a clinical trial commences at such institution, approve the information regarding the trial and the consent form that must be provided to
each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Additionally, some trials are overseen by an
independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides
authorization as to whether or
12
Table of Contents
not a trial may move forward at designated check points based on available data from the study. There also are requirements governing the reporting of
ongoing clinical trials and completed clinical trial results to public registries.
Clinical trials generally are conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, which may overlap.
•
•
•
Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose
and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action,
side effect tolerability and safety of the drug.
Phase 2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time,
safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a
preliminary evaluation of efficacy is conducted.
Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate
the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide
an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments. The duration of
treatment is often extended to mimic the actual use of a product during marketing.
Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain
additional experience from the treatment of patients in the intended therapeutic indication.
Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted
to the FDA and the investigators for serious and unexpected suspected adverse events, findings from animal or in vitro testing or other studies that suggest
a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol
or investigator brochure.
Clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at
any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB
can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or
if the drug or biologic has been associated with unexpected serious harm to patients. Results from one trial are not necessarily predictive of results from
later trials. Concurrent with clinical trials, companies usually complete additional animal studies and must develop additional information about the
chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in
accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among
other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging
must be selected and tested, and stability studies must be conducted to demonstrate that JTX-8064, vopratelimab, JTX-4014, JTX-1811 and future product
candidates do not undergo unacceptable deterioration over their shelf life.
Information about clinical trials must be submitted within specific time frames to the National Institutes of Health, or NIH, for public dissemination on its
ClinicalTrials.gov website. Similar requirements for posting clinical trial information are present in the European Union (EudraCT) website:
https://eudract.ema.europa.eu/ and other countries, as well.
Expanded Access to an Investigational Drug for Treatment Use
Expanded access, sometimes called “compassionate use,” is the use of investigational new drug products outside of clinical trials to treat patients with
serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and
regulations related to expanded access are intended to improve access to investigational drugs for patients who may benefit from investigational therapies.
FDA regulations allow access to investigational drugs under an IND by the company or the treating physician for treatment purposes on a case-by-case
basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient
populations; and larger populations for use of the drug under a treatment protocol or Treatment IND Application.
On December 13, 2016, the 21st Century Cures Act established (and the 2017 Food and Drug Administration Reauthorization Act later amended) a
requirement that sponsors of one or more investigational drugs for the treatment of a serious disease(s) or condition(s) make publicly available their policy
for evaluating and responding to requests for expanded access for individual patients. Although these requirements were rolled out over time, they have
now come into full effect. This provision requires drug and biologic companies to make publicly available their policies for expanded access for individual
patient access to products intended for serious diseases. Sponsors are required to make such policies publicly available upon the earlier of initiation of a
Phase 2 or Phase 3 study; or 15 days after the drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine
advanced therapy.
13
Table of Contents
In addition, on May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to
access certain investigational new drug products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under
certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA
expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to
Try Act, but the manufacturer must develop an internal policy and respond to patient requests according to that policy.
NDA/BLA and FDA Review Process
The results of preclinical studies and clinical trials, together with other detailed information, including proposed labeling, chemistry and manufacturing
information, are submitted to the FDA as part of an NDA or BLA. The NDA or BLA is a request for approval to market the drug or biologic for one or
more specified indications and must contain proof of safety and efficacy for a drug or safety, purity and potency for a biologic. The FDA must approve the
NDA or BLA before a drug or biologic may be marketed in the United States.
Under the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA or BLA must be accompanied by a user fee. Under federal law, the
submission of most applications is subject to an application user fee, which for federal fiscal year 2021 is $2,875,842 for an application requiring clinical
data. The sponsor of an approved application is also subject to an annual program fee, which for fiscal year 2021 is $336,432. These fees may be increased
or decreased annually, and fee waivers, reductions or deferrals are available in certain circumstances.
The FDA reviews each NDA and BLA for administrative completeness and reviewability within 60 days following receipt by the FDA of the NDA or
BLA. If the submission is found to be complete, the FDA will file the NDA or BLA, triggering a full review. The FDA may refuse to file any NDA or BLA
that it deems incomplete or not properly reviewable at the time of submission. The established goal of the FDA is to review applications within ten months
of the filing date for a new molecular-entity NDA or original BLA and within six months from the filing date for a new molecular-entity NDA or original
BLA designated for priority review. The FDA does not always meet its goal dates for standard and priority NDAs or BLAs, and the review process is often
extended by FDA requests for additional information or clarification.
Before approving an NDA or BLA, the FDA may inspect the manufacturing facilities for the new product and will not approve the product unless the
facilities comply with cGMP requirements. The FDA may refer applications for novel drug products or drug products which present difficult questions of
safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to
whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it
considers such recommendations when making decisions on approval. Additionally, the FDA may audit data from clinical trials to ensure compliance with
GCP requirements and likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during
the review process. After the FDA evaluates an NDA or BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes
commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter describes additional work
that must be done before the application can be approved, such as requiring additional clinical data, additional pivotal Phase 3 clinical trial(s) and/or other
significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Even if such data and information are
submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive
and the FDA may interpret data differently than we interpret the same data.
Orphan Drug Designation
Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is
generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and
for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or
condition will be recovered from sales of the product.
Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the
therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the
duration of the regulatory review and approval process. These circumstances are where another product shows clinical superiority to the product with
orphan drug exclusivity because it is shown to be safer, more effective or makes a major contribution to patient care. This is the case despite an earlier court
opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan exclusivity regardless of a showing of clinical superiority.
14
Table of Contents
If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the
product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same
indication for seven years from the date of such approval, except in limited circumstances.
Competitors may also receive approval of either a different product for the same indication or the same product for a different indication but that could be
used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products if a competitor obtains approval
before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if one of our products is determined to be
contained within the scope of the competitor’s product for the same indication or disease. If one of our products designated as an orphan drug receives
marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the
European Union has similar, but not identical, requirements and benefits.
Expedited Development and Review Programs
The FDA has various programs, including a fast track program, priority review and accelerated approval, that are intended to expedite or facilitate the
process for reviewing new drugs and biologics that, generally, are intended to treat a serious or life-threatening condition, demonstrate the potential to
address unmet medical needs and that offer meaningful benefits over existing treatments. The fast track program is designed to facilitate the development
and review of drugs to treat serious or life-threatening diseases or conditions and fulfill unmet needs. Priority review is designed to give drugs that offer
major advances in treatment or provide treatment where no adequate therapy exists. The FDA will attempt to direct additional resources to the evaluation of
an application for a new drug or biologic designated for priority review in an effort to facilitate the review.
A candidate product may also be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful
advantage over available therapies. In addition, the investigational product must demonstrate an effect on a surrogate endpoint that is reasonably likely to
predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, which is reasonably likely to
predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving
accelerated approval perform adequate and well-controlled post-marketing clinical trials.
Additionally, a drug or biologic may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or
more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate
substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy
designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program.
Fast track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may
expedite the development or approval process.
Pediatric Information
Under the Pediatric Research Equity Act, an NDA or BLA or supplement to an NDA or BLA must contain data to assess the safety and efficacy of the drug
for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the
product is safe and effective. The assessment must also support dosing and administration for each pediatric subpopulation for which the product is safe
and effective. The Food and Drug Administration Safety and Innovation Act, or FDASIA, requires the submission of a pediatric study plan prior to the
assessment of data, which must contain proposed pediatric study, including study design and objectives, any deferral or waiver requests, and any other
information required by regulation. The FDA may grant deferrals for submission of pediatric data until after the approval of the drug for use in adults or
full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extensions
of deferrals are contained in FDASIA.
Post-marketing Requirements
Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other
things, monitoring and record-keeping activities, reporting of adverse experiences, complying with promotion and advertising requirements, which include
restrictions on promoting drugs for unapproved uses or patient populations (known as “off-label use”) and limitations on industry-sponsored scientific and
educational activities.
The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. The FDA and other agencies actively
enforce the laws and regulations prohibiting the promotion of off label uses, and a company that is found to have improperly promoted off label uses may
be subject to significant liability. If a company is found to have promoted off-label uses, it may become subject to adverse public relations and
administrative and judicial enforcement by the
15
Table of Contents
FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities.
The FDA may also place other conditions on approvals, including imposing limitations on the uses for which the product may be marketed, requiring that
warning statements be included in the product labeling, requiring that additional studies be conducted following approval as a condition of the approval,
imposing restrictions and conditions on product distribution, prescribing or dispensing in the form of a REMS or otherwise limiting the scope of any
approval. Product approvals may be withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.
FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP regulations. We rely, and expect to
continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These
manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and
documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and
distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies. The discovery of violative
conditions, including failure to conform to cGMP regulations, could result in enforcement actions, and the discovery of problems with a product after
approval may result in restrictions on a product, manufacturer or holder of an approved NDA or BLA, including recall.
Companion Diagnostics and Complementary Diagnostics
We believe that the success of our product candidates may depend, in part, on the development and commercialization of either a companion diagnostic or
complementary diagnostic. Companion diagnostics and complementary diagnostics can identify patients who are most likely to benefit from a particular
therapeutic product, identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product, or
monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness.
Companion diagnostics and complementary diagnostics are regulated as medical devices by the FDA and, as such, require either clearance or approval
prior to commercialization. The level of risk combined with available controls to mitigate risk determines whether a companion diagnostic device requires
Premarket Approval Application approval or is cleared through the 510(k) premarket notification process. Under FDA guidance, for a novel therapeutic
product for which a companion diagnostic device is essential for the safe and effective use of the product, the companion diagnostic device should be
developed and approved or 510(k)-cleared contemporaneously with the therapeutic. The use of the companion diagnostic device will be stipulated in the
labeling of the therapeutic product. This is also true for a complementary diagnostic, although it is not a prerequisite for receiving the therapeutic.
If safe and effective use of a therapeutic depends on an in vitro diagnostic, then the FDA generally will require approval or clearance of that diagnostic,
known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance
clarifying the requirements that will apply to approval of therapeutic products and in vitro companion diagnostics. According to the guidance, if FDA
determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, FDA generally will not
approve the therapeutic product or new therapeutic product indication if the companion diagnostic device is not approved or cleared for that indication.
Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance
characteristics in the intended population. The review of in vitro companion diagnostics in conjunction with the review of our therapeutic treatments for
cancer will, therefore, likely involve coordination of review by the FDA’s Center for Drug Evaluation and Research and the FDA’s Center for Devices and
Radiological Health Office of In Vitro Diagnostics Device Evaluation and Safety.
Other Regulatory Matters
Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the
United States in addition to the FDA, including the Centers for Medicare & Medicaid Services, other divisions of the Department of Health and Human
Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the
Occupational Safety & Health Administration, the Environmental Protection Agency and state and local governments.
For example, in the United States, sales, marketing and scientific and educational programs also must comply with state and federal fraud and abuse laws.
These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting
on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the
purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as
Medicare or Medicaid.
16
Table of Contents
Although we would not submit claims directly to payors, manufacturers also can be held liable under the federal False Claims Act, which prohibits anyone
from knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services,
including drugs or biologics, that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or
services. In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to
calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, and the sale and
marketing of our products, are subject to scrutiny under this law.
Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent
requirements in the Affordable Care Act. The distribution of pharmaceutical products is subject to additional requirements and regulations, including
extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.
The failure to comply with any of these laws or regulatory requirements subjects us to possible legal or regulatory action. Depending on the circumstances,
failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, requests for recall, seizure of
products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts,
including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur
significant legal expenses and divert our management’s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of
future products marketed by us could materially affect our business in an adverse way.
Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to
our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional
record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.
U.S. Patent Term Restoration and Non-Patent Exclusivity
Depending upon the timing, duration and specifics of FDA approval of JTX-8064, vopratelimab, JTX-4014, JTX-1811 and future product candidates, some
of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984,
commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit restoration of the patent term of up to five years as
compensation for patent term lost during product development and FDA regulatory review process. Patent term restoration, however, cannot extend the
remaining term of a patent beyond a total of 14 years from the product’s approval date. The United States Patent and Trademark Office, or USPTO, in
consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of
patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical
trials and other factors involved in the filing of the relevant NDA or BLA.
Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year
period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity; a drug is a
new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion
responsible for the action of the drug substance.
An abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product
was created by the Biologics Price Competition and Innovation Act of 2009, or BPCI Act, as part of the Affordable Care Act. Biosimilarity, which requires
that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be
no clinically meaningful differences between the product and the reference product in terms of safety, purity and potency, can be shown through analytical
studies, animal studies and a clinical trial or trials. Complexities associated with the larger, and often more complex, structure of biological products as
compared to small molecule drugs, as well as the processes by which such products are manufactured, pose significant hurdles to implementation that are
still being worked out by the FDA.
A reference biological product is granted twelve years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an
application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the
reference product. “First licensure” typically means the initial date the particular product at issue was licensed in the United States. It is necessary to
determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or
potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity and, for subsequent applications,
such determinations are made a case-by-case basis with data submitted by the sponsor. As of December 17, 2020, the FDA has approved 29 biosimilar
products for use in the United States. No interchangeable biosimilars have been approved.
17
Table of Contents
Pediatric Exclusivity
Pediatric exclusivity is another type of regulatory exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing regulatory
exclusivity periods or patent protection. This six-month exclusivity may be granted based on the voluntary completion of a pediatric trial in accordance
with an FDA-issued “Written Request” for such a trial. Furthermore, a biological product seeking licensure as biosimilar to or interchangeable with a
reference product indicated for a rare disease or condition and granted seven years of orphan drug exclusivity may not be licensed by the FDA for the
protected orphan indication until after the expiration of the seven-year orphan drug exclusivity period or the 12-year reference product exclusivity,
whichever is later.
Foreign Regulation
As in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our future
products and medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained.
Certain countries outside of the United States have a process that requires the submission of a clinical trial application, or CTA, much like the IND prior to
the commencement of human clinical studies. In the European Union, for example, a CTA must be submitted for each clinical trial to the national health
authority and an independent ethics committee in each country in which the company intends to conduct clinical trials. Once the CTA is approved in
accordance with a country’s requirements, the clinical trial may proceed. In all cases, the clinical trials must be conducted in accordance with GCPs and
other applicable regulatory requirements and ethical principles.
In April 2014, the European Union adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive
2001/20/EC. The new legislation aims at simplifying and streamlining the approval of clinical trials in the European Union. Under the new coordinated
procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one EU Member State will only be required to
submit a single application for approval of a clinical trial to a reporting EU Member State. The Clinical Trials Regulation also aims to streamline and
simplify the rules on safety reporting for clinical trials. As of January 20, 2021, the website of the European Medicines Agency reported that the new
Clinical Trials Regulation will be implemented when the clinical trials portal and database goes live, which is expected to be in December 2021.
To obtain regulatory approval of an investigational product under European Union regulatory systems, we must submit a marketing authorization
application under either a centralized or decentralized procedure. The centralized procedure is compulsory for medicinal products produced by
biotechnology. The application used to file the BLA in the United States is similar to that required in the European Union, with the exception of, among
other things, region-specific document requirements.
The European Union also provides opportunities for market exclusivity. For example, upon receiving marketing authorization, innovative medicinal
products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If grated, data exclusivity prevents regulatory
authorities in the European Union from referencing the innovator’s data to assess a generic or biosimilar application. There is no guarantee that a product
will be considered by the European Union’s regulatory authorities to be an innovative medicinal product, and products may not qualify for data exclusivity.
Products receiving orphan designation in the European Union can receive ten years of market exclusivity, during which time no similar medicinal product
for the same indication may be placed on the market. An orphan product can also obtain an additional two years of market exclusivity in the European
Union for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.
If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of
regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.
Brexit and the Regulatory Framework in the United Kingdom
The United Kingdom left the European Union on January 31, 2020, which is commonly referred to as Brexit, and in December 2020, the United Kingdom
and the European Union agreed on a trade and cooperation agreement, under which the United Kingdom and the European Union will now form two
separate markets governed by two distinct regulatory and legal regimes.
Because the regulatory framework for pharmaceutical products in the United Kingdom covering quality, safety, and efficacy of pharmaceutical products,
clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from European Union directives and
regulations, Brexit could materially impact the future regulatory regime that applies to products and the approval of product candidates in the United
Kingdom, as the U.K. legislation now has the potential
18
Table of Contents
to diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for medicinal products and devices in the United
Kingdom in the long-term. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to
restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our
business.
General Data Protection Regulation
The collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to
the EU General Data Protection Regulation, or GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes
numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining
consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing
safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging
third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the U.S., and permits data
protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to €20 million or 4% of annual global revenues,
whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory
authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a
rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full
compliance.
Reimbursement
Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs,
commercial insurance and managed healthcare organizations. In the United States, no uniform policy of coverage and reimbursement for drug or biological
products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made
on a payor-by-payor basis. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide
scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be
obtained.
The United States government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to
limit the growth of government-paid health care costs, including price-controls, restrictions on reimbursement and requirements for substitution of generic
products for branded prescription drugs. If we obtain approval in the future to market any our product candidates, we may seek approval and coverage for
those products under Medicaid, Medicare and the Public Health Service pharmaceutical pricing program and may seek approval to sell the products to
federal agencies. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and
measures, could limit payments for pharmaceutical drugs.
Medicaid is a joint federal and state program that is administered by the states for low income and disabled beneficiaries. The Medicaid Drug Rebate
Program requires pharmaceutical manufacturers to pay a rebate for each product reimbursed by the state Medicaid programs. The amount of the rebate for
each product is set by law and may be subject to an additional discount if certain pricing increases more than inflation.
Medicare is a federal program that is administered by the federal government. The program covers individuals age 65 and over as well as those with certain
disabilities. Medicare Part D provides coverage to enrolled Medicare patients for self-administered drugs (i.e., drugs that are not administered by a
physician). Medicare Part D is administered by private prescription drug plans approved by the U.S. government and each drug plan establishes its own
Medicare Part D formulary for prescription drug coverage and pricing, which the drug plan may modify from time to time.
Medicare Part B covers most injectable drugs given in an in-patient setting, and some drugs administered by a licensed medical provider in hospital
outpatient departments and doctors’ offices. Medicare Part B is administered by Medicare Administrative Contractors, which generally have the
responsibility of making coverage decision. Subject to certain payment adjustments and limits, Medicare generally pays for Part B covered drugs based on
a percentage of a manufacturer-reported average sales price.
As noted above, the marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-
party payors fail to provide adequate coverage and reimbursement. An increasing emphasis on cost containment measures in the United States has
increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may
change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval,
less favorable coverage policies and reimbursement rates may be implemented in the future.
19
Table of Contents
In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing
drug pricing and reimbursement vary widely from country to country. There can be no assurance that any country that has price controls or reimbursement
limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products
launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.
Healthcare Reform
A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last
few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical
products, government control and other changes to the healthcare system in the United States. By way of example, the United States and state governments
continue to propose and pass legislation designed to reduce the cost of healthcare. In March 2010, the United States Congress enacted the Affordable Care
Act, or ACA, which, among other things, includes changes to the coverage and payment for products under government health care programs.
Since enactment of the ACA, there have been numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For
example, with enactment of the Tax Cuts and Jobs Act of 2017, Congress repealed the “individual mandate.” The repeal of this provision, which requires
most Americans to carry a minimal level of health insurance, became effective in 2019.
In addition, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an
essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Cuts and Jobs Act, the remaining
provisions of the ACA are invalid as well. On December 18, 2019, the Court of Appeals for the Fifth Circuit court affirmed the lower court’s ruling that the
individual mandate portion of the ACA is unconstitutional, and it remanded the case to the district court for reconsideration of the severability question and
additional analysis of the provisions of the ACA. The U.S. Supreme Court agreed to hear this case. Oral argument in the case took place on November 10,
2020. On February 10, 2021, the Biden Administration withdrew the Department of Justice’s support for this lawsuit. A ruling by the Court is expected
sometime this year. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.
Further, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among
other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs
under Medicare and reform government program reimbursement methodologies for drug products. At the state level, individual states are increasingly
aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing.
Human Capital
As of December 31, 2020, we had 128 full-time employees. Of these full-time employees, 39 have Ph.D. or M.D. degrees and 98 are engaged in research
and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our
relationship with our employees to be good.
Corporate Information
Our principal offices are located at 780 Memorial Drive, Cambridge, MA 02139, and our telephone number is (857) 259-3840.
We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company until
the earlier of: (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of the our initial public offering in February 2017, (b) in
which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market
value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th, and (ii) the date on which we have issued more
than $1.0 billion in non-convertible debt during the prior three-year period.
We are also a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual
revenue was less than $100 million during our most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the
market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently
completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time
we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller
20
Table of Contents
reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial
statements and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive
compensation.
Our website address is www.jouncetx.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed
to be incorporated by reference in, and are not considered part of, this Annual Report on Form 10-K. Through our website, we make available, free of
charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, any amendments to those reports, proxy and
registration statements, and all of our insider Section 16 reports, as soon as reasonably practicable after such material is electronically filed with, or
furnished to, the Securities and Exchange Commission, or the SEC. These SEC reports can be accessed through the “Investors & Media” section of our
website. The information found on our website (or that may be accessed through links on our website) is not part of this or any other report we file with, or
furnish to, the SEC. You should not rely on any such information in making your decision whether to purchase our common stock.
In addition, the SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file
electronically with the SEC, including us, and any document we file may be viewed at the SEC’s internet address at http://www.sec.gov (this website
address is not intended to function as a hyperlink, and the information contained in the SEC’s website is not intended to be a part of this filing).
Our code of conduct, corporate governance guidelines and the charters of our Audit Committee, Compensation Committee, Nominating and Corporate
Governance Committee and Science and Technology Committee are available through our website at www.jouncetx.com.
21
Table of Contents
Item 1A. Risk Factors
Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those
expressed in forward-looking statements made by us or on our behalf in this Annual Report on Form 10-K and other filings with the Securities and
Exchange Commission, or the SEC, press releases, communications with investors, and oral statements. Actual future results may differ materially from
those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new
information, future events, or otherwise.
Risks Related to Product Development and Regulatory Process
The ongoing COVID-19 pandemic has adversely affected, and may continue to adversely affect, our business, including our clinical trials and
preclinical studies.
The COVID-19 pandemic has caused many governments to implement measures to slow the spread of the outbreak through quarantines, strict travel
restrictions, heightened border scrutiny and other measures. The COVID-19 pandemic and government measures taken in response have had a significant
impact, both direct and indirect, on business and commerce, as supply chains have been disrupted; facilities and production have been suspended; and
demand for certain goods and services, such as medical services and supplies, have increased dramatically, while demand for other goods and services,
such as travel, has fallen. The future progression of the COVID-19 pandemic and its effects on our business and operations are uncertain.
In response to the spread of COVID-19, we have restricted access to our headquarters by limiting the number of staff in our research and development
laboratory and office space, and directing and then recommending our employees who are able to work remotely to continue their work outside of our
office. We believe the COVID-19 pandemic has had, and may continue to have, an impact on our clinical trials. For example, as a result of the COVID-19
pandemic, the timing of our release of clinical data from our SELECT clinical trial has been delayed due in part to difficulty sourcing components for
sample-collection kits. As a result of the COVID-19 pandemic, we may experience disruptions that could severely impact our business, clinical trials and
preclinical studies, including:
•
•
•
•
•
•
•
•
•
•
•
•
additional delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;
delays or difficulties in enrolling patients in our clinical trials;
delays or difficulties in developing diagnostics or conducting biomarker analysis by third-party vendors who support our clinical trials;
diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and
hospital staff supporting the conduct of our clinical trials;
interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by
federal or state governments, employers and others or interruption of clinical trial patient visits and study procedures that are deemed non-
essential, which may impact the integrity of subject data and clinical study endpoints;
additional delays or difficulties in completing the analysis of or reporting results from our clinical trials;
interruption or delays in the operations of the Food and Drug Administration, or the FDA, or comparable foreign regulatory authorities, which
may impact clinical trial timelines or approval timelines;
interruption of, or delays in receiving, supplies of our product candidates and/or supplies used in the conduct of our clinical trials from our
contract manufacturing organizations due to raw materials shortages, staffing shortages, production slowdowns or stoppages, disruptions in
delivery systems and government restrictions or limitations, such as those imposed by the Defense Production Act;
interruption of or delays in the performance of contractual duties by third parties on whom we rely to conduct our clinical trials;
limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because
of sickness of employees or their families, the desire of employees to avoid contact with large groups of people or changes to governmental orders
related to essential services;
increased reliance on personnel working from home may negatively impact productivity; and
difficulties raising capital on favorable terms when needed.
22
Table of Contents
The COVID-19 pandemic continues to evolve. The extent to which the COVID-19 pandemic may further impact our business, clinical trials and preclinical
studies and supply chain will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of
the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the
effectiveness of actions taken in the United States and other countries to contain and treat the disease.
We are early in our development efforts. If we are unable to advance our product candidates through clinical development, advance future product
candidates to clinical development or obtain marketing approval and ultimately commercialize any product candidates or experience significant delays
in doing so, our business will be materially harmed.
We are early in our development efforts: JTX-8064, vopratelimab and JTX-4014 are our clinical-stage product candidates, and JTX-1811 and future
product candidates are in preclinical or earlier stages of development. We have invested substantially all of our efforts and financial resources in the
identification of targets and early stage, preclinical and clinical development of monoclonal antibodies, including the development of JTX-8064,
vopratelimab, JTX-4014 and JTX-1811.
Our other efforts have been invested in early stage, preclinical and earlier development programs. Our ability to generate product revenues, which we do
not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our current and/or
future product candidates, which may never occur. We currently generate no revenues from sales of any products, and we may never be able to develop or
commercialize a marketable product. In August 2020, we entered into an agreement to grant an exclusive license for the development, manufacture and
commercialization of JTX-1811 to Gilead Sciences, Inc., or Gilead, and we may never receive any payments from Gilead for the achievement of
development, regulatory or commercial milestones, or royalties from potential future sales of JTX-1811. Our current and future product candidates will
require additional preclinical and clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United
States and other markets, demonstrating effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical
development and commercial production, building of a commercial organization, and substantial investment and significant marketing efforts before we
generate any revenues from product sales. In addition, our product development programs contemplate the development of companion diagnostics and/or
complementary diagnostics, which are assays or tests to identify an appropriate patient population. Complementary diagnostics and companion diagnostics
are subject to regulation as medical devices and, if there are no adequate companion diagnostics and/or complementary diagnostics currently on the market
for our product candidates, we may elect to advance a diagnostic and that diagnostic would have to be approved or cleared for marketing by the FDA or
comparable foreign regulatory agencies before we could commercialize it. The success of our current and future product candidates will depend on several
factors, including the following:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
successful completion of preclinical studies and advancement to clinical development of our product candidates;
acceptance of investigational new drug applications for our planned clinical trials or future clinical trials;
successful enrollment and completion of clinical trials;
demonstration of a benefit/risk profile for our current and future product candidates that is sufficient to support a successful biologics license
application, or BLA;
successful development and marketing approval and clearance of companion diagnostics and/or complementary diagnostics for use with our
current and future product candidates, if applicable;
receipt and maintenance of marketing approvals from applicable regulatory authorities;
approval by national pricing and reimbursement agencies (such as NICE, National Institute for Health Care and Excellence in the United
Kingdom);
establishing agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product
candidates are approved;
obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;
launching commercial sales of our current and future product candidates, if and when approved;
acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;
effectively competing with other therapies;
obtaining and maintaining healthcare coverage and adequate reimbursement;
enforcing and defending intellectual property rights and claims;
23
Table of Contents
•
•
successful completion of clinical confirmatory trials to verify clinical benefit, if applicable; and
maintaining a continued acceptable safety profile of the product candidates following approval.
If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully
commercialize our current and future product candidates, which would materially harm our business. If we do not receive marketing approvals for our
current and future product candidates, we may not be able to continue our operations.
Clinical product development involves a lengthy and expensive process, with an uncertain outcome. We will incur additional costs in connection with,
and may experience delays, in completing, or ultimately be unable to complete, the development and commercialization of our current and future
product candidates, and any companion diagnostics and/or complementary diagnostics.
The risk of failure for our product candidates at any stage of clinical or preclinical development is high. It is impossible to predict when or if our current
and future product candidates will prove effective and safe in humans and will receive marketing approval. Before obtaining marketing approval from
regulatory authorities for the sale of our product candidates, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate
the safety and efficacy of our current and future product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take
many years to complete or may be delayed and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The
outcome of preclinical development and testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a
clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and
many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to
obtain marketing approval of their product candidates. Our preclinical studies and clinical trials may not be successful.
The FDA or comparable foreign regulatory authorities could change their position on the acceptability of our trial designs or the clinical endpoints selected,
which may require us to complete more preclinical studies or provide additional data before continuing clinical trials. In the event we are required to satisfy
additional FDA requests, the completion of our clinical trials for JTX-8064, vopratelimab and JTX-4014 may be delayed. Successful completion of our
clinical trials is a prerequisite to submitting a BLA to the FDA and a Marketing Authorization Application, or MAA, in the European Union for our current
and future product candidates and, consequently, the ultimate approval and commercial marketing of our current and future product candidates. We do not
know whether any of our clinical trials will be completed on schedule, if at all.
We may experience delays in completing our preclinical studies and initiating or completing clinical trials, and we may experience numerous unforeseen
events during, or as a result of, any potential future clinical trials that could delay or prevent our ability to receive marketing approval of our current and
future product candidates, including:
•
•
•
•
•
•
•
•
interruption of key clinical trial activities as a result of the COVID-19 pandemic, such as developing diagnostics, conducting biomarker analysis,
clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or
interruption of clinical trial subject visits and study procedures that are deemed non-essential, which may impact the integrity of subject data and
clinical study endpoints;
patients may be affected by COVID-19 and the virus could impact pharmacodynamic biomarkers studied in our clinical trials and the
interpretation of related data;
regulators, institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or
conduct a clinical trial at a prospective trial site;
we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract
research organizations, or CROs;
clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical
studies or clinical trials or abandon product development programs;
the number of patients required for clinical trials may be larger than we anticipate;
it may be difficult to enroll a sufficient number of patients with a predictive biomarker or enrollment in these clinical trials may be slower than we
anticipate, or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;
our third-party contractors, trial sites or investigators may fail to comply with regulatory requirements or meet their contractual obligations to us in
a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial
sites or investigators;
24
Table of Contents
•
•
•
•
•
•
•
we may elect to, or regulators or IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research for
various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unreasonable and
significant health risks;
the cost of clinical trials may be greater than we anticipate;
the supply or quality of materials or other materials necessary to conduct clinical trials may be insufficient or inadequate due to supply chain
interruptions caused by COVID-19 or other factors;
the size of the patient population required to validate our biomarker-driven strategy may be larger than we anticipate;
competitors may obtain regulatory approval ahead of us for products or antibodies similar to ours, preventing us from obtaining regulatory
approval despite positive clinical data;
our product candidates may have undesirable side effects or other unexpected characteristics, causing us to suspend or terminate the trials, or
reports may arise from preclinical or clinical testing of other similar cancer therapies that raise safety or efficacy concerns about our product
candidates; and
the FDA or other regulatory authorities may require us to submit additional data or impose other requirements before permitting us to initiate or
continue a clinical trial.
We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted or
ethics committees, or by the FDA or other regulatory authorities, or recommended for suspension or termination by the data safety monitoring board for
such trial. Such authorities or we may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in
accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory
authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including those issues or effects seen in other drugs
or drug candidates in the class to which our drug candidates belong, failure to demonstrate a benefit from using a product, changes in governmental
regulations or lack of adequate funding to continue the clinical trial. Many of the factors that result in a delay in the commencement or completion of
clinical trials may also ultimately lead to the denial of marketing approval of our product candidates. Further, regulatory authorities may disagree with our
clinical trial design and our interpretation of data from clinical trials or may change the requirements for approval even after such authorities have reviewed
and commented on the design for our clinical trials.
If we are required to conduct additional clinical trials or other testing, if the results of these trials or tests are not positive or are only modestly positive or if
there are safety concerns, or if we are unable to successfully complete clinical trials or other testing of our current and future product candidates, we may:
•
•
•
•
•
be delayed in obtaining marketing approval for our product candidates;
not obtain marketing approval at all;
obtain approval for indications or patient populations that are not as broad as intended or desired;
be subject to post-marketing testing requirements; or
have the product removed from the market after obtaining marketing approval.
Our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any of our clinical
trials will need to be restructured, will be completed on schedule, or will begin as planned, if at all. Any delays in our preclinical or future clinical
development programs may harm our business, financial condition and prospects significantly.
Our current and future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other
approved pharmaceutical products or investigational new drugs that could halt their clinical development, prevent their marketing approval, limit their
commercial potential or result in significant negative consequences.
Although our current and future product candidates will undergo safety testing to the extent possible and, where applicable, under such conditions
discussed with regulatory authorities, not all adverse effects of drugs can be predicted or anticipated. In order to obtain marketing approval of a product
candidate, we must demonstrate safety in various non-clinical and clinical tests. At the time of initiating human clinical trials, we may not have conducted
or may not conduct the types of non-clinical testing ultimately required by regulatory authorities, or future non-clinical tests may indicate that our product
candidates are not safe for use. Non-clinical testing and clinical testing are both expensive and time-consuming and have uncertain outcomes.
25
Table of Contents
Immunotherapy, and its method of action of enabling the body’s immune system, is powerful and could lead to serious side effects that we only discover in
clinical trials. Undesirable or clinically unmanageable side effects could occur and cause us or regulatory authorities to interrupt, delay or halt clinical trials
and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. Results of
our trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Unforeseen side effects from our
current and future product candidates could arise either during clinical development or, if such side effects are more rare, after our current and future
product candidates have been approved by regulatory authorities and the approved product has been marketed, resulting in the exposure of additional
patients. Although we have observed that vopratelimab and JTX-4014 each have an acceptable safety profile in studies to date, we cannot predict if future
clinical trials of our product candidates, including JTX-8064, either alone or in combination with other therapies, will demonstrate safety in humans. If any
of our current or future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain marketing approval, we will not be able to
generate revenue and our business will be harmed.
We cannot predict whether future safety and toxicology studies may cause undesirable effects. Success in initial tests does not ensure that later testing will
be successful. Our product candidates could cause undesirable side effects similar to those toxicities observed in other immunotherapies. It remains
possible that new or more severe toxicities could be seen if any product candidate is used in combination with other agents. Such toxicities, if observed,
could result in development delays, a determination by the FDA or other regulatory authorities that additional safety testing is required, delay or denial of
approval, or limit the labeling and thus overall market scope for such product candidate.
If unacceptable toxicities arise in the development of our current and future product candidates, we or an existing or future collaborator or licensee could
suspend or terminate clinical trials, or the FDA or comparable foreign regulatory authorities could order us, a collaborator or licensee to cease clinical trials
or deny approval of our current and future product candidates for any or all targeted indications. Treatment-related side effects could also affect patient
recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be
appropriately recognized or managed by the treating medical staff, particularly outside of our collaborators or licensees, as toxicities resulting from cancer
immunotherapies are not normally encountered in the general patient population or by medical personnel. We expect to have to train medical personnel
using any of our product candidates to understand the side effect profile of such product candidates for both our ongoing and planned clinical trials and
upon commercialization of such product candidates. The inability to recognize and manage the potential side effects of our product candidates could result
in patient deaths. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may
harm our business, financial condition and prospects significantly.
If we encounter difficulties enrolling or retaining patients in our clinical trials, our clinical development activities could be delayed or otherwise be
adversely affected.
The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll and retain a sufficient
number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment and retention in our clinical trials for
a variety of reasons. The enrollment and retention of patients depend on many factors, including:
•
•
•
•
•
•
•
•
•
•
•
the patient eligibility criteria defined in the protocol;
the development of diagnostics and/or biomarker analysis by third parties;
our ability to identify and enroll sufficient number of patients with a predictive biomarker;
the size of the population that we must screen to identify a sufficient number of patients with a predictive biomarker;
the size of the patient population required for analysis of the trial’s primary endpoints;
the proximity of patients to study sites;
the design of the trial;
our ability to recruit clinical trial investigators with the appropriate competencies and experience;
clinicians’ and patients’ perceptions of the potential advantages of the product candidate being studied in relation to other available therapies;
our ability to obtain and maintain patient consents for participation in our clinical trials and, where appropriate, biopsies to understand our product
candidates better and for future patient enrichment efforts;
the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they are late-stage cancer patients, will not
survive the full terms of the clinical trials;
26
Table of Contents
•
•
the ability of our clinical trial sites to continue key activities, such as clinical trial site data monitoring and patient visits, due to limitations on
travel imposed or recommended by federal or state governments, employers and others as a result of the COVID-19 pandemic; and
the risk that patients may be affected by COVID-19 or measures taken in response to the COVID-19 pandemic and are unable to travel to our
clinical trial sites.
In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our current and future
product candidates. This competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in
our trials may instead opt to enroll in a trial conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect
to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are
available for our clinical trials at such sites. Moreover, because our current and future product candidates represent a departure from more commonly used
methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll
patients in our ongoing or any future clinical trial.
Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent
completion of these trials and adversely affect our ability to advance the development of our current and future product candidates.
We may not be able to conduct clinical trials in some jurisdictions outside of the United States.
We are currently conducting SELECT outside of the United States, and we may conduct future trials in markets outside the United States. Our ability to
successfully initiate, enroll and complete a clinical trial in any country outside of the United States is subject to numerous additional risks unique to
conducting business in jurisdictions outside the United States, including:
•
•
•
•
•
•
•
•
•
difficulty in establishing or managing relationships with qualified CROs, physicians and clinical trial sites;
different local standards for the conduct of clinical trials;
difficulty in complying with various and complex import laws and regulations when shipping drug to certain countries;
the potential burden of complying with a variety of laws, medical standards and regulatory requirements, including the regulation of
pharmaceutical and biotechnology products and treatments;
lack of consistency in standard of care from country to country;
diminished protection of intellectual property in some countries;
foreign exchange fluctuations;
cultural differences in medical practice and clinical research; and
changes in country or regional regulatory requirements.
Furthermore, the COVID-19 pandemic may also have an impact on our ability to successfully conduct trials outside of the United States. For example, we
are conducting SELECT in countries where clinical trial site staff have been diverted to care for COVID-19 patients and where regulatory authorities are
short staffed due to the COVID-19 pandemic. If we have difficulty conducting our clinical trials in jurisdictions outside the United States as planned, we
may need to delay, limit or terminate ongoing or planned clinical trials, any of which could have a material adverse effect on our business.
We are currently conducting SELECT outside the United States and may conduct future clinical trials for our product candidates at sites outside the
United States, and the FDA may not accept data from trials conducted in such locations or the complexity of regulatory burdens may otherwise
adversely impact us.
Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain conditions
imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with
good clinical practices, or GCPs, and the FDA must be able to validate the data from the trial through an onsite inspection, if necessary. Generally, the
patient population for any clinical trials conducted outside the United States must be representative of the population for which we intend to seek approval
in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its
determination that the trials also complied with all applicable U.S. laws and regulations. Nonetheless, there can be no assurance that the FDA will accept
data from trials conducted outside the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would
likely result in the need for additional clinical trials, which
27
Table of Contents
would be costly and time-consuming and delay or permanently halt our development of any applicable product candidates. Furthermore, certain
jurisdictions require data from trials conducted in their country in order to obtain approval in that country.
We rely on our Translational Science Platform to identify and develop product candidates. Our competitive position could be materially harmed if our
competitors develop a platform similar to our Translational Science Platform and develop rival product candidates.
We rely on unpatented know-how, inventions and other proprietary information, to maintain our competitive position. We consider know-how to be our
primary intellectual property with respect to our Translational Science Platform. Know-how can be difficult to protect. In particular, we anticipate that with
respect to this platform, this know-how may over time be disseminated within the industry through independent development, the publication of journal
articles describing the methodology, and the movement of skilled personnel.
We cannot rule out that our competitors may have or obtain the knowledge necessary to analyze and characterize tumors for the purpose of identifying and
developing products that could compete with the product candidates we develop. Our competitors may also have significantly greater financial, product
development, technical, and human resources and access to other human tumors than we do and may have significantly greater experience in using
translational science methodology to identify and develop product candidates.
We may not be able to prohibit our competitors from using translational science methods to develop product candidates, including such methods that are
the same as or similar to our own. If our competitors use translational science methods to identify and develop products that compete with our current and
future product candidates, our ability to develop and market a promising product or product candidate may diminish substantially, which could have a
material adverse effect on our business prospects, financial condition, and results of operations.
Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time consuming and uncertain
and may prevent us or any of our existing or future collaborators or licensees from obtaining approvals for the commercialization of our current and
future product candidates.
Our product candidates and the activities associated with their development and commercialization, including research, testing, manufacturing, labeling,
approval and license maintenance, selling, import and export, marketing and distribution are subject to extensive regulation by the FDA and comparable
foreign regulatory authorities. Neither we nor any existing or future collaborator or licensee is permitted to market any future product in the United States
until we receive approval of a BLA from the FDA. We have never submitted an application for, or received, marketing approval. Obtaining approval of a
BLA can be a lengthy, expensive and uncertain process. Even if we believe the preclinical or clinical data for our current and future product candidates are
promising, such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities.
Marketing approval of a BLA is not guaranteed, and the approval process is expensive and may take several years. The FDA also has substantial discretion
in the approval process. Despite the time and expense exerted, failure can occur at any stage, and we could encounter problems that cause us to abandon or
repeat clinical trials or perform additional preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for
FDA approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations
applicable to any particular product candidate. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay,
limit or deny approval of a product candidate, or we may experience delays or rejections based upon government regulation or changes in regulatory
agency policy during the period of product development. Regulatory agencies also may impose significant limitations in the form of narrow indications,
warnings, precautions or contraindications with respect to conditions of use or may grant approval subject to the performance of costly post-marketing
clinical trials or may not approve the price we intend to charge for our product candidates. Any of the foregoing scenarios could materially harm the
commercial prospects for our current and future product candidates.
If our current and future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain marketing approval, our business will be
harmed.
28
Table of Contents
We may seek a Breakthrough Therapy Designation or Fast Track Designation by the FDA for our current and future product candidates, and we may
be unsuccessful. If we are successful, the designation may not actually lead to a faster development or regulatory review or approval process, and it
does not increase the likelihood that our current and future product candidates will receive marketing approval.
We may seek a Breakthrough Therapy Designation or Fast Track Designation for our current and future product candidates. A breakthrough therapy is
defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and
preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically
significant endpoints, such as substantial treatment effects observed early in clinical development. Fast Track Designation may be available if a product is
intended for the treatment of a serious or life-threatening condition, and preclinical or clinical data demonstrate the potential to address an unmet medical
need for this condition. Drugs that receive Breakthrough Therapy Designation or Fast Track Designation by the FDA are eligible for accelerated approval
and priority review.
The FDA has broad discretion whether or not to grant Breakthrough Therapy Designation or Fast Track Designation. Even if we receive Breakthrough
Therapy Designation or Fast Track Designation for a product candidate, such designation may not result in a faster development process, review or
approval compared to conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one of our current or future
product candidates receives Breakthrough Therapy Designation or Fast Track Designation, the FDA may later decide that the drugs no longer meet the
conditions for qualification and rescind the designation.
We may seek Orphan Drug Designation for our current and future product candidates, and we may be unsuccessful or may be unable to maintain the
benefits associated with Orphan Drug Designation, including the potential for market exclusivity.
As part of our business strategy, we may seek Orphan Drug Designation for our current and future product candidates, and we may be unsuccessful. In the
United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax
advantages and user-fee waivers.
In Europe, Orphan Drug Designation entitles a party to a number of incentives, such as protocol assistance and scientific advice specifically for designated
orphan medicines, and potential fee reductions depending on the status of the sponsor.
Generally, if a drug with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such
designation, the drug is entitled to a period of marketing exclusivity, which precludes the European Medicines Agency or the FDA from approving another
marketing application for the same drug and indication for a set time period, except in limited circumstances.
Even if we obtain orphan drug exclusivity for a drug, that exclusivity may not effectively protect the drug from competition because different drugs can be
approved for the same condition, or the drug may be used off-label. Even after an orphan drug is approved, the FDA can subsequently approve another
drug for the same condition if the FDA concludes that the other drug is clinically superior. In addition, a designated orphan drug may not receive orphan
drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive
marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the
manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan Drug Designation
neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.
While we may seek Orphan Drug Designation for applicable indications for our current and future product candidates, we may never receive such
designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.
We may choose not to develop a potential product candidate, or we may suspend or terminate one or more discovery or preclinical programs or our
product candidates.
At any time and for any reason, we may determine that one or more of our discovery programs, preclinical programs or product candidates does not have
sufficient potential to warrant the allocation of resources toward such program or product candidate. Furthermore, because we have limited financial and
personnel resources, we have placed significant focus on the development of our product candidates JTX-8064, vopratelimab and JTX-4014. Accordingly,
we may choose not to develop a product candidate or elect to suspend or terminate one or more of our discovery or preclinical programs. If we suspend or
terminate a program or product candidate in which we have invested significant resources, we will have expended resources on a program or product
candidate that will not provide a full return on our investment. As a result, we may have missed an opportunity to have allocated those resources to
potentially more productive uses, including existing or future programs or product candidates. If we do not accurately evaluate the commercial potential or
target market for a particular future product candidate, we may relinquish valuable rights to future product candidates through collaboration, licensing or
other royalty arrangements.
29
Table of Contents
Obtaining and maintaining marketing approval of our current or future product candidates in one jurisdiction does not mean that we will be successful
in obtaining marketing approval of that product candidate in other jurisdictions.
Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not guarantee that we will be able to
obtain or maintain marketing approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate,
comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those
countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than,
those in the United States, including additional preclinical studies or clinical trials.
Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us
and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international
markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our current
and future product candidates will be harmed. Even if we obtain approval for our product candidates and ultimately commercialize them in foreign markets,
we would be subject to separate risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting
and legal requirements and the reduced protection of intellectual property rights in some foreign countries.
The United Kingdom left the European Union on January 31, 2020, commonly referred to as Brexit. In December 2020, the United Kingdom and the
European Union agreed on a trade and cooperation agreement under which the United Kingdom and the European Union will now form two separate
markets governed by two distinct regulatory and legal regimes. Depending on the application and terms of the trade and cooperation agreement, we could
face new regulatory costs and challenges. Any delay in obtaining, or an inability to obtain, any marketing approvals as a result of Brexit or otherwise, may
force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially
harm our business.
Our failure to successfully identify, discover, acquire, develop or commercialize additional products or product candidates could impair our ability to
grow.
Although a substantial amount of our efforts will focus on the clinical testing and potential approval of our most advanced product candidates, JTX-8064,
vopratelimab and JTX-4014, an element of our long-term growth strategy is to in-license products or product candidates for development and
commercialization. We may never be able to identify, discover, acquire, develop or commercialize any products or product candidates, which would have a
material adverse effect on our business.
Because our internal research capabilities are limited, we may be dependent upon pharmaceutical and biotechnology companies, academic scientists, and
other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to identify, select, and acquire
promising pharmaceutical product candidates and products. The process of proposing, negotiating and implementing a license or acquisition of a product
candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales
resources, may compete with us for the license or acquisition of product candidates and approved products. Acquisitions and in-licenses include numerous
risks, including potential failure to achieve the expected benefits of the acquisition or license and potential unknown liabilities associated with the product
or technology. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses, and technologies,
integrate them into our current infrastructure and manage our development efforts.
Even if we receive marketing approval of our current or future product candidates, we will be subject to ongoing regulatory obligations and continued
regulatory review.
Any marketing approvals that we receive for our current and future product candidates may be subject to limitations on the approved indicated uses for
which the product may be marketed or the conditions of approval or contain requirements for potentially costly post-market testing and surveillance to
monitor the safety and efficacy of the product candidate. In addition, if the FDA or a comparable foreign regulatory authority approves any of our current
or future product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion,
import and export and record keeping for our current and future product candidates will be subject to extensive and ongoing regulatory requirements. These
requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current
good manufacturing practice, or cGMP, and GCPs for any clinical trials that we conduct post-approval. Failure to comply with regulatory requirements,
may result in, among other things:
•
•
restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or product recalls;
fines, untitled and warning letters, or holds on clinical trials;
30
Table of Contents
•
•
•
refusal by the FDA to approve pending applications or supplements to approved applications we filed or suspension or revocation of license
approvals;
product seizure or detention, or refusal to permit the import or export of our product candidates; and
injunctions or the imposition of civil or criminal penalties.
We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the
United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are
not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain
profitability.
Even if our current and future product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians,
patients, third-party payors and others in the medical community necessary for commercial success.
If our current and future product candidates receive marketing approval, whether as a single agent or in combination with other therapies, they may
nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. If our current and
future product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues or receive significant milestone
or royalty payments, and we may not become profitable.
Risks Related to Manufacturing, Commercialization and Reliance on Third Parties
We rely and expect to continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual
duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our
product candidates and our business could be substantially harmed.
We do not have the ability to independently conduct clinical trials. We rely and will rely on medical institutions, clinical investigators, contract laboratories,
and other third parties, such as CROs, to conduct or otherwise support our ongoing clinical trials, including processing of human blood and tumor samples
and analysis of biomarkers from the clinical trials. We rely and will rely heavily on these parties for execution of clinical trials for our current and future
product candidates, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is
conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third parties
including CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our clinical trials, we
could be subject to untitled and warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.
We and our clinical investigators and CROs are required to comply with regulations and requirements, including GCP, for conducting, monitoring,
recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are
adequately informed of the potential risks of participating in clinical trials and their rights are protected. If we or our clinical investigators or CROs fail to
comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory
authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure stockholders that, upon
inspection, the FDA will determine that any of our current or future clinical trials will comply with GCP. In addition, our clinical trials must be conducted
with product candidates produced under cGMP regulations. Our failure or the failure of our clinical investigators or CROs to comply with these regulations
may require us to repeat clinical trials, which would delay the marketing approval process and could also subject us to enforcement action. We also are
required to register certain ongoing clinical trials and provide certain information, including information relating to the trial’s protocol, on a government-
sponsored database, ClinicalTrials.gov, within specific time frames. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.
Although we designed the clinical trials for JTX-8064, vopratelimab and JTX-4014 and intend to design the clinical trials for future product candidates,
clinical investigators or CROs will conduct all of the clinical trials. As a result, many important aspects of our development programs, including their
conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct clinical trials will also result in less direct control over the
management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside
parties can be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may also face internal challenges
that may materially adversely affect the willingness or ability of such parties to conduct our clinical trials and may subject us to unexpected cost increases
that are beyond our control. If the clinical investigators or CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail
to comply with regulatory requirements, the development, marketing approval and commercialization of our current and future product candidates may be
delayed, or our development programs may be materially and irreversibly harmed. If we are unable to rely on clinical data collected by our
31
Table of Contents
clinical investigators and CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct, and this could
significantly delay commercialization and require significantly greater expenditures.
If clinical investigators or CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced
or if the quality or accuracy of the clinical data they obtain are compromised due to the failure to adhere to our clinical protocols, regulatory requirements
or for other reasons, any clinical trials such clinical investigators or CROs are associated with may be extended, delayed or terminated. For example, in
EMERGE, due to a site error, we enrolled additional patients to achieve the number of patients required for our statistical analysis. If our clinical trials are
extended, delayed or terminated, we believe that our financial results and the commercial prospects for our current and future product candidates in the
subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed.
Furthermore, if clinical investigators or CROs experience adverse impacts from the COVID-19 pandemic, including staffing shortages, travel restrictions,
prioritization of healthcare resources toward pandemic efforts, our clinical development efforts and plans for data disclosures may be delayed.
Because we rely on third-party manufacturing and supply partners, including a single supplier for some of our materials, our supply of research and
development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.
We rely on third-party contract manufacturers to manufacture our preclinical and clinical trial product supplies. We do not own manufacturing facilities for
producing such supplies. There can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, or of
satisfactory quality or continue to be available at acceptable prices. Our or a third party’s failure to execute on our manufacturing requirements, or to do so
on commercially reasonable terms and comply with cGMP could adversely affect our business in a number of ways, including:
•
•
•
•
•
an inability to initiate or continue clinical trials of our current or future product candidates under development;
delay in submitting regulatory applications, or receiving marketing approvals, for our current or future product candidates;
loss of cooperation of an existing or future collaborator;
subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; and
requirements to cease distribution or to recall batches of our current or future product candidates.
In the event that any of our manufacturers fails to comply with applicable regulatory requirements and facility and process validation tests or to perform its
obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other
reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an
agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required
to manufacture our future product candidates may be unique or proprietary to the original manufacturer, which would increase our reliance on such
manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture such future product candidates. In
particular, any replacement of our manufacturer could require significant effort and expertise because there may be a limited number of qualified
replacements. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and
procedures that comply with quality standards and with all applicable regulations and guidelines, which could negatively affect our ability to develop
product candidates in a timely manner or within budget.
Certain raw materials necessary for the manufacture of our product candidates under our current manufacturing process, such as growth media, resins and
filters, are available from a single supplier. We do not have agreements in place that guarantee our supply or the price of these raw materials. Any
significant delay in the acquisition or decrease in the availability of these raw materials could considerably delay the manufacture of our current and future
product candidates, which could adversely impact the timing of any planned trials or the marketing approval of that product candidate.
If any of our third-party manufacturing and supply partners experience adverse impacts from the COVID-19 pandemic, including staffing shortages,
production slowdowns, disruptions in delivery systems or government restrictions or limitations, the development of diagnostics for our clinical trials or
our supply chain may be disrupted. For example, under the Defense Production Act, the U.S. government may, among other things, require domestic
industries to provide essential goods and services needed for the national defense, such as drug material or other supplies needed to diagnose or treat
COVID-19 patients, which could require third parties to allocate resources in a way that impacts our operations. These impacts may limit our ability
32
Table of Contents
to conduct our clinical trials, continue our research and development operations, and manufacture our product candidates for our clinical trials.
We expect to continue to rely on third-party manufacturers if we receive marketing approval for any product candidate. If we are unable to obtain or
maintain third-party manufacturing for our current and future product candidates, or to do so on commercially reasonable terms, we may not be able to
develop and commercialize our current or future product candidates successfully. We do not yet have sufficient information to reliably estimate the cost of
the commercial manufacture of any future product candidate.
In addition, in order to conduct clinical trials of our current and future product candidates, we will need to work with third-party manufacturers to
manufacture them in large quantities. Our manufacturing partners or our third-party collaborators may be unable to successfully increase the manufacturing
capacity of our current and future product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up
activities. If our manufacturing partners or collaborators are unable to successfully scale up the manufacture of our current or future product candidates in
sufficient quality and quantity, the development, testing, and clinical trials of that product candidate may be delayed or infeasible, and marketing approval
or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.
We expect to develop our current and future product candidates in combination with other drugs. If we are unable to enter into a strategic
collaboration for, or if we are unable to purchase on commercially reasonable terms, an approved or investigational cancer drug to use in combination
with our product candidates, we may be unable to develop or obtain approval for our current and future product candidates in combination with other
drugs.
We intend to develop our current and future product candidates in combination with one or more other cancer drugs. If the FDA or similar regulatory
authorities outside of the United States revoke or do not grant approval of any drugs we use in combination with our current or future product candidates,
we will not be able to market any products in combination with such drugs.
If safety or efficacy issues arise with any of these drugs, we could experience significant regulatory delays, and the FDA or similar regulatory authorities
outside of the United States may require us to redesign or terminate the applicable clinical trials. If the drugs we use are replaced as the standard of care for
the indications we choose for our current or future product candidates, the FDA or similar regulatory authorities outside of the United States may require us
to conduct additional clinical trials. In addition, if manufacturing or other issues result in a shortage of supply of the drugs with which we determine to
combine with our current or future product candidates, we may not be able to complete clinical development of vopratelimab, JTX-4014 or future product
candidates on our current timeline or at all.
Even if our current or future product candidates were to receive marketing approval or be commercialized for use in combination with other existing drugs,
we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of such
existing drugs or that safety, efficacy, manufacturing or supply issues could arise with such drugs.
We may form or seek strategic collaborations to evaluate and, if approved, market JTX-8064, vopratelimab and JTX-4014 in combination with another
approved or investigational cancer drug. If we are unable to enter into a strategic collaboration on commercially reasonable terms or fail to realize the
benefits of any such collaboration, we may be required to purchase an approved cancer drug to use in combination with JTX-8064, vopratelimab and/or
JTX-4014. The failure to enter into a successful collaboration or the expense of purchasing an approved cancer drug may delay our development timelines,
increase our costs and jeopardize our ability to develop JTX-8064, vopratelimab and JTX-4014.
We are subject to manufacturing risks that could substantially increase our costs and limit the supply of our products.
The process of manufacturing our current or future product candidates is complex, highly regulated and subject to several risks, including:
•
•
We do not have the capability internally to manufacture drug products or drug substances for clinical use. We use third-party manufacturers for
manufacturing JTX-8064, vopratelimab and JTX-4014 for our ongoing and anticipated clinical trials. Any changes in our manufacturing processes
as a result of scaling-up may require additional approvals or may delay the development and marketing approval of our current and future product
candidates and ultimately affect our success.
The manufacturing facilities in which our current and future product candidates are made could be adversely affected by equipment failures,
contamination, vendor error, labor shortages, natural disasters, power failures and numerous other factors.
33
Table of Contents
•
•
Any adverse developments affecting manufacturing operations for our current or future product candidates, if any are approved, may result in
shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also
have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation
efforts or seek more costly manufacturing alternatives.
Biologics, such as JTX-8064, vopratelimab and JTX-4014, that have been produced and are stored for later use may degrade, become
contaminated, suffer other quality defects or may not be used within their shelf life, which may cause the affected product candidates to no longer
be suitable for their intended use in clinical trials or other development activities. If the defective product candidates cannot be replaced in a timely
fashion, we may incur significant delays in our development programs that could adversely affect the value of such product candidates.
We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than any of our
current or future product candidates, our commercial opportunities will be negatively impacted.
The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing therapeutics that will
compete with other products and therapies that currently exist or are being developed, such as approved immunotherapy antibodies, the anti-ILT4 antibody
of Merck & Co., Inc., the anti-ICOS antibodies of Bristol Myers Squibb, GlaxoSmithKline plc, or Kymab Group Ltd., or Xencor, Inc.’s anti-PD-1 and anti-
ICOS bispecific antibody. Products we may develop in the future are also likely to face competition from other products and therapies, some of which we
may not currently be aware. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete,
less competitive or not economical.
We have both domestic and international competitors, including major multinational pharmaceutical companies, established biotechnology companies,
specialty pharmaceutical companies, universities and other research institutions and small and other early-stage companies. Many of our competitors have
significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical
companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, establishing clinical trial sites, recruiting patients and
in manufacturing pharmaceutical products and may succeed in discovering, developing and commercializing products in our field before we do. Currently,
GlaxoSmithKline plc is conducting a Phase 3 trial of its anti-ICOS antibody and, given their resources, they will likely be able to develop their product
candidate faster than we are able to develop vopratelimab. We also face competition in recruiting and retaining qualified scientific and management
personnel, as well as in acquiring technologies complementary to, or necessary for, our programs.
There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology
companies. These treatments consist both of small molecule drug products, as well as biologics, as approaches to address cancer. These treatments are often
combined with one another in an attempt to maximize the response rate and clinical benefit.
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have
fewer or less severe side effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any
products that we may develop. Our competitors also may obtain FDA, European Commission or other marketing approval for their products more rapidly
than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.
Even if our current and future product candidates achieve marketing approval, they may be priced at a significant premium over competitive products,
resulting in reduced competitiveness. In addition, if any of our current or future product candidates are approved by the FDA, the approval of a biosimilar
product to one of our products could have a material impact on our business.
We will depend on Gilead to develop, manufacture and commercialize JTX-1811 and may depend on additional third parties for the development and
commercialization of our other product candidate programs. If these programs are not successful, we may not receive significant payments from such
third parties or we may not be able to capitalize on the market potential of these product candidates.
In August 2020, we entered into a License Agreement, or the Gilead License Agreement, with Gilead pursuant to which we granted Gilead an exclusive,
worldwide license to develop, manufacture and commercialize JTX-1811. The Gilead License Agreement provides for potential payments to us from
Gilead upon the achievement of specified development, regulatory and sales milestones, and potential royalty-based revenue if JTX-1811 is successfully
commercialized. As a result of this license, we will not control the nature, timing or cost of bringing JTX-1811 to market. We cannot provide any assurance
with respect to the success of the license, and we may never receive any milestone or royalty payments pursuant to the Gilead License Agreement.
34
Table of Contents
We may form or seek other strategic alliances, joint ventures, or collaborations, or enter into additional licensing arrangements with third parties that we
believe will complement or augment our development and commercialization efforts with respect to our current and future product candidates that we may
develop.
Collaborations and other strategic transactions, including licensing arrangements, involving our product candidates pose the following risks to us:
•
•
•
•
•
•
•
•
•
•
•
Collaborators, including licensors, have significant discretion in determining the efforts and resources that they will apply to these collaborations.
For example, after the clearance of an Investigational New Drug application for JTX-1811 by the FDA or an earlier date specified by Gilead,
development and commercialization plans and strategies for JTX-1811 will be conducted by Gilead.
Collaborators may not pursue development and commercialization of any of our current or future product candidates or may elect not to continue
or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to the acquisition of
competitive products, availability of funding or other external factors such as a business combination that diverts resources or creates competing
priorities.
Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a product candidate,
repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing.
Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
candidates.
A collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and
distribution.
Collaborators may in-license, own or co-own intellectual property covering our products that results from our collaborating with them, and in such
cases, we would not have the exclusive right to develop, commercialize, enforce, maintain or defend such intellectual property. For example,
Gilead has the first right to enforce, maintain or defend our intellectual property rights for JTX-1811 under the Gilead License Agreement.
Collaborators may not properly enforce, maintain or defend our intellectual property rights or may use our proprietary information in a way that
gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to
potential litigation, or other intellectual property proceedings.
Disputes may arise between a collaborator and us that cause the delay or termination of the research, development or commercialization of our
current and future product candidates, or that result in costly litigation or arbitration that diverts management attention and resources.
Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or
commercialization of the applicable product candidates.
Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all.
Collaboration or licensing agreements may restrict our right to independently pursue new product candidates.
As a result, if we enter into additional collaboration agreements and strategic partnerships or license our intellectual property, products or businesses, we
may not be able to realize the benefit of, or generate revenues from, such arrangements.
All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to
the activities of Gilead with respect to the development and commercialization of JTX-1811 and would also apply to the activities of any future licensees or
collaborators.
We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter
our development and commercialization plans.
Our drug development programs and the potential commercialization of our product candidates will require substantial additional resources. For some of
our product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential
commercialization of those product candidates. Any of these relationships may require us to incur non-recurring and other charges, increase our near and
long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.
We face significant competition in seeking appropriate strategic partners and the negotiation process is time consuming and complex. Whether we reach a
definitive agreement for other collaborations will depend, among other things, upon our
35
Table of Contents
assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation
of our business. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for future product candidates
because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the
requisite potential to demonstrate safety and efficacy. In addition, there have been a significant number of recent business combinations among large
pharmaceutical companies that have resulted in a reduced number of potential future collaborators.
We may also be restricted under existing agreements from entering into future agreements on certain terms with potential collaborators. For example, under
the Gilead License Agreement, we have granted worldwide exclusive rights to Gilead for any antibody or other agent that is specifically directed to CCR8,
and this exclusivity would limit our ability to enter into future strategic collaborations with other partners.
We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the
development of the product candidate for which we are seeking to collaborate, reduce or delay its development program, delay or reduce the scope of
potential commercialization activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we
elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may
not be available to us on acceptable terms or at all.
The market opportunities for our current and future products, if and when approved, may be limited to those patients who are ineligible for established
therapies or for whom prior therapies have failed, and may be small.
Cancer therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for third-line
use. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy, and, increasingly,
immunotherapies or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second and third-line therapies are
administered to patients when prior therapy is not effective. We expect to initially seek approval of our current and future product candidates as a therapy
for patients who have received one or more prior treatments. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would
expect to seek approval potentially as a first-line therapy, but there is no guarantee that any of our product candidates, even if approved, would be approved
for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.
Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers who have received
one or more prior treatments, and who have the potential to benefit from treatment with our current and future product candidates, are based on our beliefs
and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, and
market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of
patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current and future product candidates
may be limited or may not be amenable to treatment with any of our products, if and when approved. Even if we obtain significant market share for any of
our products, if and when approved, because the potential target populations may be small, we may never achieve profitability without obtaining marketing
approval for additional indications, including to be used as first- or second-line therapy.
We may develop companion diagnostics and/or complementary diagnostics for our current and future product candidates. If we are unable to
successfully develop such companion diagnostics or complementary diagnostics, or experience significant delays in doing so, we may not realize the
full commercial potential of our current or future product candidates.
Because we are focused on patient selection and enrichment strategies, in which predictive biomarkers may be used to identify the right patients for our
product candidates, we believe that our success may depend, in part, on our ability to develop companion diagnostics and/or complementary diagnostics,
which are assays or tests to identify an appropriate patient population for our product candidates. There has been limited success to date industry-wide in
developing these types of companion diagnostics and/or complementary diagnostics. To be successful, we need to address a number of scientific, technical
and logistical challenges. We have not yet initiated development of companion diagnostics and/or complementary diagnostics, and the process of obtaining
or creating such a diagnostic is time consuming and costly. We have little experience in the development of diagnostics and may not be successful in
developing appropriate diagnostics to pair with any of our product candidates that receive marketing approval. Companion diagnostics and/or
complementary diagnostics are subject to regulation by the FDA and similar regulatory authorities outside the United States as medical devices and require
separate regulatory approval or clearance prior to commercialization. Given our limited experience in developing diagnostics, we expect to rely in part or in
whole on third parties for their design and manufacture. If we are unable to engage a third party to assist us, or if we, or any third parties that we engage,
are unable to successfully develop companion diagnostics and/or complementary diagnostics for our current and future product candidates, or experience
delays in doing so:
36
Table of Contents
•
•
•
the development of our current and future product candidates may be adversely affected if we are unable to appropriately select patients for
enrollment in our clinical trials;
our current and future product candidates may not receive marketing approval if safe and effective use of a product candidate depends on
companion diagnostics and/or complementary diagnostics and such a diagnostic is not commercially available or otherwise approved or cleared by
the appropriate regulatory authority; and
we may not realize the full commercial potential of our current and future product candidates that receive marketing approval if, among other
reasons, we are unable to appropriately identify, or it takes us longer to identify, patients who are likely to benefit from therapy with our products,
if approved.
If any of these events were to occur, our business would be harmed, possibly materially.
If product liability lawsuits are brought against us, we may incur substantial liabilities.
We face an inherent risk of product liability as a result of the clinical testing of our current and future product candidates. For example, we may be sued if
our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or
sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the
product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully
defend ourselves against product liability claims, we may incur substantial liabilities. Even successful defense would require significant financial and
management resources. Regardless of the merits or eventual outcome, we may experience financial or reputational losses in the future due to such product
liability claims.
Insurance coverage is increasingly expensive. We may not be able to maintain insurance at a reasonable cost or in an amount adequate to satisfy any
liability that may arise, if at all. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no
coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by
our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate
collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.
Adverse events in the field of immuno-oncology could damage public perception of our product candidates and negatively affect our business.
The commercial success of our products will depend in part on public acceptance of the use of cancer immunotherapies. Adverse events in clinical trials of
any of our current or future product candidates or other similar products and the resulting publicity, as well as any other adverse events in the field of
immuno-oncology that may occur, including in connection with competitor therapies such as approved immunotherapy antibodies, the clinical-stage anti-
ILT4 antibody of Merck, anti-ICOS antibodies of Bristol Myers Squibb, GlaxoSmithKline plc or Kymab Group Ltd., or Xencor, Inc.’s anti-PD-1 and anti-
ICOS bispecific antibody, could result in a decrease in demand for JTX-8064, vopratelimab, JTX-4014 or other products that we may develop. If public
perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our or our competitors’ therapies, our products may
not be accepted by the general public or the medical community.
Future adverse events in immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling
requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of
obtaining marketing approval for our current and future product candidates.
Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.
In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the
Affordable Care Act, or ACA, was passed, which substantially changes the way health care is financed by both governmental and private insurers, and
significantly impacts the U.S. pharmaceutical industry.
Since its enactment, there have been numerous judicial, administrative, executive and legislative challenges to certain aspects of the ACA, and we expect
there be to additional challenges and amendments to the ACA in the future. Various portions of the ACA are currently undergoing legal and constitutional
challenges in the United States Supreme Court; the Trump Administration issued various Executive Orders that eliminated cost sharing subsidies and
various provisions that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of
pharmaceuticals or medical devices; and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. The
United States Supreme Court is expected to rule on a legal challenge to the constitutionality of the ACA in early 2021.
37
Table of Contents
The implementation of the ACA is ongoing, and the law appears likely to continue the downward pressure on pharmaceutical pricing. Litigation and
legislation related to the ACA are likely to continue, with unpredictable and uncertain results. It is unclear whether the ACA will be overturned, repealed,
replaced, or further amended. We cannot predict what effect further changes to the ACA would have on our business. We expect that additional state and
federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for
healthcare products and services, which could result in reduced demand for our product candidates, companion diagnostics or complementary diagnostics,
or additional pricing pressures.
Our future relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable
anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which
could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and
future earnings.
Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and
regulations. In addition, we may be subject to transparency laws and patient privacy regulation by the U.S. federal and state governments and by
governments in foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may
affect our ability to operate include the federal Anti-Kickback Statute, the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 the federal legislation commonly referred to as the
Physician Payments Sunshine Act, and analogous state and foreign laws and regulations, any of which may constrain the business or financial
arrangements and relationships through which we sell, market and distribute any products for which we obtain marketing approval.
Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that
some of our business activities could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is also
uncertain and any investigation or settlement could be time- and resource-consuming, divert management’s attention, increase our costs or otherwise have
an adverse effect on our business.
If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to
various significant penalties, any of which could harm our ability to operate our business and our financial results. In addition, the approval and
commercialization of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned
above, among other foreign laws.
Risks Related to our Financial Position and Need for Additional Capital
We have accumulated significant losses since our inception and anticipate that we will continue to incur substantial net losses in the foreseeable future.
We are a clinical-stage biopharmaceutical company with a limited operating history, and we are in the early stages of our development efforts. Investment
in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any
potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain marketing approval and become commercially
viable. We have financed our operations primarily through the sale of equity securities and through our license and collaboration arrangements with
Celgene and Gilead. Since our inception, most of our resources have been dedicated to the preclinical and clinical development of our product candidates
and discovery programs. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we
continue to incur significant research and development and other expenses related to our ongoing operations.
While we recognized net income of $56.8 million for the year ended December 31, 2019 as a result of revenue recognized under our agreements with
Celgene, we incurred a net loss of $43.8 million for the year ended December 31, 2020. As of December 31, 2020, we had an accumulated deficit of $151.0
million. We expect to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and
development of, and seek marketing approvals for, our current and future product candidates.
Even if we succeed in receiving marketing approval for and commercialize our product candidates, we will continue to incur substantial research and
development and other expenditures to develop and market additional potential products. We may encounter unforeseen expenses, difficulties,
complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of
future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an
adverse effect on our stockholders’ equity and working capital.
38
Table of Contents
We have never generated any revenue from product sales and our ability to generate revenue from product sales and become profitable depends on our
success on a number of factors.
We have no products approved for commercial sale, have not generated any revenue from product sales, and do not anticipate generating any revenue from
product sales until some time after we have received marketing approval for the commercial sale of a product candidate, if ever. Our ability to generate
revenue and achieve profitability depends significantly on our success in many factors, including:
•
•
•
•
•
•
•
•
•
•
•
•
completing clinical development of JTX-8064, vopratelimab and JTX-4014;
completing preclinical development of JTX-1811 and obtaining IND clearance;
completing research, discovery, preclinical and clinical development of future product candidates;
obtaining marketing approvals for our current and future product candidates for which we complete clinical trials;
developing a sustainable and scalable manufacturing process for our product candidates, including establishing and maintaining commercially
viable supply and manufacturing relationships with third parties;
launching and commercializing our product candidates for which we obtain marketing approvals, either directly or with a collaborator or
distributor;
obtaining market acceptance of our current and future product candidates as viable treatment options;
addressing any competing technological and market developments;
identifying, assessing, acquiring and developing new product candidates;
negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;
obtaining, maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and
attracting, hiring and retaining qualified personnel.
Even if our product candidates or future product candidates that we develop are approved for commercial sale, we anticipate incurring significant costs
associated with commercializing any approved product candidate. These costs may fluctuate or exceed our expectations and our revenues will depend on
many factors that we cannot control or estimate. If we are not able to generate revenue from the sale of any approved products, we may never become
profitable.
We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay,
limit, reduce or terminate our product development or commercialization efforts.
Our operations have consumed substantial amounts of cash since inception. As of December 31, 2020, our cash, cash equivalents, short-term and long-term
investments were $213.2 million. We expect to continue to spend substantial amounts to continue the clinical development of JTX-8064, vopratelimab and
JTX-4014 and preclinical and clinical development of future product candidates. If we are able to gain marketing approval for any of our product
candidates, we will require significant additional amounts of cash in order to launch and commercialize those product candidates to the extent that such
launch and commercialization are not the responsibility of a collaborator or a licensee. In addition, other unanticipated costs may arise. Because the design
and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully
complete the development and commercialization of our current and future product candidates. Our future capital requirements depend on many factors,
including:
•
•
•
•
•
the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials,
including the impacts of the COVID-19 pandemic on the timing and progress of our ongoing and planned clinical trials;
the timing of, and the costs involved in, obtaining marketing approvals for our product candidates if clinical trials are successful;
the cost of commercialization activities for our product candidates, that are approved for sale, including marketing, sales and distribution costs;
the cost of manufacturing our product candidates for clinical trials in preparation for marketing approval and in preparation for commercialization;
our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements;
39
Table of Contents
•
•
•
•
the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and
the outcome of such litigation;
the timing, receipt, and amount of sales of, or royalties on, our future products, if any;
the emergence of competing cancer therapies and other adverse market developments; and
the requirement for and cost of developing companion diagnostics and/or complementary diagnostics.
Until we can generate sufficient product and royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future
cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other
marketing or distribution arrangements. Based on our research and development plans, we expect that our existing cash, cash equivalents, short-term and
long-term investments will enable us to fund our operating expenses and capital expenditure requirements through the second quarter of 2023.
If we are unable to obtain adequate financing on favorable terms when needed, we may have to delay, reduce the scope of or suspend one or more of our
clinical trials or research and development programs or our commercialization efforts. Further, our ability to raise additional capital may be adversely
impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and
worldwide resulting from the ongoing COVID-19 pandemic.
Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or our
current and future product candidates.
Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of private and public
equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the
sale of common stock or securities convertible or exchangeable into common stock, stockholders’ ownership interest will be diluted, and the terms of these
securities may include liquidation or other preferences that adversely affect our stockholders’ rights. Debt financing, if available, would increase our fixed
payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends.
If we are unable to raise additional funds through equity or debt financings when needed, and instead raise additional capital through marketing and
distribution agreements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable
rights to our current and future product candidates, technologies, future revenue streams or discovery programs or grant licenses on terms that may not be
favorable to us.
Risks Related to Intellectual Property
If we are unable to obtain, maintain and protect our intellectual property rights for our product candidates or if our intellectual property rights are
inadequate, our competitive position could be harmed.
Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and
other countries with respect to our product candidates. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and
other agreements with employees and third parties, all of which offer only limited protection. We currently, or will in the future, seek to protect our
proprietary position by filing and prosecuting patent applications in the United States and abroad related to our current and future product candidates, and
any future novel technologies that are important to our business.
The steps we, our licensees or our licensors have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our
proprietary information or infringement of our intellectual property rights, both inside and outside of the United States. Filing, prosecuting and defending
patents on our current and future product candidates throughout the world would be prohibitively expensive, and intellectual property rights in some
countries outside the United States can be less extensive than those in the United States.
If we, our licensees or our licensors are unable to obtain and maintain patent protection for our current and future product candidates, or if the scope of the
patent protection obtained is not sufficient, our competitors could develop and commercialize products similar or superior to ours, and our ability to
successfully commercialize our current and future product candidates and future technologies may be adversely affected.
Our pending applications cannot be enforced against third parties unless and until a patent issues from such applications and, even after issuance, such
patents may be challenged in the courts or patent offices in the United States and abroad. We are currently involved in an opposition proceeding in the
European Patent Office, and this proceeding may be ongoing for a number of years and may divert employee resources from our business. Additionally,
this and other such proceedings may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity or unenforceability of
such patents, which
40
Table of Contents
could limit our ability to stop others from using or commercializing similar or identical products or limit the duration of the patent protection for our
current and future product candidates.
Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. Any efforts
to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the
intellectual property we develop or license. Moreover, many countries have compulsory licensing laws under which a patent owner may be compelled to
grant licenses to third parties. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business,
our competitive position may be impaired, and our business and results of operations may be adversely affected.
Furthermore, we cannot predict whether any of our future patent applications will result in the issuance of patents that effectively protect our current and
future product candidates, or if any of our issued patents or if any of our licensor’s issued patents will effectively prevent others from commercializing
competitive products. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation of our intellectual property
rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult. If we are unable to obtain, maintain, and
protect our intellectual property our competitive advantage could be harmed, and it could result in a material adverse effect on our business, financial
condition, and the results of operations and prospects.
Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and our current and future
product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.
Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might
expire before or shortly after such candidates are commercialized. We expect to seek patent term extensions of patent terms in the United States for our
issued patents, licensed patents and any patents we own in the future and, if available, in other countries where that may be available when we are
prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five
years beyond the normal expiration of the patent, which is limited to the approved indication. However, the applicable authorities, including the FDA and
the United States Patent and Trademark Office, or USPTO, in the United States, and any equivalent regulatory authority in other countries, may not agree
with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than
we request. We may not be granted an extension because of, for example, failure to exercise due diligence during the testing phase or regulatory review
process, failure to apply within applicable deadlines, failure to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable
requirements. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may be able to take
advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might
otherwise be the case, which could result in a material adverse effect on our business, financial condition, results of operation and prospects.
The Biologics Price Competition and Innovation Act of 2009, or BPCIA, established legal authority for the FDA to review and approve biosimilar
biologics, including the possible designation of a biosimilar as “interchangeable” based on its similarity to an existing brand product. Under the BPCIA, an
application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. The law
is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to
uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a
material adverse effect on the future commercial prospects for our biological products.
We intend to seek market exclusivity for our biological product candidates that is subject to its own BLA for 12 years in the United States, 10 years in
Europe and other durations in other markets. However, the term of the patents that cover such product candidates may not extend beyond the applicable
market exclusivity awarded by a particular country. For example, in the United States, if all of the patents that cover our particular biologic product expire
before the 12-year market exclusivity expires, a third party could submit a marketing application for a biosimilar product four years after approval of our
biologic product, and the FDA could immediately review the application and approve the biosimilar product for marketing 12 years after approval of our
biologic. Alternatively, a third party could submit a BLA for a similar or identical product any time after approval of our biologic product, and the FDA
could immediately review and approve the similar or identical product for marketing and the third party could begin marketing the similar or identical
product upon expiry of all of the patents that cover our particular biologic product.
Additionally, there is a risk that this exclusivity could be shortened due to congressional action, potentially creating the opportunity for biosimilar
competition sooner than anticipated. The extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way
that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory
factors that are still developing.
41
Table of Contents
If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be
adversely affected.
In addition to seeking patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and confidential and
proprietary information. To maintain the confidentiality of our trade secrets and proprietary information, we enter into confidentiality agreements with our
employees, consultants, collaborators and other third parties who have access to our trade secrets. These agreements require that all confidential
information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept
confidential and not disclosed to third parties. Our agreements with employees also provide that any inventions conceived by the individual in the course of
rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we
have these agreements may not comply with their terms. The assignment of intellectual property rights may not be self-executing, or the assignment
agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the
ownership of what we regard as our intellectual property. In addition, in the event of unauthorized use or disclosure of our trade secrets or proprietary
information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information.
Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. Enforcing a claim that a party illegally
disclosed or misappropriated a trade secret is difficult, expensive, and time consuming, and the outcome is unpredictable. In addition, some courts are less
willing or unwilling to protect trade secrets. The disclosure of our trade secrets or the independent development of our trade secrets by a competitor or other
third party would impair our competitive position and may materially harm our business, financial condition, results of operations and prospects.
Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain
and could harm our business.
Our commercial success depends on our ability and the ability of our current or future licensees or collaborators to develop, manufacture, market and sell
our product candidates, and to use our related proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property
and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other
intellectual property rights. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with
respect to our current and future product candidates. For example, we are aware of third-party patents or patent applications that may be construed to cover
the targets of JTX-8064, vopratelimab, JTX-4014 or JTX-1811. If we are found to infringe a third-party’s intellectual property rights, and we are
unsuccessful in demonstrating that such intellectual property rights are invalid or unenforceable, we could be required to obtain a license from such third
party to continue developing, manufacturing and commercializing our product candidates. However, we may not be able to obtain any required license on
commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third
parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We also could be forced,
including by court order, to cease developing, manufacturing, and commercializing our product candidates. In addition, in any such proceeding or
litigation, we could be found liable for significant monetary damages, including treble damages and attorneys’ fees, if we are found to have willfully
infringed a patent or other intellectual property right. Any of the foregoing could have a material adverse effect on our business, financial condition, results
of operations and prospects.
Furthermore, we are testing JTX-8064, vopratelimab and JTX-4014 and expect to test our future product candidates with other products that are covered by
patents held by other companies or institutions. In the event that a labeling instruction is required in product packaging recommending that combination,
we could be accused of, or held liable for, infringement of the third-party patents covering the product candidate or product recommended for
administration with our product candidates. In such a case, we could be required to obtain a license from the other company or institution to use the
required or desired package labeling, which may not be available on commercially reasonable terms, or at all.
42
Table of Contents
If we breach any of our license agreements or collaboration agreements, it could have a material adverse effect on our commercialization efforts for
our product candidates.
Our commercial success depends on our ability, and at times, the ability of our licensors and current or future licensees and collaborators to develop,
manufacture, market, and sell our product candidates, and use our licensors’ proprietary technologies without infringing the property rights of third parties.
For example, we have entered into an exclusive license agreement with Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer
Center and Memorial Hospital for Cancer and The University of Texas MD Anderson Cancer Center related to certain uses of our vopratelimab, and we
may enter into additional licenses in the future. These and other licenses may not provide exclusive rights to use such intellectual property and technology
in all relevant fields of use and in all territories in which we may wish to develop or commercialize our products in the future. As a result, we may not be
able to prevent competitors from developing and commercializing competitive products in territories included in all our licenses.
In addition, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent
applications covering the technology that we license to or from third parties. For example, under the Gilead License Agreement, Gilead has the first right to
enforce, maintain or defend our intellectual property rights with respect to JTX-1811. In such cases, we cannot be certain that these patents and patent
applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If Gilead
or any other of our licensors or licensees fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications,
the rights we have licensed may be reduced or eliminated and our right to develop and commercialize our product candidates that are the subject of such
licensed rights could be adversely affected. Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third
parties.
Certain of our license agreements also require us to meet development thresholds to maintain the license, including establishing a set timeline for
developing and commercializing products. If we fail to comply with the obligations under our license agreements, including payment and diligence terms,
our licensors may have the right to terminate our agreements. Such an occurrence could materially adversely affect the value of the product candidate being
developed under any such agreement. Termination of our license agreements or reduction or elimination of our rights under them may result in our having
to negotiate a new or reinstated agreement, which may not be available to us on equally favorable terms, or at all.
If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially
acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect
on our business, financial conditions, results of operations and prospects.
Further, the resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant
intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could
have a material adverse effect on our business, financial condition, results of operations and prospects.
We may not be successful in obtaining necessary rights to our product candidates we may develop or obtain through acquisitions and in-licenses.
We currently have rights to intellectual property, through licenses from third parties, for certain uses of vopratelimab. Because our current and future
product candidates may require the use of proprietary rights held by third parties, the growth of our business likely will depend, in part, on our ability to
acquire, in-license or use these proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other
intellectual property rights from third parties that we identify as necessary for our current and future product candidates. The licensing or acquisition of
third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party
intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size,
capital resources and greater clinical development and commercialization capabilities.
If we are unable to successfully obtain required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may
have to abandon or alter our plans for the development or commercialization of the relevant program or product candidate, which could have a material
adverse effect on our business, financial condition, results of operations and prospects.
43
Table of Contents
Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other
requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these
requirements.
The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payments and other
similar provisions during the patent application process and to maintain patents after they are issued. In certain circumstances, we rely on our licensing
partners to take the necessary action to comply with these requirements with respect to our licensed intellectual property. While an unintentional lapse can
be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in
abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we fail to obtain
and maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor from marketing products that
are the same as or similar to our current and future product candidates, which would have a material adverse effect on our business.
Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to
protect our product candidates.
As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and
enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and
inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs.
The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances
or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the
relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our
ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Changes in patent law could increase the
uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have
a material adverse effect on our business, financial condition, results of operations and prospects.
We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and
have a material adverse effect on the success of our business.
Competitors may infringe our licensed patents or any patent we own in the future or misappropriate or otherwise violate our intellectual property rights. We
may also be required to defend against claims of infringement and our licensed patents and any patents we own in the future may become involved in
priority or other intellectual property related disputes. To counter infringement or unauthorized use, litigation may be necessary to enforce or defend our
intellectual property rights or to determine the validity and scope of our own intellectual property rights or the proprietary rights of others. Also, third
parties may initiate legal proceedings against us or our licensors to assert that we are infringing their intellectual property rights or to challenge the validity
or scope of our owned or licensed intellectual property rights. Litigation and other intellectual property related proceedings could result in substantial costs
and diversion of management resources, which could harm our business and financial results. Despite our best efforts, we may not be able to prevent third
parties from infringing upon or misappropriating our intellectual property. In addition, an adverse result in any litigation or other intellectual property
related proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be disclosed during this type of litigation. There could also be public announcements of the results of hearings, motions or
other interim proceedings or developments in any such proceedings. If securities analysts or investors perceive these results to be negative, it also could
have a material adverse effect on the price of shares of our common stock. Any of the foregoing may have a material adverse effect on our business,
financial condition, results of operations and prospects.
We may be subject to claims by third parties asserting that our collaborators, licensors, employees or we have misappropriated their intellectual
property, have wrongfully used or disclosed confidential information of third parties or are in breach of non-competition or non-solicitation
agreements with our competitors.
Many of our employees, our collaborators’ employees and our licensors’ employees, including our senior management, are currently or previously were
employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these
employees, including each member of our senior management, executed proprietary rights, non-disclosure and non-competition agreements, or similar
agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-
how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property of any
44
Table of Contents
such individual’s current or former employer. In addition, we could be subject to claims that we or our employees have inadvertently or otherwise used or
disclosed alleged trade secrets or other confidential information of former employers or competitors, that we caused an employee to breach the terms of his
or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade
secrets or other proprietary information of a former employer or competitor. Litigation may be necessary to defend against such claims. If we fail in
defending any such claims, we may lose valuable intellectual property rights or personnel or sustain monetary damages. Even if we are successful in
defending against such claims, litigation could result in substantial costs and be a distraction to management. Any of the foregoing may have a material
adverse effect on our business, financial condition, results of operations and prospects.
Issued patents covering our current and future product candidates could be found invalid or unenforceable if challenged in court or before the USPTO
or comparable foreign authority.
If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our current or future product
candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. The outcome following legal
assertions of invalidity and unenforceability is unpredictable. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we
would lose at least part, and perhaps all, of the patent protection on our current and future product candidates. Such a loss of patent protection could have a
material adverse impact on our business.
Risks Related to Employee Matters, Managing our Growth and Other Risks Related to our Business
We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may
not be able to successfully implement our business strategy.
Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain
highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, particularly our chief executive officer,
Richard Murray, and our scientific and medical personnel. The loss of the services of any of our executive officers, key employees, and scientific and
medical advisors, and our inability to find suitable replacements, could result in delays in product development and harm our business.
Our Cambridge, Massachusetts headquarters is located in a region that is home to many other biopharmaceutical companies and many academic and
research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly
qualified personnel on acceptable terms or at all. We expect that we will need to recruit talent from outside of our region and doing so may be costly and
difficult.
To induce valuable employees to remain at our Company, in addition to salary and cash incentives, we have provided equity awards that vest over time.
The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control
and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key
employees, these employment agreements provide for at-will employment, meaning that such employees could leave our employment at any time, with or
without notice. We do not maintain “key man” insurance policies on the lives of all of these individuals or the lives of any of our other employees.
We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and
sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.
We currently have no sales, marketing, or distribution capabilities and have no experience in marketing products. If any of our product candidates receives
appropriate regulatory approval, we intend to develop an in-house marketing organization and sales force, which will require significant capital
expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and
retain marketing and sales personnel.
If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the
sales and marketing of our products; however, we cannot assure stockholders that we will be able to establish or maintain such collaborative arrangements,
on favorable terms if at all. We cannot assure stockholders that we will be able to develop in-house sales and distribution capabilities or establish or
maintain relationships with third-party collaborators to commercialize any current or future product candidates.
45
Table of Contents
Our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in misconduct or other improper
activities, including non-compliance with regulatory standards and requirements and insider trading.
We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in fraudulent
conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized
activities to us that violate the regulations of the FDA and comparable foreign regulatory authorities, including those laws requiring the reporting of true,
complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; anti-corruption and
anti-bribery laws, including the Foreign Corrupt Practices Act, and various other anti-corruption laws in countries outside of the United States; or laws that
require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are
subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. We have adopted a
code of conduct applicable to all of our employees, but it is not always possible to identify and deter misconduct, and the precautions we take to detect and
prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or
other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could
allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves
or asserting our rights, those actions could result in significant penalties and could have a material adverse effect on our ability to operate our business and
our results of operations.
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could
have a material adverse effect on the success of our business.
We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use,
storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including
chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the
disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury
resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also
could incur significant costs associated with civil or criminal fines and penalties.
Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from
the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for
environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive
materials.
If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt
or assume contingent liabilities, and subject us to other risks.
We may evaluate various acquisitions and additional strategic partnerships, including licensing or acquiring complementary products, intellectual property
rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:
•
•
•
•
•
•
•
•
increased operating expenses and cash requirements;
the assumption of additional indebtedness or contingent liabilities;
the issuance of our equity securities;
assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new
personnel;
the diversion of our management’s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;
retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;
risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or
product candidates and marketing approvals; and
our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even
to offset the associated acquisition and maintenance costs.
In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire
intangible assets that could result in significant future amortization expense. Moreover, we may not
46
Table of Contents
be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be
important to the development of our business.
Our internal information technology systems, or those used by our CROs or other third parties, may fail or suffer security breaches and cyber-attacks,
which could compromise our intellectual property or other sensitive information, could result in a material disruption of our business or could subject
us to regulatory actions that could result in significant fines.
We, our CROs and other third parties rely significantly upon information technology systems, and despite the implementation of security measures, our
internal information technology systems are vulnerable to damage from computer viruses and unauthorized access. While we have not to our knowledge
experienced any such material system failure or security breach to date, if such an event were to occur, it could result in a material disruption of our
business operations. We, our CROs, contractors and other third parties rely on information technology networks and systems to process, personal
identifying information and payroll data, including operational and financial transactions and records. In particular, we rely on third parties for many
aspects of our business, including manufacturing product candidates and conducting clinical trials. The secure maintenance of this information is critical to
our business and reputation. We believe that companies have been increasingly subject to a wide variety of security incidents, cyber-attacks and other
attempts to gain unauthorized access. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-
sponsored attack. Cyber threats may be generic, or they may be custom-crafted against our information systems. Over the past few years, cyber-attacks
have become more prevalent and much harder to detect and defend against. Additionally, our increased reliance on personnel working from home could
increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could
adversely impact our business operations or delay necessary interactions with regulators, CROs, clinical trial sites or third-party manufacturing and supply
partners.
Our network and storage applications and those of CROs and other third parties may be subject to unauthorized access by hackers or breached due to
operator error, malfeasance or other system disruptions. It is often difficult to anticipate or immediately detect such incidents and the damage caused by
them. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property
and expose sensitive business information. A security breach, cyber-attack or unauthorized access of our clinical data or other data could damage the
integrity of our clinical trials, impact our regulatory filings, cause significant risk to our business, compromise our ability to protect our intellectual
property, and subject us to regulatory actions, including under privacy or security rules under federal, state or other international laws protecting
confidential information, that could be expensive to defend and could result in significant fines or other penalties. Although we maintain a cyber risk
management insurance policy, cyber-attacks could cause us to incur significant remediation costs, disrupt key business operations and divert attention of
management and key information technology resources. Our network security and data recovery measures and those of our CROs, licensees, collaborators,
contractors and vendors may not be adequate to protect against such security breaches and disruptions.
We, or the third parties upon whom we depend, may be adversely affected by unforeseen or catastrophic events, including the emergence of a pandemic
or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
The COVID-19 pandemic has had adverse effects on our business, including difficulty sourcing the components of sample collection kits for our clinical
trials, and may have further adverse effects, the extent or nature of which we are not able to predict at this time. In addition, other unforeseen or
catastrophic events could severely disrupt our operations and our supply chain, and have a material adverse effect on our business. If a natural disaster,
power outage or other event occurred that damaged critical infrastructure, such as our headquarters or the manufacturing facilities of our third-party
contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a
substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or
similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, could have
a material adverse effect on our business.
Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.
Our general business strategy may be adversely affected by any economic downturn, volatile business environment or unpredictable and unstable
conditions in global credit and financial markets. We cannot assure stockholders that deterioration of the global credit and financial markets would not
negatively impact our stock price, our current portfolio of cash equivalents or investments, or our ability to meet our financing objectives. Foreign currency
fluctuations could result in increased operating expenses and other obligations incident to doing business in another country. If the current equity and credit
markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary
financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and
could require us to delay or abandon clinical development plans.
47
Table of Contents
Risks Related to our Common Stock
The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common
stock.
Our stock price is likely to be volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme
volatility that has often been unrelated to the operating performance of particular companies. As a result, we may face difficulties raising capital through
sales of our common stock or such sales may be on unfavorable terms. The market price for our common stock may be influenced by many factors,
including:
•
•
•
•
•
•
•
•
•
•
•
•
•
the success of competitive products or technologies;
results of our clinical trials or those of our competitors;
regulatory or legal developments in the United States and other countries;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment or departure of key personnel;
the level of expenses related to our product candidates or clinical development programs;
the results of our efforts to discover, develop, acquire or in-license additional product candidates or drugs;
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
variations in our financial results or those of companies that are perceived to be similar to us;
changes in the structure of healthcare payment systems;
market conditions in the pharmaceutical and biotechnology sectors;
general economic, industry and market conditions; and
the other factors described in this “Risk Factors” section.
We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.
We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or
paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.
Our executive officers, directors, principal stockholders and their affiliates will continue to exercise control over our company, which will limit your
ability to influence corporate matters and could delay or prevent a change in corporate control.
As of December 31, 2020, our executive officers and directors, combined with our stockholders who owned more than five percent of our outstanding
common stock, and their affiliates, beneficially owned approximately 55 percent of our outstanding common stock. As a result, these stockholders, if they
act together, could be able to control the outcome of matters submitted to our stockholders for approval, including the election of directors and any sale,
merger, consolidation, or sale of all or substantially all of our assets. In addition, this concentration of ownership might adversely affect the market price of
our common stock by:
•
•
•
delaying, deferring or preventing a change of control;
impeding a merger, consolidation, takeover or other business combination; or
discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control.
Our ability to utilize our net operating loss carryforwards and certain other tax attributes has been limited by “ownership changes” and may be further
limited.
Under Section 382 of the Internal Revenue Code of 1986, as amended, or the IRC, if a corporation undergoes an “ownership change” (generally defined as
a greater than 50 percent change (by value) in the ownership of its equity over a three-year period), the corporation’s ability to use its pre-change net
operating loss, or NOL, carryforwards and certain other pre-change tax attributes to offset its post-change income may be limited. An IRC Section 382
study, completed in August 2016, identified three previous ownership changes for purposes of IRC Section 382. No additional ownership changes were
identified in a study completed in May 2020. As a result of these ownership changes, our net operating loss and tax credit carryforwards allocable to
48
Table of Contents
the periods preceding each such ownership change are subject to limitations under IRC Section 382. We may experience ownership changes in the future as
a result subsequent shifts in our stock ownership, some of which are outside our control, which may also be subject to limitations by “ownership changes”
in the future, which could result in increased tax liability to us.
There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or
otherwise become unavailable to offset future income tax liabilities. As described below in “Changes in tax laws or in their implementation or
interpretation may adversely affect our business and financial condition,” the Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security
Act, or CARES Act, includes changes to U.S. federal tax rates and the rules governing NOL carryforwards that may significantly impact our ability to
utilize our NOLs to offset taxable income in the future. In addition, state NOLs generated in one state cannot be used to offset income generated in another
state. For these reasons, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes.
Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.
Changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the U.S. government enacted the Tax Act, which
significantly reformed the IRC. The Tax Act, among other things, contained significant changes to corporate taxation, including a reduction of the
corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted
taxable income (except for certain small businesses), the limitation of the deduction for NOLs arising in taxable years beginning after December 31, 2017
to 80% of current year taxable income and elimination of net operating loss carrybacks for losses arising in taxable years ending after December 31, 2017
(though any such NOLs may be carried forward indefinitely), the imposition of a one-time taxation of offshore earnings at reduced rates regardless of
whether they are repatriated, the elimination of U.S. tax on foreign earnings (subject to certain important exceptions), the allowance of immediate
deductions for certain new investments instead of deductions for depreciation expense over time, and the modification or repeal of many business
deductions and credits.
As part of Congress’s response to the COVID-19 pandemic, the Families First Coronavirus Response Act, or FFCR Act, was enacted on March 18, 2020,
and the CARES Act was enacted on March 27, 2020. Both contain numerous tax provisions. In particular, the CARES Act retroactively and temporarily
(for taxable years beginning before January 1, 2021) suspends application of the 80%-of-income limitation on the use of NOLs, which was enacted as part
of the Tax Act. It also provides that NOLs arising in any taxable year beginning after December 31, 2017, and before January 1, 2021 are generally eligible
to be carried back up to five years. The CARES Act also temporarily (for taxable years beginning in 2019 or 2020) relaxes the limitation of the tax
deductibility for net interest expense by increasing the limitation from 30% to 50% of adjusted taxable income.
Regulatory guidance under the Tax Act, the FFCR Act and the CARES Act is and continues to be forthcoming, and such guidance could ultimately
increase or lessen impact of these laws on our business and financial condition. Congress is also considering and may enact further tax law changes in
connection with the COVID-19 pandemic, some of which could have an impact on our company. In addition, state tax legislation or administrative
guidance conforming to or decoupling from particular provisions of the Tax Act, the FFCR Act and the CARES Act could affect our business or financial
condition.
We are incurring and will continue to incur significantly increased costs as a result of operating as a public company, and our management is required
to devote substantial time to compliance initiatives.
As a public company, we are incurring and will continue to incur significant legal, accounting and other expenses, particularly after we are no longer an
emerging growth company. We are subject to the reporting requirements of the Exchange Act, as well as various requirements imposed by the Sarbanes-
Oxley Act, rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, and the Dodd-Frank Wall Street
Reform and Consumer Protection Act. Stockholder activism, the current political environment and the current high level of government intervention and
regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the
manner in which we operate our business in ways we cannot currently anticipate.
Our management and other personnel will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules
and regulations will increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, we expect
these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to
incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to
respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on
our board of directors, our board committees or as executive officers.
49
Table of Contents
Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
Certain stockholders hold a substantial number of shares of our common stock. If such stockholders sell, or indicate an intention to sell, substantial
amounts of our common stock in the public market, the trading price of our common stock could decline.
In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our stock incentive plans will
become eligible for sale in the public market extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the
Securities Act of 1933, as amended, or the Securities Act, and, in any event, we have filed a registration statement permitting shares of common stock
issued on exercise of options to be freely sold in the public market. If these additional shares of common stock are sold, or if it is perceived that they will be
sold, in the public market, the trading price of our common stock could decline.
Certain holders of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these
shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by
affiliates. Any sales of securities by these stockholders who have exercised registration rights could have a material adverse effect on the trading price of
our common stock.
Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to
fall below expectations or our guidance.
Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. From time to
time, we may enter into license or collaboration agreements with other companies that include development funding and significant upfront and milestone
payments and/or royalties, which may become an important source of our revenue. Accordingly, our revenue may depend on development funding and the
achievement of development and clinical milestones under current and any potential future license and collaboration agreements and sales of our products,
if approved. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant
fluctuation in our operating results from one period to the next.
Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict,
including the following:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
the timing and cost of, and level of investment in, research and development activities relating to our current and future product candidates, which
will change from time to time;
our ability to enroll patients in clinical trials and the timing of enrollment;
the cost of manufacturing our current and future product candidates, which may vary depending on FDA guidelines and requirements, the quantity
of production and the terms of our agreements with manufacturers;
expenditures that we will or may incur to acquire or develop additional product candidates and technologies;
the timing and outcomes of clinical trials for our current product candidates or competing product candidates;
competition from existing and future products that may compete with our current and future product candidates, and changes in the competitive
landscape of our industry, including consolidation among our competitors or partners;
any delays in regulatory review or approval of any of our current or future product candidates;
the level of demand for our current and future product candidates, if approved, which may fluctuate significantly and be difficult to predict;
our ability to commercialize our current and future product candidates, if approved;
the success of our exclusive license to Gilead and our ability to establish and maintain other collaborations, licensing or other arrangements;
our ability to adequately support future growth;
potential unforeseen business disruptions that increase our costs or expenses;
future accounting pronouncements or changes in our accounting policies;
the impact of the COVID-19 pandemic, including precautions to mitigate the spread of COVID-19; and
the changing and volatile global economic environment.
50
Table of Contents
The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result,
comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our
future performance. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the
market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline
substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue and/or earnings guidance we may
provide.
Moreover, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is
especially relevant for us as pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could
result in substantial costs and a diversion of management’s attention and resources.
If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock
could decline.
The trading market for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our business.
If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these
analysts cease to cover our stock, we could lose visibility in the market for our stock, which, in turn, could cause our stock price to decline.
Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our
stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us or a change
in our management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders and the ability
of our board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by
the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15 percent of our
outstanding voting stock to merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value
for stockholders by requiring potential acquirors to negotiate with our board of directors, they would apply even if an offer rejected by our board were
considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove
our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the
members of our management.
Our bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that
may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our
directors, officers or employees.
Our bylaws, provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and
exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by
any of our directors, officers and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware
General Corporation Law, our certificate of incorporation or our bylaws, or (iv) any action asserting a claim that is governed by the internal affairs doctrine,
in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. Any person
purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision
of our bylaws.
This exclusive forum provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended,
which provides for exclusive jurisdiction of the federal courts. It could apply, however, to a suit that falls within one or more of the categories enumerated
in the exclusive forum provision and asserts claims under the Securities Act of 1933, as amended, or the Securities Act, inasmuch as Section 22 of the
Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act
or the rules and regulations thereunder, provided, that with respect to claims under the Securities Act, our stockholders will not be deemed to have waived
our compliance with the federal securities laws and the rules and regulations thereunder.
This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our
directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if
successful, might benefit our stockholders. Stockholders who do bring a claim
51
Table of Contents
in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of Delaware.
The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action
may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders.
Alternatively, if a court were to find this provision of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of,
one or more of the specified types of actions or proceedings, we may incur additional costs, which could have a material adverse effect on our business,
financial condition or results of operations.
Item 1B. Unresolved Staff Comments
Not applicable.
Item 2. Properties
We lease a facility containing our research and development, laboratory and office space, which consists of approximately 51,000 square feet located at
780 Memorial Drive, Cambridge, Massachusetts. Our lease expires on March 31, 2025. This facility is our corporate headquarters. We believe that our
facilities are sufficient to meet our current needs.
Item 3. Legal Proceedings
We are not currently a party to any material legal proceedings.
Item 4. Mine Safety Disclosures
Not applicable.
52
Table of Contents
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information and Holders
Our common stock trades on the Nasdaq Global Select Market under the symbol “JNCE”. As of February 19, 2021, we had approximately 17 holders of
record of our common stock. This number does not include beneficial owners whose shares were held by nominees in street name.
Dividend Policy
We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings, if any, to fund
the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to
pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of
operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors.
Investors should not purchase our common stock with the expectation of receiving cash dividends.
Recent Sales of Unregistered Securities
None.
Purchase of Equity Securities
We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form 10‑K.
Item 6. Selected Financial Data
Not applicable.
53
Table of Contents
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial
statements and related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical information, this discussion and analysis
contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in
these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and
elsewhere in this Annual Report on Form 10-K, including those factors set forth in the section entitled “Cautionary Note Regarding Forward-Looking
Statements and Industry Data” and in the section entitled “Risk Factors” in Part I, Item 1A.
Overview
We are a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system
to attack tumors and provide long-lasting benefits to patients. Our strategy is to use a biomarker-driven approach from discovery through clinical
development. We have developed a suite of integrated technologies that comprise our Translational Science Platform, enabling us to comprehensively
interrogate the cellular and molecular composition of tumors. By focusing on specific cell types, both immune and non-immune, within tumors, we can
prioritize targets and then identify related biomarkers designed to match the right therapy to the right patient. Our pipeline is focused on product candidates
to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors, which represent significant opportunities requiring different biological
approaches. We aim to develop product candidates that address the unmet medical need of patients in both of these populations.
Our highest priority program, JTX-8064, is being developed for patients with either PD-(L)1-inhibitor resistant or PD-(L)1 inhibitor sensitive tumors. JTX-
8064 is the first tumor-associated macrophage candidate to emerge from our Translational Science Platform. JTX-8064 is an antibody that binds to
Leukocyte Immunoglobulin Like Receptor B2, or LILRB2 (also known as ILT4), which is a cell surface receptor expressed on macrophages. In January
2021, we began enrollment in the INNATE trial, our Phase 1 dose-escalation clinical trial of JTX-8064 as a monotherapy and in combination with either
our PD-1 inhibitor, JTX-4014, or pembrolizumab in patients with advanced solid tumors. Our goal is to advance this program rapidly, and, as a result,
INNATE is a proof-of-concept trial that includes indication-specific expansion cohorts.
Vopratelimab is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, or ICOS, a protein on the surface of
certain T cells commonly found in many solid tumors. We are currently enrolling patients in the SELECT trial, which is evaluating vopratelimab in
combination with JTX-4014, our anti-PD-1 antibody, compared to JTX-4014 alone in biomarker-selected, immunotherapy-naive second-line non-small cell
lung cancer, or NSCLC, patients. We identify patients for SELECT using TIS
, an 18 gene signature that includes genes relevant to both CD8 and CD4
T cell biology. TIS
has been optimized to predict for emergence of ICOS hi CD4 T cells in the peripheral blood, which have been associated with
clinical benefit in patients treated with vopratelimab alone or in combination with nivolumab. SELECT is a randomized Phase 2 clinical trial outside the
United States, and we dosed the first patient in October 2020. Due to COVID-19-related delays, we now expect to report clinical data from SELECT in
2022.
vopra
vopra
JTX-4014 is a clinical-stage anti-PD-1 antibody that we are developing primarily for potential use in combination with our product candidates, as we
believe that combination therapy has the potential to be a mainstay of cancer immunotherapy. We presented safety and preliminary efficacy data from a
Phase 1 clinical trial of JTX-4014 monotherapy in 2019. Based on the results of that clinical trial, we are using JTX-4014 in combination with
vopratelimab in SELECT, and we plan to use JTX-4014 in combination with JTX-8064 in INNATE.
Beyond our product candidates, we continue to advance and build our discovery pipeline. We are discovering and developing next-generation
immunotherapies by leveraging our Translational Science Platform to systematically and comprehensively interrogate cell types within the tumor
microenvironment. Our broad discovery pipeline includes multiple programs targeting myeloid cells such as macrophages, T regulatory cells and non-
immune cells, such as stromal cells. We believe that the use of our Translational Science Platform to efficiently identify novel immuno-oncology targets
and advance them from discovery to investigational new drug application, or IND, stage is a sustainable approach that we plan to continually apply across
our broad discovery pipeline and target selection process.
In August 2020, we entered into an agreement to exclusively license JTX-1811 to Gilead Sciences, Inc., or Gilead. JTX-1811 is the most recent product
candidate to emerge from our Translational Science Platform, and, is a monoclonal antibody that is designed to selectively deplete T regulatory cells in the
tumor microenvironment, or TME, by targeting a receptor called CCR8, which is preferentially expressed on intra-tumoral T regulatory cells. Pursuant to
our exclusive license agreement with Gilead, or the Gilead License Agreement, we granted Gilead a worldwide license to develop, manufacture and
commercialize JTX-1811 and certain derivatives thereof, as well as backup antibodies defined within the agreement. Concurrently with the license
agreement, we entered into a stock purchase agreement with Gilead, or the Stock Purchase Agreement, and a registration rights agreement.
54
Table of Contents
Under the terms of the Gilead License Agreement and Stock Purchase Agreement, Gilead paid us a one-time, non-refundable upfront payment of
$85.0 million and $35.0 million to purchase 5,539,727 shares of our common stock pursuant to the Stock Purchase Agreement. Under the terms of the
Gilead License Agreement, we will advance JTX-1811 until the clearance of an IND application or an earlier date specified by Gilead, at which time the
program will be transitioned to Gilead. We are entitled to receive payments from Gilead upon the achievement of specified clinical, regulatory and sales
milestones, including potential clinical development and regulatory milestone payments up to an aggregate total of $510.0 million and potential sales
milestone payments up to an aggregate total of $175.0 million. We are also eligible to receive tiered royalty payments based on a percentage of annual
worldwide net sales ranging from the high-single digits to mid-teens, based on future annual net sales of licensed products, on a licensed product-by-
licensed product and country-by-country basis.
On July 22, 2019, we entered into an exclusive license agreement with Celgene, or the Celgene License Agreement, granting Celgene a worldwide and
exclusive license to develop, manufacture and commercialize JTX-8064 and certain derivatives thereof, as well as any antibody or other biologic controlled
by us that is specifically directed to the LILRB2 receptor. Under the terms of the Celgene License Agreement, Celgene paid us a one-time, non-refundable
upfront payment of $50.0 million.
Celgene was subsequently acquired by Bristol Myers Squibb, or BMS, in November 2019 and the Celgene License Agreement was terminated effective
June 3, 2020. We now have sole worldwide rights to JTX-8064, and all of our intellectual property rights pertaining to JTX-8064 and licensed to Celgene
were reacquired by us.
In July 2016, we entered into a Master Research and Collaboration Agreement, or the Celgene Collaboration Agreement, and a Series B-1 Preferred Stock
Purchase Agreement with Celgene. Under the terms of these agreements, we received a $225.0 million upfront cash payment and $36.1 million from the
sale of 10,448,100 shares of our Series B-1 convertible preferred stock, which shares converted into 2,831,463 shares of common stock upon the
completion of our initial public offering, or IPO, in 2017. We terminated the Celgene Collaboration Agreement concurrently with entry into the Celgene
License Agreement.
Since inception, our operations have focused on organizing and staffing our company, business planning, raising capital, developing our Translational
Science Platform and conducting research, preclinical studies and clinical trials. We do not have any products approved for sale. We are subject to a number
of risks comparable to those of other similar companies, including dependence on key individuals; the need to develop commercially viable products;
competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the
development of our products. We have funded our operations primarily through proceeds received from public offerings and private placements of our
stock totaling $298.5 million and up-front payments from our Celgene and Gilead collaboration and license agreements totaling $360.0 million.
Due to our significant research and development expenditures, we have accumulated substantial losses since our inception. As of December 31, 2020, we
had an accumulated deficit of $151.0 million. We expect to incur substantial additional losses in the future as we expand our research and development
activities.
The spread of COVID-19 during 2020 has caused an economic downturn on a global scale. As of February 25, 2021, we have not experienced a significant
financial impact directly related to the COVID-19 pandemic but have experienced some disruptions to clinical operations and to our supply chain. As the
pandemic continues to unfold, the extent of its effect on our operational and financial performance will depend in large part on future developments, which
cannot be predicted with confidence at this time.
Financial Operations Overview
Revenue
For the year ended December 31, 2020, we recognized $62.3 million of license revenue under the Gilead License Agreement entered into in October 2020.
For the year ended December 31, 2019, we recognized $147.9 million of license and collaboration revenue, which was comprised of $50.0 million of
license revenue under the Celgene License Agreement and $97.9 million of collaboration revenue under the Celgene Collaboration Agreement. The
Celgene Collaboration Agreement was terminated effective July 22, 2019, at which time all remaining deferred revenue was recognized as we had no
further performance obligations.
In the future, we may generate revenue from product sales or collaboration agreements, strategic alliances and licensing arrangements, including potential
milestone payments and royalties under the Gilead License Agreement. We expect that our revenue will fluctuate from quarter-to-quarter and year-to-year
as a result of the timing and amount of license fees, milestones, reimbursement of costs incurred and other payments, if any, and product sales, to the extent
any products are successfully commercialized. If we or third parties fail to complete the development of our product candidates in a timely manner or
obtain
55
Table of Contents
regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely
affected.
Operating Expenses
Research and Development Expenses
Research and development expenses represent costs incurred by us for the discovery, development and manufacture of our current and future product
candidates and include: external research and development expenses incurred under arrangements with third parties, including contract research
organizations, contract manufacturing organizations, academic and non-profit institutions and consultants; salaries and personnel-related costs, including
non-cash stock-based compensation expense; license fees to acquire in-process technology and other expenses, which include direct and allocated expenses
for laboratory, facilities and other costs.
We use our employee and infrastructure resources across multiple research and development programs directed toward developing our Translational
Science Platform and for identifying, testing and developing product candidates. We manage certain activities such as contract research and manufacture of
our product candidates and discovery programs through our third-party vendors.
At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the
development of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales of our product
candidates. This is due to the numerous risks and uncertainties associated with developing such product candidates, including the uncertainty of:
•
•
•
•
•
•
•
•
•
•
•
•
addition and retention of key research and development personnel;
establishing an appropriate safety profile with IND-enabling toxicology studies;
the cost to acquire or make therapies to study in combination with our immunotherapies;
successful enrollment in and completion of clinical trials, including the impacts of the COVID-19 pandemic on the timing and progress of our
ongoing and planned clinical trials;
establishing agreements with third-party contract manufacturing organizations for clinical supply for our clinical trials and commercial
manufacturing, if our product candidates are approved;
receipt of marketing approvals from applicable regulatory authorities;
commercializing products, if and when approved, whether alone or in collaboration with others;
the cost to develop companion diagnostics and/or complementary diagnostics as needed for each of our development programs;
the costs associated with the development of any additional product candidates we acquire through third-party collaborations or identify through
our Translational Science Platform;
the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder;
obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our products, if and when approved; and
continued acceptable safety profiles of the products following approval.
A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs,
timing and viability associated with the development of that product candidate. We plan to increase our research and development expenses for the
foreseeable future as we advance our product candidates through clinical trials and continue the enhancement of our Translational Science Platform and the
progression of our pipeline.
Due to the inherently unpredictable nature of preclinical and clinical development, we do not allocate all of our internal research and development expenses
on a program-by-program basis as they primarily relate to personnel and lab consumables costs that are deployed across multiple programs under
development. Our research and development expenses also include external costs, which we do track on a program-by-program basis following the
program’s nomination as a development candidate. We began incurring such external costs for vopratelimab in 2015, JTX-4014 in 2016, JTX-8064 in 2017
and JTX-1811 in 2019.
56
Table of Contents
Included below are external research and development and external clinical and regulatory costs for vopratelimab, JTX-4014, JTX-1811, JTX-8064, and
our pre-development candidates:
(in thousands)
Vopratelimab
Vopratelimab / JTX-4014 combination
JTX-4014
JTX-1811
JTX-8064
Pre-development candidates
Total external research and development and clinical and regulatory costs
Year Ended December 31,
2020
2019
$
$
13,613 $
10,504
2,866
7,007
1,674
1,328
36,992 $
16,778
—
2,785
138
5,225
950
25,876
Research and development activities account for a significant portion of our operating expenses. As we continue to implement our business strategy, we
expect our research and development expenses to increase over the next several years. We expect that these expenses will increase as we:
•
•
•
•
•
continue our clinical development of JTX-8064, including our Phase 1 INNATE clinical trial of JTX-8064 as a monotherapy and in combination
with either JTX-4014 or pembrolizumab;
continue our clinical development of vopratelimab, including our Phase 2 SELECT clinical trial of vopratelimab and JTX-4014;
complete preclinical, IND-enabling and other development activities for JTX-1811 and transition the program to Gilead in accordance with the
terms of the Gilead License Agreement;
continue to identify and develop potential predictive biomarkers and companion diagnostics and/or complementary diagnostics for our product
candidates; and
continue to develop and enhance our Translational Science Platform and advance our pipeline of immunotherapy programs and our early research
activities into IND-enabling activities.
Product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development,
primarily due to the increased size and duration of later-stage clinical trials.
General and Administrative Expenses
General and administrative expenses consist of salaries and personnel-related costs, including non-cash stock-based compensation expense, for our
personnel in executive, business development, legal, finance and accounting, human resources and other administrative functions, consulting fees, facility
costs not otherwise included in research and development expenses, fees paid for accounting and tax services, insurance expenses and legal costs. Legal
costs include general corporate legal fees, patent legal fees and related costs. We anticipate that our general and administrative expenses will increase in the
future to support our continued operations.
Other Income, Net
Other income, net, consists primarily of interest and investment income on our cash, cash equivalents and investments.
Critical Accounting Policies and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which
have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these consolidated financial
statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an
ongoing basis, our management evaluates our estimates which include, but are not limited to, estimates related to revenue recognized under the Gilead
License Agreement and Celgene Collaboration Agreement (including estimates of internal and external costs expected to be incurred to satisfy performance
obligations), accrued expenses, stock-based compensation expense and income taxes. In addition, in 2019, we made estimates to determine the discount
rate utilized in the initial application of Accounting Standards Codification, or ASC, Topic 842, Leases, or ASC 842. We base our estimates on historical
experience and other market specific or other relevant assumptions we believe to be reasonable under the circumstances. Actual results could differ from
those estimates.
While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this
Annual Report on Form 10-K, we believe the following accounting policies to be most critical to the judgments and estimates used in the preparation of our
consolidated financial statements.
57
Table of Contents
Revenue Recognition
We recognize revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, or ASC 606. Under ASC 606, an entity recognizes
revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in
exchange for those goods or services. In applying ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify
the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance
obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations. We only apply the five-step model to contracts
when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services we transfer to the customer. At
contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract,
determine those that are performance obligations and assess whether each promised good or service is distinct. We then recognize as revenue the amount of
the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. We do not assess
whether a contract has a significant financing component if the expectation at contract inception is that the period between payment by the customer and
the transfer of promised goods or services to the customer will be one year or less.
The terms of our license agreements include upfront and license fees, milestones and other contingent payments for the achievement of defined certain
clinical, regulatory and sales-based milestone events, as well as royalties on sales of commercialized products. Arrangements that include upfront payments
may require deferral of revenue recognition to a future period until obligations under such arrangements are fulfilled. The event-based milestone payments
represent variable consideration, and we use the “most likely amount” method to estimate this variable consideration. Given the high degree of uncertainty
around the occurrence of these events, we determined the milestone and other contingent amounts to be fully constrained until the uncertainty associated
with these payments is resolved. Revenue will be recognized from sales-based royalty payments when or as the sales occur. We will re-evaluate the
transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur. See Note 3 to our consolidated
financial statements included within Part IV, Item 15 of this Annual Report on Form 10-K for further information on the application of ASC 606 to the
Celgene Collaboration Agreement, the Celgene License Agreement and the Gilead License Agreement.
Accrued Research and Development Expenses
As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses as of
each balance sheet date. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended
in each period. This process involves reviewing open contracts and purchase orders, communicating with internal personnel to identify services that have
been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been
invoiced or otherwise notified of the actual cost. We periodically confirm the accuracy of our estimates with our service providers and make adjustments if
necessary. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. The financial
terms of agreements with these service providers are subject to negotiation, vary from contract-to-contract and may result in uneven payment flows. In
circumstances where amounts have been paid in excess of costs incurred, we record a prepaid expense.
Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services
performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any
particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.
Stock-based Compensation
We account for stock-based payments in accordance with ASC Topic 718, Compensation—Stock Compensation. This guidance requires all stock-based
payments to employees, including grants of employee stock options, restricted stock awards and restricted stock units, to be recognized as expense in the
consolidated statements of operations and comprehensive income (loss) based on their grant date fair values. For stock options granted to employees and to
members of our board of directors for their services on the board of directors, we estimate the grant date fair value of each stock option using the Black-
Scholes option-pricing model. For restricted stock awards and restricted stock units granted to employees, we estimate the grant date fair value of each
award using intrinsic value, which is based on the value of the underlying common stock less any purchase price. For stock-based payments subject to
service-based vesting conditions, we recognize stock-based compensation expense equal to the grant date fair value of stock-based payment on a straight-
line basis over the requisite service period.
The Black‑Scholes option pricing model requires the input of certain subjective assumptions, including (i) the calculation of expected term of the stock-
based payment, (ii) the risk‑free interest rate, (iii) the expected stock price volatility and (iv) the expected dividend yield. We use the simplified method as
prescribed by SEC Staff Accounting Bulletin No. 107 to calculate the
58
Table of Contents
expected term for stock options granted to employees as we do not have sufficient historical exercise data to provide a reasonable basis upon which to
estimate the expected term. We determine the risk‑free interest rate based on a treasury instrument whose term is consistent with the expected term of the
stock options. Because there had been no public market for our common stock prior to our IPO, there is a lack of historical and implied volatility data.
Accordingly, we base our estimates of expected volatility on the historical volatility of a group of publicly-traded companies with similar characteristics to
us, including stage of product development and therapeutic focus within the life sciences industry. Historical volatility is calculated over a period of time
commensurate with the expected term of the stock-based payment. We use an assumed dividend yield of zero as we have never paid dividends on our
common stock, nor do we expect to pay dividends on our common stock in the foreseeable future.
We account for forfeitures of all stock-based payments when such forfeitures occur.
Income Taxes
Income taxes are recorded in accordance with ASC Topic 740, Income Taxes, which provides for deferred taxes using an asset and liability approach. We
recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial
statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets
and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance against deferred tax
assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
We account for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of
uncertain tax positions is based on factors, including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken
in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position.
Recent Accounting Pronouncements
See Note 2 to our consolidated financial statements included within Part IV, Item 15 of this Annual Report on Form 10-K for a description of recent
accounting pronouncements applicable to our business.
Results of Operations
Comparison of the Years Ended December 31, 2020 and 2019
The following table summarizes our results of operations for the years ended December 31, 2020 and 2019:
(in thousands)
Revenue:
License and collaboration revenue—related party
Operating expenses:
Research and development
General and administrative
Total operating expenses
Operating (loss) income
Other income, net
(Loss) income before provision for income taxes
Provision for income taxes
Net (loss) income
License and Collaboration Revenue
Year Ended December 31,
2020
2019
$ Change
62,339 $
147,872 $
(85,533)
78,690
28,766
107,456
(45,117)
1,289
(43,828)
14
(43,842) $
67,135
27,920
95,055
52,817
4,052
56,869
46
56,823 $
11,555
846
12,401
(97,934)
(2,763)
(100,697)
(32)
(100,665)
$
$
For the year ended December 31, 2020, we recognized $62.3 million of license revenue under the Gilead License Agreement entered into in October 2020.
For the year ended December 31, 2019, we recognized $147.9 million of license and collaboration revenue, which was comprised of $50.0 million of
license revenue under the Celgene License Agreement and $97.9 million of collaboration revenue under the Celgene Collaboration Agreement. The
Celgene Collaboration Agreement was terminated effective July 22, 2019, at which time all remaining deferred revenue was recognized as we had no
further performance obligations.
59
Table of Contents
Research and Development Expenses
The following table summarizes our research and development expenses for the years ended December 31, 2020 and 2019:
(in thousands)
Employee compensation
External clinical and regulatory
External research and development
Lab consumables
Facility costs
Research consulting
Other research
Total research and development expenses
Year Ended December 31,
2020
2019
$ Change
$
$
27,880 $
25,340
11,652
6,042
5,522
505
1,749
78,690 $
25,002 $
17,414
8,462
6,841
5,813
917
2,686
67,135 $
2,878
7,926
3,190
(799)
(291)
(412)
(937)
11,555
Research and development expenses increased by $11.6 million from $67.1 million for the year ended December 31, 2019 to $78.7 million for the year
ended December 31, 2020. The increase in research and development expenses was primarily attributable to:
•
•
•
•
•
$7.9 million of increased external clinical and regulatory costs primarily attributable to our SELECT clinical trial which commenced in 2020;
$3.2 million of increased external research and development costs primarily attributable to IND-enabling expenses related to JTX-1811, partially
offset by reduced expenses related to JTX-8064 incurred during the year ended December 31, 2020;
$2.9 million of increased employee compensation costs primarily attributable to increased headcount, merit and bonus expense;
partially offset by $0.9 million of decreased other research costs primarily attributable to reduced travel expenses resulting from COVID-19 travel
limitations; and
$0.8 million of decreased lab consumables costs.
General and Administrative Expenses
The following table summarizes our general and administrative expenses for the years ended December 31, 2020 and 2019:
(in thousands)
Employee compensation
Professional services
Facility costs
Other
Total general and administrative expenses
Year Ended December 31,
2020
2019
$ Change
$
$
15,137 $
4,927
4,332
4,370
28,766 $
13,606 $
5,134
4,580
4,600
27,920 $
1,531
(207)
(248)
(230)
846
General and administrative expenses increased by $0.8 million from $27.9 million for the year ended December 31, 2019 to $28.8 million for the year
ended December 31, 2020. The increase in general and administrative expenses was primarily attributable to $1.5 million of increased employee
compensation costs related to increased merit and bonus expense for the year ended December 31, 2020.
Other Income, net
Other income, net, decreased by $2.8 million from $4.1 million for the year ended December 31, 2019 to $1.3 million for the year ended December 31,
2020. The decrease in other income, net is attributable to reduced interest rates due to current market conditions.
60
Table of Contents
Liquidity and Capital Resources
Sources of Liquidity
We have funded our operations primarily through proceeds received from public offerings and private placements of our stock totaling $298.5 million and
up-front payments from our Celgene and Gilead collaboration and license agreements totaling $360.0 million. As of December 31, 2020, we had cash, cash
equivalents and investments of $213.2 million.
On December 17, 2019, we entered into a Sales Agreement with Cowen and Company, LLC, or Cowen, pursuant to which we offered and sold shares of
our common stock with an aggregate offering price of up to $50.0 million under the ATM Offering. The Sales Agreement provides that Cowen will be
entitled to a sales commission equal to 3.0% of the gross sales price per share of all shares sold under the ATM Offering. As of December 31, 2020, we had
sold an aggregate of 2,522,121 shares under the ATM Offering at an average price of $7.47 per share for net proceeds of $18.0 million after deducting sales
commissions and offering expenses, of which $14.5 million was received during the year ended December 31, 2020.
In January 2021, we sold an aggregate of 3,156,200 shares at an average price of $9.87 per share for net proceeds of $30.2 million. Consequently, we have
completed the sale of all available amounts under the ATM Offering, of which three investors account for $43.1 million of all funds raised (see Note 16 to
our consolidated financial statements included within Part IV, Item 15 of this Annual Report on Form 10-K).
Funding Requirements
Our plan of operation is to continue implementing our business strategy, the research and development of our current product candidates, our preclinical
development activities, the expansion of our research pipeline and the enhancement of our internal research and development capabilities. Due to the
inherently unpredictable nature of preclinical and clinical development and given the early stage of our programs and product candidates, we cannot
reasonably estimate the costs we will incur and the timelines that will be required to complete development, obtain marketing approval, and commercialize
our products, if and when approved. For the same reasons, we are also unable to predict when, if ever, we will generate revenue from product sales or
whether, or when, if ever, we may achieve profitability. Clinical and preclinical development timelines, the probability of success, and development costs
can differ materially from expectations. In addition, we cannot forecast which products, if and when approved, may be subject to future collaborations,
when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.
Due to our significant research and development expenditures, we have generated substantial operating losses since inception. We have incurred an
accumulated deficit of $151.0 million through December 31, 2020. We expect to incur substantial additional losses in the future as we expand our research
and development activities and continue to advance our programs. Based on our research and development plans, we expect that our existing cash, cash
equivalents and investments of $213.2 million will enable us to fund our operating expenses and capital expenditure requirements through the second
quarter of 2023. However, we have based this estimate on assumptions that may prove to be incorrect, and we could exhaust our capital resources sooner
than we expect. The timing and amount of our operating expenditures will depend largely on:
•
•
•
•
•
•
•
•
•
the timing and progress of preclinical and clinical development activities, including the impacts of the COVID-19 pandemic on the timing and
progress of our ongoing and planned clinical trials;
the cost to access, acquire or develop therapies to study in combination with our immunotherapies;
successful enrollment in and completion of clinical trials;
the cost to develop companion diagnostics and/or complementary diagnostics as needed for each of our development programs;
our ability to establish agreements with third-party manufacturers for clinical supply for our clinical trials and, if any of our product candidates are
approved, commercial manufacturing;
the costs associated with the development of any additional product candidates we acquire through acquisition or third-party collaborations or
identify through our Translational Science Platform;
our ability to maintain our current research and development programs and enhancement of our Translational Science Platform;
addition and retention of key research and development personnel;
our efforts to enhance operational, financial and information management systems, and hire additional personnel, including personnel to support
development of our product candidates;
61
Table of Contents
•
•
•
•
the legal patent costs involved in prosecuting patent applications and enforcing patent claims and other intellectual property claims;
the costs and ongoing investments to in-license or acquire additional technologies, including the in-license of intellectual property related to our
potential product candidates;
the progress and success of our exclusive license of JTX-1811 to Gilead; and
the terms and timing of any other collaboration, license or other arrangement, including the terms and timing of any option and milestone
payments thereunder.
A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the
costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need
additional funds to meet operational needs and capital requirements associated with such operating plans.
In addition to the variables described above, if and when any of our product candidates successfully complete development, we expect to incur substantial
additional costs associated with regulatory filings, marketing approval, post-marketing requirements, maintaining our intellectual property rights, and
regulatory protection, in addition to other costs. We cannot reasonably estimate these costs at this time.
Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt
financings, collaborations, licensing arrangements and strategic alliances. We currently do not have a credit facility or committed sources of capital. To the
extent that we raise additional capital through the future sale of equity or debt, the ownership interests of our stockholders will be diluted, and the terms of
these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional
funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. We may require additional capital
beyond our currently anticipated amounts. Additional capital may not be available on reasonable terms, or at all. If we raise additional funds through
collaboration arrangements in the future, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or
grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may
be required to delay, limit, reduce, or terminate development or future commercialization efforts, or grant rights to develop and market product candidates
that we would otherwise prefer to develop and market ourselves.
Cash Flows
The following table provides information regarding our cash flows for the years ended December 31, 2020 and 2019:
(in thousands)
Net cash (used in) provided by:
Operating activities
Investing activities
Financing activities
Net increase in cash, cash equivalents and restricted cash
Cash Used in Operating Activities
Year Ended December 31,
2020
2019
$
$
(27,788) $
51,298
70,742
94,252 $
(30,129)
31,382
4,082
5,335
Net cash used in operating activities for the year ended December 31, 2020 was $27.8 million, compared to net cash used in operating activities of $30.1
million for the year ended December 31, 2019. Cash used in operating activities decreased by $2.3 million primarily due to $62.3 million in revenue
recognized under the Gilead License Agreement in 2020, partially offset by $50.0 million in revenue recognized under the Celgene License Agreement
during 2019 and increased operating expenses during the year ended December 31, 2020.
Cash Provided by Investing Activities
Net cash provided by investing activities for the year ended December 31, 2020 was $51.3 million, compared to net cash provided by investing activities of
$31.4 million for the year ended December 31, 2019. Cash provided by investing activities increased by $19.9 million as cash was reinvested into cash
equivalents, as opposed to other short-term and long-term investments, due to current market conditions during the year ended December 31, 2020.
Proceeds received from maturities and sales of investments were either re-invested or used to fund operations.
62
Table of Contents
Cash Provided by Financing Activities
Net cash provided by financing activities for the year ended December 31, 2020 was $70.7 million, compared to net cash provided by financing activities
of $4.1 million for the year ended December 31, 2019. Cash provided by financing activities increased by $66.7 million due to Gilead’s equity investment
of $55.7 million, at fair value at the closing, and the receipt of $14.5 million of net proceeds from our ATM Offering during the year ended December 31,
2020.
Off-Balance Sheet Arrangements
We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.
Item 7A. Quantitative and Qualitative Disclosures about Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.
Item 8. Financial Statements and Supplementary Data
The financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report on Form 10-K. An index of those financial
statements is found in Part IV, Item 15.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure
controls and procedures as of December 31, 2020. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the
Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in
the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the
Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed
to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and
communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as
appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in
evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of
December 31, 2020, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures
were effective at the reasonable assurance level.
Management’s Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting
is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, a company’s principal executive
officer and principal financial officer, or persons performing similar functions, and effected by a company’s board of directors, management, and other
personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles and includes those policies and procedures that:
•
•
•
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of a company’s assets;
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that a company’s receipts and expenditures are being made only in accordance with authorizations of the
company’s management and directors; and
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have
a material effect on the financial statements.
63
Table of Contents
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.
Under the supervision of and with the participation of our principal executive officer and principal financial officer, our management assessed the
effectiveness of our internal control over financial reporting as of December 31, 2020 based on the criteria set forth by the Committee of Sponsoring
Organizations of the Treadway Commission in Internal Control—Integrated Framework (2013). Based on this assessment, management concluded that our
internal control over financial reporting was effective as of December 31, 2020.
This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm due to a transition period
established by rules of the SEC for newly public companies.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) that occurred
during the fourth quarter of the year ended December 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control
over financial reporting.
Item 9B. Other Information
None.
64
Table of Contents
Item 10. Directors, Executive Officers and Corporate Governance
PART III
Board of Directors
Board Composition and Structure
The Board of Directors is currently comprised of nine members. Below is a list of the names, ages as of February 19, 2021, and classification of the
individuals who currently serve as our directors.
Name
Luis A. Diaz, Jr., M.D.
Barbara Duncan
J. Duncan Higgons
Robert Iannone, M.D., M.S.C.E.
Robert Kamen, Ph.D.
Perry Karsen
Richard Murray, Ph.D.
Cary Pfeffer, M.D.
Luisa Salter-Cid, Ph.D.
Director Biographies
Age
50
56
66
53
76
65
62
58
56
Position
Director (Class II)
Director (Class II)
Director (Class I)
Director (Class I)
Director (Class II)
Chairman of the Board of Directors (Class III)
Director (Class III); Chief Executive Officer and President
Director (Class III)
Director (Class I)
Luis Diaz, Jr., M.D.—Dr. Diaz has served as the head of the solid tumor oncology division and a faculty member at the Memorial Sloan Kettering Cancer
Center since December 2016. From 2004 to December 2016, Dr. Diaz was a faculty member and physician at Johns Hopkins University School of
Medicine. Dr. Diaz is also a founder and board member, and from 2010 to April 2016 served as president, chief executive officer and chief medical officer,
of Personal Genome Diagnostics Inc., a private cancer genome analysis company. He received his M.D. from the University of Michigan, where he also
received his B.A. in Microbiology. We believe Dr. Diaz is qualified to serve on our board of directors due to his background as a physician focused on
oncology and his experience as a faculty member at a major hospital and medical center.
Barbara Duncan—Ms. Duncan served as the chief financial officer of Intercept Pharmaceuticals Inc., a public biopharmaceutical company, from May 2009
to June 2016 and as treasurer from 2010 to June 2016. She has served on the board of directors of Adaptimmune Therapeutics plc since June 2016, Atea
Pharmaceuticals, Inc. since October 2020, Fusion Pharmaceuticals Inc. since October 2020, ObsEva SA since December 2016 and Ovid Therapeutics, Inc.
since June 2017, each of which is a public therapeutics company. She previously served on the board of public companies Immunomedics Inc. from March
2019 to October 2020, Aevi Genomic Medicine, Inc. (formerly Medgenics, Inc.) from June 2015 to February 2020 and Innoviva, Inc. from September 2016
to April 2018. Ms. Duncan holds an M.B.A. from the Wharton School of Business and a B.S. from Louisiana State University. We believe Ms. Duncan is
qualified to serve on our board of directors because of her experience in the biopharmaceutical industry, her experience in the financial sector and
membership on boards of directors of other public and private companies.
J. Duncan Higgons—Mr. Higgons served as chief operating officer of Agios Therapeutics, Inc., a public biopharmaceutical company, from 2009 to January
2016. Mr. Higgons serves on the board of directors of Rheos Medicines, Inc., PsiOxus Therapeutics Ltd. and previously served on the board of Auron
Therapeutics, Inc., all of which are private life science companies. He holds a B.Sc. in Mathematics from King's College University of London and a M.Sc.
in Economics from London Business School. We believe that Mr. Higgons is qualified to serve on our board of directors due to his leadership and
management experience.
Robert Iannone, M.D., M.S.C.E.—Dr. Iannone has served as the Executive Vice President, Research and Development of Jazz Pharmaceuticals plc since
May 2019. Previously, he served as the Chief Medical Officer and Head of Research and Development at Immunomedics, Inc. from April 2018 until May
2019. Dr. Iannone has also held leadership roles at AstraZeneca and Merck & Co. At AstraZeneca, from July 2014 until April 2018, he was employed in
the roles of Senior Vice President and Head of Immuno-oncology, Global Medicines Development. At Merck & Co., Dr. Iannone served in various roles,
culminating with his role as Executive Director and Section Head of Oncology Clinical Development. Dr. Iannone received a B.S. from The Catholic
University of America, an M.D. from the Yale School of Medicine and an M.S.C.E. from the University of Pennsylvania Perelman School of Medicine. We
believe Dr. Iannone is qualified to serve on our board of directors due to his background as a physician focused on oncology and his leadership experience
in the life science industry.
65
Table of Contents
Robert Kamen, Ph.D.—Dr. Kamen has been a venture partner at Third Rock Ventures, LLC, or TRV, since December 2017, and he previously served as an
entrepreneur-in-residence at TRV from 2010 through 2017. Dr. Kamen also served as our interim chief technology officer from February 2013 to December
2015. Dr. Kamen served on the board of directors of Neon Therapeutics, Inc., a public immuno-oncology company, from 2015 through May 2020 and
serves on the boards of directors for several private companies, including EpimAb Biotherapeutics, Inc. and Lycera Corporation. Dr. Kamen holds a Ph.D.
in biochemistry and molecular biology from Harvard University and a B.S. in biophysics from Amherst College. We believe that Dr. Kamen is qualified to
serve on our board of directors because of his experience in the venture capital and life sciences industries, membership on various other boards of
directors, and his leadership and management experience.
Perry Karsen—Mr. Karsen has served as the chairman of our board of directors since April 2016. Mr. Karsen retired from Celgene Corporation at the end
of 2015 and currently is a venture partner at Samsara BioCapital, as well as the executive chair of Autobahn Labs. He serves as a member of the board of
Jiya Acquisition Corp., a public blank check special purpose acquisition company affiliated with Samsara BioCapital, the executive chair of the board of
directors of Nitrome Biosciences, and a member of the boards of directors for ESCAPE Bio, Inc., Graphite Bio, Inc. and the Gladstone Foundation.
Previously, Mr. Karsen served on the boards of directors of Intellia Therapeutics, Inc. from April 2016 to December 2020, Voyager Therapeutics, Inc. from
July 2015 to August 2019, OncoMed Pharmaceuticals, Inc. from January 2016 to April 2019, Agios Pharmaceuticals, Inc. from November 2011 to March
2016, each of which is a public life sciences company. Mr. Karsen received a Masters of Management from Northwestern University's Kellogg Graduate
School of Management, a Masters of Arts in Teaching of Biology from Duke University and a B.S. in Biological Sciences from the University of Illinois,
Urbana-Champaign. We believe Mr. Karsen is qualified to serve on our board of directors because of his executive leadership experience and membership
on boards of directors of other public companies.
Richard Murray, Ph.D.—Dr. Murray has served as our president, chief executive officer and a member of our board of directors since July 2014. Prior to
joining Jounce, Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co., a global healthcare
company, from 2009 to June 2014 where he was responsible for the advancement of biologics and vaccines, including Merck's cancer immunotherapy
pipeline. Since June 2019, he has served as a director of Platelet Biogenesis, Inc., a private biotechnology company. Dr. Murray holds a Ph.D. in
microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts,
Amherst. We believe that Dr. Murray is qualified to serve on our board of directors due to his operating and historical experience gained from serving as
our president, chief executive officer and as a board member, combined with his experience in drug research and development.
Cary Pfeffer, M.D.—Dr. Pfeffer is a partner at TRV, which he joined in 2007. Dr. Pfeffer served as the chairman of our board from July 2014 to April 2016
and as our interim chief executive officer from February 2013 to July 2014. Dr. Pfeffer was the interim chief executive officer of Faze Medicines, Inc. from
December 2020 to January 2021, the interim chief executive officer of Neon Therapeutics, Inc. from October 2015 to September 2016, the interim chief
business officer of Rheos Medicines, Inc. from March 2018 to November 2018, and the interim chief business officer of Casma Therapeutics, Inc. from
May 2018 to December 2018. Dr. Pfeffer serves on the boards of directors for several private companies, including Casma Therapeutics, Inc., Faze
Medicines, Inc., Rheos Medicines, Inc. and Tango Therapeutics, Inc. Previously, he served as a director of Neon Therapeutics, Inc., a public immuno-
oncology company, from May 2015 to May 2020. From August 2009 to September 2016, Dr. Pfeffer served as a director of Eleven Biotherapeutics, Inc., a
public biologics oncology company, and as its chief business officer from February 2010 to September 2011. Dr. Pfeffer received an M.B.A. from the
Wharton School of Business, an M.D. from the University of Pennsylvania School of Medicine and a B.A. in biochemistry from Columbia University. We
believe that Dr. Pfeffer is qualified to serve on our board of directors because of his experience in the venture capital industry, life sciences industry,
membership on various other boards of directors, his prior service as our president and chief executive officer, and his leadership and management
experience.
Luisa Salter-Cid, Ph.D.—Dr. Salter-Cid has served as the Chief Scientific Officer of Gossamer Bio, Inc., or Gossamer, a publicly-traded clinical-stage
biopharmaceutical company, since August 2018. Prior to joining Gossamer, Dr. Salter-Cid worked at Bristol Myers Squibb in increasing positions of
responsibility from 2005 to August 2018, most recently as Vice President and Head of Immunology, small molecule Immuno-Oncology and Genomics
Discovery where she focused on target validation and development of innovative biologic and small-molecule therapeutics to address significant unmet
needs in autoimmune diseases and cancer. She was a member of the Scientific Advisory Board of Enterome SA until July 2018. Dr. Salter-Cid holds a B.S.
in Biology from University of Lisbon and a Ph.D. in Immunology from the University of Miami School of Medicine. We believe that Dr. Salter-Cid is
qualified to serve on our board of directors because of her leadership experience in the life science industry and experience in immuno-oncology.
66
Table of Contents
Executive Officers
The following table sets forth our executive officers as of February 19, 2021.
(1)
Name
Richard Murray, Ph.D.
Kimberlee C. Drapkin
Hugh M. Cole
Elizabeth G. Trehu, M.D.
Age
62
53
55
60
Position
President, Chief Executive Officer and Director
Chief Financial Officer and Treasurer
Chief Business Officer and Head of Corporate Development
Chief Medical Officer
(1) Richard Murray, Ph.D. is also a member of the Board of Directors and his biographical information appears above.
Kimberlee C. Drapkin—Ms. Drapkin has served as our chief financial officer since August 2015, and our treasurer since February 2013. From 2009 to
August 2015, Ms. Drapkin was the owner of KCD Financial LLC, through which she served as our interim chief financial officer from 2012 to August
2015, and consulted for numerous biotechnology companies. Ms. Drapkin began her career at PricewaterhouseCoopers LLP, is a certified public accountant
and holds a B.S. in accounting from Babson College.
Hugh M. Cole—Prior to joining Jounce in August 2017, Mr. Cole served as chief business officer for ARIAD Pharmaceuticals, Inc., an oncology company,
from March 2014 to June 2017, where he led numerous business development transactions. Previously, Mr. Cole served as senior vice president, strategic
planning and program management at Shire plc, a global biopharmaceutical company, from 2007 to March 2014. Mr. Cole earned his M.B.A. in health care
management and finance at the Wharton School of Business and his A.B. in chemistry from Harvard University.
Elizabeth G. Trehu, M.D.—Dr. Trehu joined Jounce as our chief medical officer in November 2015. Prior to joining Jounce, Dr. Trehu served as the chief
medical officer of Promedior, Inc., a biotechnology company, from 2012 to November 2015. Dr. Trehu holds an M.D. from the New York University
School of Medicine and an A.B. in English from Princeton University.
Code of Ethics
We have adopted a written code of business conduct and ethics that applies to our directors, officers, and employees, including our principal executive
officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the code is posted on the
Corporate Governance section of our website, which is located at www.jouncetx.com. If we make any substantive amendments to, or grant any waivers
from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a
current report on Form 8-K. We will provide any person, without charge, a copy of such Code of Business Conduct and Ethics upon written request, which
may be mailed to 780 Memorial Drive, Cambridge, MA 02139, Attn: Corporate Secretary.
Additional information required by this Item 10 will be included in the sections captioned “Proposal 1 - Election of Three Class I Directors” and
“Corporate Governance” and “Delinquent Section 16(a) Reports,” if applicable, in our definitive Proxy Statement for our 2021 Annual Meeting of
Stockholders to be filed with the SEC within 120 days of December 31, 2020, which information is incorporated herein by reference.
Item 11. Executive Compensation
The information required by this Item 11 will be included in the section captioned “Executive and Director Compensation” in our definitive Proxy
Statement for our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2020, which information is
incorporated herein by reference.
Item 12. Security Ownership of Certain of Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item 12 will be included in the section captioned “Principal Stockholders” and “Equity Compensation Plan Information”
in our definitive Proxy Statement for our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2020, which
information is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions and Director Independence
The information required by this Item 13 will be included in the sections captioned “Corporate Governance” and “Transactions with Related Persons” in
our definitive Proxy Statement for our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2020, which
information is incorporated herein by reference.
67
Table of Contents
Item 14. Principal Accountant Fees and Services
The information required by this Item 14 will be included in the section captioned “Ratification of the Selection of Independent Registered Public
Accounting Firm” in our definitive Proxy Statement for our 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days of
December 31, 2020, which information is incorporated herein by reference.
68
Table of Contents
Item 15. Exhibits and Financial Statement Schedules
(1) Financial Statements
PART IV
The following documents are attached hereto and are filed as part of this Annual Report on Form 10-K.
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets
Consolidated Statements of Operations and Comprehensive (Loss) Income
Consolidated Statements of Stockholders’ Equity
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
(2) Financial Statement Schedules
F-1
F-2
F-3
F-4
F-5
F-6
Schedules have been omitted since they are either not required or not applicable or the information is otherwise included herein.
(3) Exhibits
The exhibits filed or furnished as part of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the signatures, which
Exhibit Index is incorporated herein by reference.
Item 16. Form 10-K Summary
None.
69
Table of Contents
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Jounce Therapeutics, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Jounce Therapeutics, Inc. (the Company) as of December 31, 2020 and 2019, the related
consolidated statements of operations and comprehensive (loss) income, stockholders' equity and cash flows for each of the two years in the period ended
December 31, 2020, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations
and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor
were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of
internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over
financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in
the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2013.
Boston, Massachusetts
February 25, 2021
F-1
Table of Contents
Jounce Therapeutics, Inc.
Consolidated Balance Sheets
(amounts in thousands, except par value amounts)
Assets:
Current assets:
Cash and cash equivalents
Short-term investments
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Long-term investments
Operating lease right-of-use asset
Other non-current assets
Total assets
Liabilities and stockholders’ equity:
Current liabilities:
Accounts payable
Accrued expenses
Deferred revenue, current—related party
Operating lease liability, current
Other current liabilities
Total current liabilities
Operating lease liability, net of current portion
Total liabilities
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value: 5,000 shares authorized at December 31, 2020 and 2019; no shares issued or
outstanding at December 31, 2020 and 2019
Common stock, $0.001 par value: 160,000 shares authorized at December 31, 2020 and 2019; 41,729 and 33,738
shares issued at December 31, 2020 and 2019, respectively; 41,729 and 33,738 shares outstanding at December 31,
2020 and 2019, respectively
Additional paid-in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
December 31,
2020
2019
147,493 $
58,985
4,913
211,391
7,336
6,710
14,856
3,943
244,236 $
2,036 $
12,044
1,931
3,271
42
19,324
13,618
32,942
53,241
115,602
4,854
173,697
10,672
1,601
17,615
2,297
205,882
2,460
8,907
—
2,901
132
14,400
16,889
31,289
—
—
42
362,270
(17)
(151,001)
211,294
244,236 $
34
281,664
54
(107,159)
174,593
205,882
$
$
$
$
The accompanying notes are an integral part of these consolidated financial statements.
F-2
Table of Contents
Jounce Therapeutics, Inc.
Consolidated Statements of Operations and Comprehensive (Loss) Income
(amounts in thousands, except per share amounts)
Revenue:
License and collaboration revenue—related party
Operating expenses:
Research and development
General and administrative
Total operating expenses
Operating (loss) income
Other income, net
(Loss) income before provision for income taxes
Provision for income taxes
Net (loss) income
Net (loss) income per share, basic
Net (loss) income per share, diluted
Weighted-average common shares outstanding, basic
Weighted-average common shares outstanding, diluted
Comprehensive (loss) income:
Net (loss) income
Other comprehensive income:
Unrealized (loss) gain on available-for-sale securities
Comprehensive (loss) income
Year Ended December 31,
2020
2019
62,339 $
147,872
78,690
28,766
107,456
(45,117)
1,289
(43,828)
14
(43,842) $
(1.24) $
(1.24) $
35,426
35,426
(43,842) $
(71)
(43,913) $
67,135
27,920
95,055
52,817
4,052
56,869
46
56,823
1.72
1.66
33,080
34,294
56,823
132
56,955
$
$
$
$
$
$
The accompanying notes are an integral part of these consolidated financial statements.
F-3
Table of Contents
Jounce Therapeutics, Inc.
Consolidated Statements Stockholders’ Equity
(amounts in thousands)
Balance at December 31, 2018
Issuance of common stock from at the
market offering, net of issuance costs
Exercise of stock options
Vesting of restricted stock awards and
restricted stock units
Stock-based compensation expense
Other comprehensive income
Cumulative effect adjustment upon
adoption of ASC 842
Net income
Balance at December 31, 2019
Issuance of common stock from at the
market offering, net of issuance costs
Issuance of common stock under a stock
purchase agreement
Exercise of stock options
Vesting of restricted stock awards and
restricted stock units
Stock-based compensation expense
Other comprehensive loss
Net loss
Balance at December 31, 2020
Common Stock
Shares
Amount
Additional Paid-
In Capital
Accumulated Other
Comprehensive (Loss)
Income
Accumulated
Deficit
Total
Stockholders’
Equity
32,941 $
33 $
268,081 $
(78) $
(163,907) $
104,129
448
185
164
—
—
—
—
33,738
2,074
5,540
128
1
—
—
—
—
—
—
34
2
6
—
3,510
437
27
9,609
—
—
—
281,664
14,511
55,724
600
249
—
—
—
41,729 $
—
—
—
—
42 $
—
9,771
—
—
362,270 $
—
—
—
—
132
—
—
54
—
—
—
—
—
(71)
—
(17) $
—
—
—
—
—
(75)
56,823
(107,159)
—
—
—
—
—
—
(43,842)
(151,001) $
3,511
437
27
9,609
132
(75)
56,823
174,593
14,513
55,730
600
—
9,771
(71)
(43,842)
211,294
The accompanying notes are an integral part of these consolidated financial statements.
F-4
Table of Contents
Jounce Therapeutics, Inc.
Consolidated Statements of Cash Flows
(amounts in thousands)
Operating activities:
Net (loss) income
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Stock-based compensation expense
Depreciation expense
Net amortization of premiums and discounts on investments
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other non-current assets
Accounts payable
Accrued expenses and other current liabilities
Deferred revenue—related party
Other liabilities
Net cash used in operating activities
Investing activities:
Purchases of investments
Proceeds from maturities of investments
Purchases of property and equipment
Net cash provided by investing activities
Financing activities:
Proceeds from at the market offering, net of issuance costs
Proceeds from issuance of common under a stock purchase agreement, at fair value
Proceeds from exercise of stock options
Net cash provided by financing activities
Net increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accrued expenses
Issuance costs in accounts payable and accrued expenses
Discount on common stock issued under a stock purchase agreement
Supplemental cash flow information:
Cash paid for lease liabilities
Cash paid for income taxes
Year Ended December 31,
2020
2019
$
(43,842) $
9,771
3,401
47
(236)
(1,469)
(296)
3,047
1,931
(142)
(27,788)
(85,895)
137,287
(94)
51,298
14,412
55,730
600
70,742
94,252
54,511
148,763 $
— $
33 $
(20,730) $
4,024 $
45 $
$
$
$
$
$
$
56,823
9,609
3,851
(1,480)
(1,375)
(728)
(944)
1,983
(97,872)
4
(30,129)
(188,999)
221,366
(985)
31,382
3,645
—
437
4,082
5,335
49,176
54,511
29
134
—
4,270
101
The accompanying notes are an integral part of these consolidated financial statements.
F-5
Table of Contents
1. Nature of Business
Jounce Therapeutics, Inc.
Notes to Consolidated Financial Statements
Jounce Therapeutics, Inc. (the “Company”) is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing
therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. The Company
is subject to a number of risks similar to those of other clinical-stage immunotherapy companies, including dependence on key individuals; the need to
develop commercially viable products; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate
additional financing to fund the development of its products.
As of December 31, 2020, the Company had cash, cash equivalents, and investments of $213.2 million. The Company expects that its existing cash, cash
equivalents and investments will enable it to fund its expected operating expenses and capital expenditure requirements for at least 12 months from
February 25, 2021, the filing date of this Annual Report on Form 10-K. The Company expects to finance its future cash needs through a combination of
equity or debt financings, collaborations, licensing arrangements and strategic alliances.
2. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Consolidation
The accompanying consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange
Commission (the “SEC”) and generally accepted accounting principles in the United States of America (“GAAP”) as found in the Accounting Standards
Codification (“ASC”) of the Financial Accounting Standards Board (“FASB”). These consolidated financial statements include the accounts of Jounce
Therapeutics, Inc. and its wholly-owned subsidiary, Jounce Mass Securities, Inc. All intercompany transactions and balances have been eliminated in
consolidation.
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating
decision-maker in deciding how to allocate resources and assess performance. The Company and the Company’s chief operating decision maker, the
Company’s chief executive officer, views the Company’s operations and manages its business as a single operating segment. The Company operates only in
the United States.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts
reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates which include, but
are not limited to, estimates related to revenue recognized under the Gilead License Agreement and Celgene Collaboration Agreement (including estimates
of standalone selling prices of each performance obligation and internal and external costs expected to be incurred to satisfy performance obligations),
accrued expenses, stock-based compensation expense and income taxes. In addition, in 2019, the Company made estimates to determine the discount rate
utilized in the initial application of ASC Topic 842, Leases (“ASC 842”). The Company bases its estimates on historical experience and other market
specific or other relevant assumptions it believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Fair Value of Financial Instruments
ASC Topic 820, Fair Value Measurement (“ASC 820”) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between
assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market
participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are
inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based
on the best information available in the circumstances.
ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a
liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC
820 establishes a three-tier fair value hierarchy that distinguishes between the following:
•
Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
F-6
Table of Contents
•
•
Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
Level 3 inputs are unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in
pricing the asset or liability. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the
fair value measurement.
To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires
more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.
A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Cash Equivalents
Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased. These
assets include investment in money market funds that invests in U.S. Treasury obligations.
Investments
Short-term investments consist of investments with maturities greater than ninety days and less than one year from the balance sheet date. Long-term
investments consist of investments with maturities of greater than one year that are not expected to be used to fund current operations. The Company
classifies all of its investments as available-for-sale securities. Accordingly, these investments are recorded at fair value. Realized gains and losses,
amortization and accretion of discounts and premiums are included in “Other income, net”. Unrealized gains and losses on available-for-sale securities are
included in “Other comprehensive income” as a component of stockholders’ equity until realized.
Property and Equipment
Property and equipment is recorded at cost and consists of laboratory equipment, furniture and office equipment, computer equipment, leasehold
improvements. The Company capitalizes property and equipment that is acquired for research and development activities and that has alternate future use.
Expenditures for maintenance and repairs are recorded to expense as incurred, whereas major betterments are capitalized as additions to property and
equipment. Leasehold improvements are depreciated over the lesser of their useful life or the term of the lease. Depreciation is calculated over the
estimated useful lives of the assets using the straight-line method.
Impairment of Long-lived Assets
The Company reviews its property and equipment whenever events or changes in circumstances indicate that the carrying value of certain assets might not
be recoverable and recognizes an impairment loss when it is probable that an asset’s realizable value is less than the carrying value.
Leases
Effective January 1, 2019, the Company adopted ASC 842. In adopting ASC 842, the Company elected to utilize a package of practical expedients under
which an entity need not reassess whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases
or initial direct costs for any existing leases. The Company also elected a practical expedient whereby an entity can utilize hindsight in determining the
lease term, including options to extend or terminate the lease. Finally, although separation of lease and non-lease components is required under ASC 842,
the Company elected a practical expedient to not separate lease and non-lease components and rather accounts for lease and non-lease components together
as a single lease component.
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances
present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term
lease liabilities, as applicable. The Company does not recognize leases with terms of one year or less on the balance sheet. Options to renew a lease are not
included in the Company’s initial lease term assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plans
to renew its material leases on a quarterly basis.
Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected
remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as
F-7
Table of Contents
incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate (“IBR”), which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the
same currency, for a similar term, and in a similar economic environment.
The Company subsequently measures its lease liability at the present value of remaining lease payments, discounted using the IBR for the lease. The right-
of-use asset is subsequently measured at the amount of the lease liability, adjusted for prepaid or accrued lease payments and the remaining balance of lease
incentives received. The Company recognizes operating lease expense on a straight-line basis over the lease term.
Revenue Recognition
The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, an entity
recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to
receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a
customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to
the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. The Company only
applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services
it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or
services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct.
The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the
performance obligation is satisfied. As part of the assessment, the Company must develop assumptions that require judgment to determine the standalone
selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the standalone selling price,
which may include reimbursement rates for personnel costs, development timelines and probabilities of regulatory success. The Company does not assess
whether a contract has a significant financing component if the expectation at contract inception is that the period between payment by the customer and
the transfer of promised goods or services to the customer will be one year or less.
Arrangements that include upfront payments may require deferral of revenue recognition to a future period until obligations under these arrangements are
fulfilled. The event-based milestone payments represent variable consideration, and the Company uses the “most likely amount” method to estimate this
variable consideration. Given the high degree of uncertainty around the occurrence of these events, the Company determined the milestone and other
contingent amounts to be fully constrained until the uncertainty associated with these payments is resolved. Revenue will be recognized from sales-based
royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved
and other changes in circumstances occur. See Note 3, “License and Collaboration Revenue”, for further information on the Company’s application of ASC
606.
Research and Development Expenses
Expenditures relating to research and development are expensed as incurred. Research and development expenses include external expenses incurred under
arrangements with third parties, academic and non-profit institutions and consultants; salaries and personnel-related costs, including non-cash stock-based
compensation expense; license fees to acquire in-process technology and other expenses, which include direct and allocated expenses for laboratory,
facilities and other costs. Non‑refundable advance payments for goods and services that will be used in future research and development activities are
expensed when the activity has been performed or when the goods have been received rather than when the payment is made.
F-8
Table of Contents
As part of the process of preparing the consolidated financial statements, the Company is required to estimate its accrued research and development
expenses as of each balance sheet date. In accruing service fees, the Company estimates the time period over which services will be performed and the
level of effort to be expended in each period. This process involves reviewing open contracts and purchase orders, communicating with internal personnel
to identify services that have been performed on the Company’s behalf and estimating the level of service performed and the associated cost incurred for
the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The Company periodically confirms the accuracy of its
estimates with its service providers and makes adjustments if necessary. The majority of the Company’s service providers invoice monthly in arrears for
services performed or when contractual milestones are met. The financial terms of agreements with these service providers are subject to negotiation, vary
from contract-to-contract and may result in uneven payment flows. In circumstances where amounts have been paid in excess of costs incurred, the
Company records a prepaid expense.
Intellectual Property Expenses
The Company expenses costs associated with intellectual property-related matters as incurred and classifies such costs as general and administrative
expenses within the consolidated statements of operations and comprehensive (loss) income.
Stock-based Compensation
The Company accounts for stock-based payments in accordance with ASC Topic 718, Compensation—Stock Compensation. This guidance requires all
stock-based payments to employees, including grants of employee stock options, restricted stock awards (“RSAs”) and restricted stock units (“RSUs”), to
be recognized as expense in the consolidated statements of operations and comprehensive (loss) income based on their grant date fair values. For stock
options granted to employees and to members of the Company’s board of directors for their services on the board of directors, the Company estimates the
grant date fair value of each stock option using the Black-Scholes option-pricing model. For RSUs and RSAs granted to employees, the Company estimates
the grant date fair value of each award using intrinsic value, which is based on the value of the underlying common stock less any purchase price. For
stock-based payments subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair
value of stock-based payment on a straight-line basis over the requisite service period.
The Black‑Scholes option pricing model requires the input of certain subjective assumptions, including (i) the calculation of expected term of the stock-
based payment, (ii) the risk‑free interest rate, (iii) the expected stock price volatility and (iv) the expected dividend yield. The Company uses the simplified
method as proscribed by SEC Staff Accounting Bulletin No. 107 to calculate the expected term for stock options granted to employees as the Company
does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The Company determines the
risk‑free interest rate based on a treasury instrument whose term is consistent with the expected term of the stock options. Because there had been no public
market for the Company’s common stock prior to the Company’s initial public offering (“IPO”), there is a lack of Company‑specific historical and implied
volatility data. Accordingly, the Company bases its estimates of expected volatility on the historical volatility of a group of publicly-traded companies with
similar characteristics to itself, including stage of product development and therapeutic focus within the life sciences industry. Historical volatility is
calculated over a period of time commensurate with the expected term of the stock-based payment. The Company uses an assumed dividend yield of zero
as the Company has never paid dividends on its common stock, nor does it expect to pay dividends on its common stock in the foreseeable future. The
Company accounts for forfeitures of all stock-based payments when such forfeitures occur.
Income Taxes
Income taxes are recorded in accordance with ASC Topic 740, Income Taxes, which provides for deferred taxes using an asset and liability approach. The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated
financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases
of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance against deferred
tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be
realized.
The Company accounts for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The
evaluation of uncertain tax positions is based on factors, including, but not limited to, changes in the law, the measurement of tax positions taken or
expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a
tax position.
F-9
Table of Contents
Comprehensive (Loss) Income
Comprehensive (loss) income is comprised of net (loss) income and other comprehensive income. Other comprehensive income for all periods presented
consists solely of unrealized gains on available-for-sale securities.
Net (Loss) Income per Share
Basic net (loss) income per share is calculated based upon the weighted-average number of common shares outstanding during the period, excluding
outstanding stock options and RSAs and RSUs that have been issued but are not yet vested. Diluted net (loss) income per share is calculated based upon the
weighted-average number of common shares outstanding during the period plus the dilutive impact of weighted-average common equivalent shares
outstanding during the period. The potentially dilutive shares of common stock resulting from the assumed exercise of outstanding stock options and the
assumed vesting of RSAs and RSUs are determined under the treasury stock method.
Concentrations of Credit Risk and Off-Balance Sheet Risk
Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The
Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds
are subject to minimal credit risk. The Company’s cash equivalents and investments are comprised of money market funds that are invested in U.S.
Treasury obligations, corporate debt securities, U.S. Treasury obligations and government agency securities. Credit risk in these securities is reduced as a
result of the Company’s investment policy to limit the amount invested in any single issuer and to only invest in securities of a high credit quality.
The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
Recently Adopted Accounting Pronouncements
In August 2018, the FASB issued Accounting Standards Updates (“ASU”) 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—
Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value
measurements. This guidance became effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.
Accordingly, the Company adopted ASU 2018-13 effective January 1, 2020, and there was no impact to the condensed consolidated financial statements
due to the adoption of this guidance.
In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for
Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This guidance aligns the requirements for capitalizing
implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to
develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of
a hosting arrangement that is a service contract is not affected. This guidance became effective for fiscal years beginning after December 15, 2019,
including interim periods within those fiscal years. The amendments in this update are able to be applied either retrospectively or prospectively to all
implementation costs incurred after the date of adoption. Accordingly, the Company adopted ASU 2018-15 effective January 1, 2020, and it elected to
apply this guidance on a prospective basis. There was no impact to the condensed consolidated financial statements due to the adoption of this guidance.
In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606,
which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606, Revenue from
Contracts with Customers (“ASC 606”) when the counterparty is a customer. In addition, ASU 2018-18 adds unit-of-account guidance to ASC Topic 808,
Collaborative Arrangements, in order to align this guidance with ASC 606 and also precludes an entity from presenting consideration from a transaction in
a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. This guidance became
effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Accordingly, the Company adopted ASU
2018-18 effective January 1, 2020, and there was no impact to the condensed consolidated financial statements due to the adoption of this guidance.
F-10
Table of Contents
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which eliminates certain
exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim
period and the recognition of deferred tax liabilities when investment ownership changes. In addition, ASU 2019-12 simplifies the accounting for the
interim period effects of changes in tax laws or rates and transactions that result in a step-up in the tax basis of goodwill. While this guidance is effective
for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, early adoption is permitted. Consequently, the
Company elected to early adopt ASU 2019-12 effective January 1, 2020. Due to the adoption of this guidance, the Company did not record an intraperiod
tax allocation to other comprehensive income for the three months ended March 31, 2020. In accordance with ASU 2019-12, the Company has applied the
new provisions related to the intraperiod tax allocation on a prospective basis.
Recent Accounting Pronouncements, Not Yet Adopted
In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.
This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and it
establishes additional disclosure requirements related to credit risks. For available-for-sale debt securities with expected credit losses, this standard now
requires allowances to be recorded instead of reducing the amortized cost of the investment. This guidance was originally effective for annual reporting
periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption was permitted. In
November 2019, the FASB subsequently issued ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815),
and Leases (Topic 842): Effective Dates, whereby the effective date of this standard for smaller reporting companies was deferred to annual reporting
periods beginning after December 15, 2022, including interim periods within those annual reporting periods, and early adoption is still permitted.
Accordingly, the Company will now adopt this standard effective January 1, 2023, and it is currently evaluating the potential impact that ASU 2016-13 may
have on the consolidated financial statements.
3. License and Collaboration Revenue
Gilead License Agreement
On August 31, 2020, the Company and Gilead entered into an exclusive license agreement (the “Gilead License Agreement”) to license the Company’s
JTX-1811 program to Gilead. Concurrently with the license agreement, the Company and Gilead entered into a stock purchase agreement (the “Stock
Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”, and together with the License Agreement and the Stock
Purchase Agreement, the “Transaction Agreements”). The transactions with Gilead were subject to review under the Hart-Scott Rodino Antitrust
Improvements Act of 1976 and other customary closing conditions, and became effective on October 16, 2020, the closing date of the agreement. Pursuant
to the Gilead License Agreement, the Company granted to Gilead a worldwide and exclusive license to develop, manufacture and commercialize JTX-1811
and certain derivatives thereof (the “Licensed Products”). Gilead paid the Company a one-time, non-refundable upfront payment of $85.0 million in
October 2020. The Company will continue to develop JTX-1811 during the initial development term, which includes conducting activities defined within
the agreement to advance JTX-1811 through the clearance of an IND application or an earlier date specified by Gilead, at which time the program will be
transitioned to Gilead.
Milestone and Royalties
The Company is entitled to receive payments from Gilead upon the achievement of specified clinical, regulatory and sales milestones, including potential
clinical development and regulatory milestone payments up to an aggregate total of $510.0 million and potential sales milestone payments up to an
aggregate total of $175.0 million.
The Company is also eligible to receive tiered royalty payments based on a percentage of annual worldwide net sales ranging from the high-single digits to
mid-teens, based on future annual net sales of the Licensed Products, on a Licensed Product-by-Licensed Product and country-by-country basis.
Termination
Gilead may terminate the License Agreement for convenience, in its sole discretion, in its entirety or on a Licensed Product-by-Licensed Product or region-
by-region basis, at any time with prior written notice to the Company. Unless terminated earlier in accordance with its terms, the Gilead License Agreement
provides that it will expire (i) on an Licensed Product-by-Licensed
F-11
Table of Contents
Product and country-by-country basis on the date of the expiration of the royalty term with respect to such Licensed Product in such country and (ii) in its
entirety upon the expiration of all applicable royalty terms with respect to the Licensed Products in all countries, following which the applicable licenses
under the License Agreement will become fully paid-up, perpetual, irrevocable and royalty-free.
Accounting Analysis
Identification of the Contract(s)
The Company assessed the Gilead License Agreement and concluded that it represents a contract with a customer within the scope of ASC 606, Revenue
from Contracts with Customers. In addition, the Company determined that the Gilead License Agreement and Stock Purchase Agreement should be
evaluated as a combined contract in accordance with ASC 606 given that the agreements were executed contemporaneously, negotiated as a package and
have the same commercial objective to provide funding to further the Company’s research and development activities.
Identification of Promises and Performance Obligations
The Company determined that the Gilead License Agreement contains the following promises: (i) delivery of a worldwide and exclusive license to develop,
manufacture and commercialize JTX-1811 (the “JTX-1811 License”), (ii) provision of certain research transition activities, specifically outlined within the
Gilead License Agreement, related to the advancement of JTX-1811 through the clearance of an IND application and transition of the JTX-1811 program to
Gilead (the “Research and Transition Services”), (iii) appointment of an individual to act as an alliance manager and primary point of contact for Gilead,
(iv) appointment of individuals to participate on the Joint Steering Committee (“JSC”), and (v) optional assistance by Jounce after completion of Research
and Transition Services upon the request of Gilead.
The Company assessed the above promises and concluded that each of the JTX-1811 License and Research and Transition Services is capable of being
distinct and distinct within the context of the Gilead License Agreement. Based upon this evaluation, the Company concluded that its promise to deliver the
JTX-1811 License and promise to perform Research and Transition Services represent separate performance obligations in the Gilead License Agreement.
The Company determined that the appointment of an individual to act as an alliance manager and primary point of contact for Gilead, participation in
alliance management meetings and the appointment of individuals to participate on the JSC do not constitute the transfer of a good or service to Gilead and
as such, do not represent performance obligations under the contract.
Finally, the Company assessed Gilead’s ability to request optional assistance by Jounce after completion of Research and Transition Services and
determined that it was both quantitatively and qualitatively immaterial in the context of the Gilead License Agreement. Accordingly, the Company did not
assess the optional assistance as a performance obligation.
Determination of Transaction Price
As noted above, the Company received a non-refundable upfront payment of $85.0 million upon the execution of the Gilead License Agreement. This
upfront payment represents an element of fixed consideration under the Gilead License Agreement.
The Company also evaluated as possible variable consideration the milestones and royalties discussed above. With respect to clinical development and
regulatory milestones, based upon the high degree of uncertainty and risk associated with these potential payments, the Company concluded that all such
amounts should be fully constrained and are not included in the initial transaction price. As part of the evaluation of the constraint the Company considered
certain factors, including that receipt of such milestones is outside the control of the Company and the probability of success criteria is estimated. Each of
these variable consideration items was evaluated under the most-likely amount method. As for royalties and sales milestones, the Company determined that
the royalties and milestones relate solely to the JTX-1811 License, which is a license of intellectual property (“IP”). Accordingly, the Company did not
include any potential royalty or sales milestone amounts in the initial transaction price, and the Company will not recognize revenue related to these
royalties and sales milestones until the associated sales occur and relevant thresholds are met.
The Company assessed proceeds of $35.0 million received under the Stock Purchase Agreement and determined that the fair value of the equity component
was $55.7 million based on the closing price of $10.06 per share on October 16, 2020. Pursuant to the agreement, the Company sold 5,539,727 shares of
common stock for aggregate cash consideration of $35.0 million, or $6.32 per share, which is equal to the daily volume weighted average per share
intraday price of the Common Stock on Nasdaq over the 30-trading day period ending on and including August 28, 2020 plus a 30% premium. As a result,
the Company
F-12
Table of Contents
determined that the gross proceeds of $35.0 million received under the Stock Purchase Agreement included a discount to the fair value of the Company’s
stock as of October 16, 2020 equal to $20.7 million. In accordance with ASC 606, the discount amount will be included in the transaction price for revenue
recognition, resulting in an initial transaction price of $64.3 million.
Allocation of Transaction Price to Performance Obligations
The Company allocated the transaction price to each performance obligation on a relative estimated standalone selling price basis. The Company developed
the estimated standalone selling price for the JTX-1811 License based on the present value of expected future cash flows associated with the license and
related clinical development and regulatory milestones. In developing such estimate, the Company applied judgement in determining the timing needed to
develop the Licensed Product, the probability of success, and the discount rate. The Company developed the estimated standalone selling price for the
Research and Transition Services obligation based on the nature of the services to be performed and the Company’s best estimate of the length of time
required to perform the services necessary to achieve clearance of an IND application for the JTX-1811 program.
Recognition of Revenue
The Company determined that the JTX-1811 License is a functional license as the underlying IP has significant standalone functionality. In addition, the
Company determined that the JTX-1811 License represents a right to use certain of the Company’s IP as it exists at a point in time. Finally, the Company
determined that October 16, 2020 represents (i) the date at which the Company made available the IP to Gilead and (ii) the beginning of the period during
which Gilead is able to use and benefit from its right to use the IP. Based upon these considerations, the Company recognized $60.8 million in revenue
related to the JTX-1811 License performance obligation during the year ended December 31, 2020.
Further, the Company determined the input method under ASC 606 is the most appropriate method of revenue recognition for the Research and Transition
Services performance obligation. The method of measuring progress towards delivery of the services incorporated actual internal and external costs
incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligation. The period over which total costs were
estimated reflected the Company’s best estimate of the period over which it would perform the research and transition services to achieve clearance of an
IND application of the JTX-1811 program and transition the program to Gilead. Based upon these considerations, the Company recognized $1.6 million in
revenue related to the Research and Transition Services performance obligation during the year ended December 31, 2020.
The following table provides a summary of the transaction price allocated to each performance obligation, in addition to revenue activity during the period
(in thousands):
JTX-1811 License
Research and Transition Services
Totals
Transaction Price Allocated
Revenue Recognized - related
party
Year Ended December 31,
2020
Deferred Revenue - related
party
As of December 31, 2020
$
$
60,776 $
3,494
64,270 $
60,776 $
1,563
62,339 $
—
1,931
1,931
As of December 31, 2020, the remaining amount of the transaction price allocated to the Research and Transition Services that was unsatisfied is expected
to be recognized in 2021 as services are performed.
Celgene License Agreement
On July 22, 2019, the Company entered into a License Agreement (the “Celgene License Agreement”) with Celgene Corporation (“Celgene”). Pursuant to
the Celgene License Agreement, the Company granted to Celgene a worldwide and exclusive license to develop, manufacture and commercialize JTX-
8064 and certain derivatives thereof (an “Initial Licensed Compound”), as well as any antibody (other than the Initial Licensed Compound) or other
biologic controlled by the Company as of July 22, 2019 that is specifically directed to the LILRB2 receptor (the “Licensed Compounds”), and Celgene paid
the Company a one-time, non-refundable upfront payment of $50.0 million.
As of November 2019, Celgene became a Bristol Myers Squibb company. As part of its Celgene integration process, Bristol Myers Squibb streamlined its
pipeline to address areas of overlap. As a result, Celgene provided the Company with a notice of
F-13
Table of Contents
termination and the Celgene License Agreement was terminated effective June 3, 2020 (the “Celgene License Agreement Termination Date”). As of the
Celgene License Agreement Termination Date, the Company has sole worldwide rights to JTX-8064, and all of the Company’s intellectual property rights
pertaining to JTX-8064 and licensed to Celgene were reacquired by the Company. No party had any further financial or service obligations to one another
beyond transition costs and efforts, which were completed during the year ended December 31, 2020.
Accounting Analysis
Identification of the Contract(s)
The Company assessed the Celgene License Agreement and concluded that it represents a contract with a customer within the scope of ASC 606.
Identification of Promises and Performance Obligations
The Company determined that the Celgene License Agreement contained the following promises: (i) delivery of a worldwide and exclusive license to
develop, manufacture and commercialize an Initial Licensed Compound and the Licensed Compounds (the “JTX-8064 License”) and (ii) provision of
certain transition activities, specifically outlined within the Celgene License Agreement, related to the delivery of the JTX-8064 License (the “Transition
Activities”).
The Company also evaluated certain other optional activities outlined within the Celgene License Agreement and concluded that none conveyed a material
right to Celgene. Accordingly, these options were not considered to be promises within the Celgene License Agreement.
The Company assessed the above promises and concluded that the JTX-8064 License was both capable of being distinct and distinct within the context of
the Celgene License Agreement. The Company also assessed its promise to perform the Transition Activities and concluded that it was both quantitatively
and qualitatively immaterial in the context of the Celgene License Agreement. Accordingly, the Company did not assess the Transition Activities as a
performance obligation. Based upon this evaluation, the Company concluded that its promise to deliver the JTX-8064 License represented the sole
performance obligation in the Celgene License Agreement.
Determination of Transaction Price
As noted above, the Company received a non-refundable upfront payment of $50.0 million upon the execution of the Celgene License Agreement. This
upfront payment represented an element of fixed consideration under the Celgene License Agreement.
The Company also evaluated as possible variable consideration clinical, regulatory and sales milestone payments and royalties that the Company was
eligible to receive under the Celgene License Agreement. With respect to clinical and regulatory milestones, based upon the high degree of uncertainty and
risk associated with these potential payments, the Company concluded that all such amounts should be fully constrained and are not included in the initial
transaction price. As for royalties and sales milestones, the Company determined that the royalties and milestones related solely to the JTX-8064 License,
which is a license of intellectual property (“IP”). Accordingly, the Company did not include any potential royalty or sales milestone amounts in the initial
transaction price, and the Company determined it would not recognize revenue related to these royalties and sales milestones until the associated sales
occurred and relevant thresholds were met.
Based upon the above considerations, the Company concluded that the initial transaction price associated with the Celgene License Agreement consisted
solely of the upfront payment of $50.0 million.
Allocation of Transaction Price to Performance Obligations
As the Company’s promise to deliver the JTX-8064 License represented the sole performance obligation in the Celgene License Agreement, the entirety of
the $50.0 million transaction price was allocated to this performance obligation.
Recognition of Revenue
The Company determined that the JTX-8064 License was a functional license as the underlying IP had significant standalone functionality. In addition, the
Company determined that the JTX-8064 License represented a right to use certain of the Company’s IP as it existed at a point in time. Finally, the Company
determined that July 22, 2019 represented (i) the date at which the Company made available the IP to Celgene and (ii) the beginning of the period during
which Celgene was able to use and benefit from its right to use the IP. Based upon these considerations, the Company recognized $50.0 million of license
F-14
Table of Contents
revenue during the year ended December 31, 2019. As the upfront payment was non-refundable, the subsequent termination of the Celgene License
Agreement had no impact on this revenue recognition. Up through the Celgene License Agreement Termination Date, the Company did not receive any
milestone or royalty payments.
Celgene Collaboration Agreement
In July 2016, the Company entered into a Master Research and Collaboration Agreement (the “Celgene Collaboration Agreement”) with Celgene. The
primary goal of the collaboration was to co-develop and co-commercialize innovative biologic immunotherapies that either activate or suppress the
immune system by binding to targets identified by leveraging the Company’s Translational Science Platform. Under the Celgene Collaboration Agreement,
the Company granted Celgene exclusive options to develop and commercialize the Company’s lead product candidate, vopratelimab, and up to four early-
stage programs, consisting of targets to be selected from a pool of certain B cell, T regulatory cell and tumor-associated macrophage targets. Additionally,
the Company granted Celgene an exclusive option to develop and commercialize the Company’s product candidate JTX-4014, an anti-PD-1 antibody,
which, upon exercise of such option, would have been a shared program to be used by both parties in and outside of the collaboration. The Company and
Celgene terminated the Celgene Collaboration Agreement effective July 22, 2019.
The Company received a non-refundable upfront cash payment of $225.0 million in July 2016 upon the execution of the Celgene Collaboration Agreement.
The Company also received $36.1 million from the sale of 10,448,100 shares of Series B-1 convertible preferred stock upon the execution of a Series B-1
Preferred Stock Purchase Agreement with Celgene, which shares converted into 2,831,463 shares of common stock upon the completion of the IPO. If
Celgene had elected to exercise any of the program options, Celgene would have been required to pay the Company an option-exercise fee that varied by
program. The initial research term of the collaboration was four years, which could have been extended, at Celgene’s option, annually for up to three
additional years.
Worldwide Development Cost and U.S. Operating Profit and Loss Sharing
Prior to Celgene exercising any of its options, the Company was responsible for all research and development activities under the Celgene Collaboration
Agreement. Upon the exercise of each program option, the parties would have entered into a co-development and co-commercialization agreement (the
“Co-Co Agreements”) or, in the case of JTX-4014, a license agreement (the “JTX-4014 License Agreement”) to govern the development and
commercialization of the applicable program. As part of the Celgene Collaboration Agreement, the parties agreed to the terms of the Co-Co Agreements
and the JTX-4014 License Agreement that would have been executed upon Celgene’s exercise of any option.
Milestones and Royalties
Under the Co-Co Agreements and the JTX-4014 License Agreement, Celgene would have been required to pay the Company for specified development,
regulatory and commercial milestones, if achieved, across all collaboration programs. Development milestones were payable on the initiation of certain
clinical trials, regulatory approval milestones were payable upon regulatory approval in the United States and outside the United States and commercial
milestones were payable upon achievement of specified aggregate product sales outside the United States for each program. The Company was also eligible
to receive royalties on product sales outside the United States.
Accounting Analysis
Identification of the Contract(s)
The Company assessed the Celgene Collaboration Agreement and concluded that it represented a contract with a customer within the scope of ASC 606.
The Company also concluded that each of the Co-Co Agreements and the JTX-4014 License Agreement, if any had been executed, would have represented
separate contracts apart from the Celgene Collaboration Agreement.
Identification of Promises and Performance Obligations
The Company determined that the Celgene Collaboration Agreement contained the following promises: (i) research and development services for
vopratelimab (“Vopratelimab Research Services”), (ii) research and development services for JTX-4014 (“JTX-4014 Research Services”), (iii) research and
development services associated with the Lead Program and Other Programs (“Lead and Other Programs Research Services”), (iv) research services
associated with target screening (“Target Screening Services”), (v) non-transferable, limited sub-licensable and non-exclusive licenses to use the
Company’s
F-15
Table of Contents
intellectual property and the Company’s rights in the collaboration intellectual property to conduct certain activities, on a program-by-program basis (the
“Research Licenses”), (vi) various record-keeping and reporting requirements on a program-by-program basis, (vii) exclusivity provisions with respect to
each Collaboration Exclusive Target and biologics binding to such Collaboration Exclusive Targets and (viii) establishment of and participation in a joint
steering committee (the “JSC”) and a joint patent committee (the “JPC”). The Company also evaluated the six program options as well as the research term
extension options and concluded that none conveyed a material right to Celgene. Accordingly, neither the program options nor the research term extension
options were considered to be promises within the Celgene Collaboration Agreement.
The Company assessed the above promises and concluded that each of the Vopratelimab Research Services, JTX-4014 Research Services, Lead and Other
Programs Research Services and Target Screening Services were both capable of being distinct and distinct within the context of the Celgene Collaboration
Agreement. Therefore, the Company concluded that each of the Vopratelimab Research Services, JTX-4014 Research Services, Lead and Other Programs
Research Services and Target Screening Services represented separate performance obligations.
The Company determined that the Research Licenses were not distinct within the context of the Celgene Collaboration Agreement as the Research
Licenses allowed Celgene to evaluate the results of the research and development services performed by the Company and the right to perform its duties
under the Celgene Collaboration Agreement, but did not provide Celgene with any commercialization rights. Celgene could only benefit from the Research
Licenses in conjunction with the related research and development services. Accordingly, the Research Licenses related to vopratelimab, JTX-4014 and the
Lead and Other Programs were combined with their respective research and development services performance obligations.
Similarly, the Company also determined that the various record-keeping and reporting requirements related to each program and the exclusivity provisions
with respect to each Collaboration Exclusive Target and biologics binding to such Collaboration Exclusive Targets were not distinct within the context of
the Celgene Collaboration Agreement. Accordingly, the various record-keeping and reporting requirements on a program-by-program basis and the
exclusivity provisions with respect to each Collaboration Exclusive Target and biologics binding to such Collaboration Exclusive Targets were combined
with their respective research and development services performance obligations.
Finally, the Company assessed its participation in the JSC and the JPC and concluded that it was both quantitatively and qualitatively immaterial in the
context of the Celgene Collaboration Agreement. Accordingly, the Company did not assess its participation in the JSC and the JPC as a performance
obligation.
Determination of Transaction Price
As noted above, the Company received a non-refundable upfront payment of $225.0 million upon the execution of the Celgene Collaboration Agreement.
This upfront payment represented an element of fixed consideration under the Celgene Collaboration Agreement. Celgene also purchased 10,448,100
shares of Series B-1 convertible preferred stock (“Series B-1 Preferred Stock”) for gross proceeds of $36.1 million, which shares converted into 2,831,463
shares of common stock upon the completion of the IPO. The Company determined the shares of Series B-1 Preferred Stock were sold at fair value.
Therefore, the proceeds from the issuance of Series B-1 Preferred Stock did not impact the transaction price to be allocated to the performance obligations.
The Company evaluated as possible variable consideration the milestones, royalties, development cost sharing and profit-sharing provisions discussed
above. The Company concluded that none of these items represented variable consideration under the Celgene Collaboration Agreement as all such
amounts were dependent upon the execution of a related Co-Co Agreement or the JTX-4014 License Agreement. The Co-Co Agreements and the JTX-
4014 License Agreement, if any had been executed, would have represented separate contracts apart from the Celgene Collaboration Agreement.
The Company also considered the existence of any significant financing component within the Celgene Collaboration Agreement given its upfront payment
structure. Based upon this assessment, the Company concluded that any difference between the promised consideration and the cash selling price of the
services under the Celgene Collaboration Agreement arose for reasons other than the provision of financing, and the difference between those amounts was
proportional to the reason for the difference. Accordingly, the Company concluded that the upfront payment structure of the Celgene Collaboration
Agreement did not result in the existence of a significant financing component.
Based upon the above considerations, the Company concluded that the transaction price associated with the Celgene Collaboration Agreement consisted
solely of the upfront payment of $225.0 million.
F-16
Table of Contents
Allocation of Transaction Price to Performance Obligations
The Company allocated the transaction price to each performance obligation on a relative standalone selling price basis. For all performance obligations,
the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected
internal and external costs for services and supplies, adjusted to reflect a reasonable profit margin. The total estimated cost of the research and development
services reflected the nature of the services to be performed and the Company’s best estimate of the length of time required to perform the services.
Recognition of Revenue
Prior to the termination of the Celgene Collaboration Agreement, the Company was recognizing revenue over time as the services related to each
performance obligation were rendered. The Company concluded that an input method under ASC 606 was a representative depiction of the transfer of
services under the Celgene Collaboration Agreement. The method of measuring progress towards delivery of the services incorporated actual internal and
external costs incurred, relative to total internal and external costs expected to be incurred to satisfy the performance obligations. The period over which
total costs were estimated reflected the Company’s estimate of the period over which it would perform the research and development services to deliver a
pre-defined data package to Celgene for each program subject to an option. The Company was recognizing revenue for each performance obligation over
periods ranging from twelve months to four years. Changes in estimates of total internal and external costs expected to be incurred were recognized in the
period of change as a cumulative catch-up adjustment.
For the year ended December 31, 2019, the Company recognized collaboration revenue of $97.9 million under the Celgene Collaboration Agreement
related to the $225.0 million upfront payment received in 2016. Following the termination of the Celgene Collaboration Agreement, which was effective
July 22, 2019, the Company had no further performance obligations. Accordingly, all remaining deferred revenue related to the Celgene Collaboration
Agreement was recognized during the year ended December 31, 2019. Up through the termination of the Celgene Collaboration Agreement, the Company
did not receive any option exercise, research term extension, milestone or royalty payments.
4. Fair Value Measurements
The Company measures the fair value of money market funds, U.S. Treasuries and government agency securities based on quoted prices in active markets
for identical securities. Investments also include corporate debt securities which are valued either based on recent trades of securities in inactive markets or
based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.
The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued
expenses approximate their fair values, due to their short-term nature.
Assets measured at fair value on a recurring basis as of December 31, 2020 were as follows (in thousands):
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
Total
Significant Other
Observable Inputs
(Level 2)
Significant
Unobservable Inputs
(Level 3)
Money market funds, included in cash equivalents
Investments:
Corporate debt securities
Government agency securities
Totals
$
$
147,492 $
147,492 $
— $
63,691
2,005
213,188 $
—
—
147,492 $
63,691
2,005
65,696 $
—
—
—
—
F-17
Table of Contents
Assets measured at fair value on a recurring basis as of December 31, 2019 were as follows (in thousands):
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
Total
Significant Other
Observable Inputs
(Level 2)
Significant
Unobservable Inputs
(Level 3)
Money market funds, included in cash equivalents
Investments:
Corporate debt securities
U.S. Treasuries
Government agency securities
Totals
$
$
50,242 $
50,242 $
— $
48,300
59,082
12,820
170,444 $
—
59,082
—
109,324 $
48,300
—
12,820
61,120 $
—
—
—
—
—
There were no changes in valuation techniques during the years ended December 31, 2020 or 2019. There were no liabilities measured at fair value on a
recurring basis as of December 31, 2020 or 2019.
5. Investments
Short-term investments consist of investments with maturities greater than ninety days and less than one year from the balance sheet date. Long-term
investments consist of investments with maturities of greater than one year that are not expected to be used to fund current operations. The Company
classifies all of its investments as available-for-sale securities. Accordingly, these investments are recorded at fair value. Realized gains and losses,
amortization and accretion of discounts and premiums are included in other income, net. Unrealized gains and losses on available-for-sale securities are
included in other comprehensive income as a component of stockholders’ equity until realized.
Cash equivalents, short-term investments and long-term investments as of December 31, 2020 were comprised as follows (in thousands):
Amortized Cost
December 31, 2020
Unrealized Gains Unrealized Losses
Fair Value
Cash equivalents and short-term investments:
Money market funds, included in cash equivalents
Corporate debt securities
Government agency securities
Total cash equivalents and short-term investments
Long-term investments:
Corporate debt securities
Total long-term investments
Total cash equivalents and investments
147,492 $
56,985
2,001
206,478
6,727
6,727
213,205 $
— $
9
4
13
—
—
13 $
— $
(13)
—
(13)
(17)
(17)
(30) $
147,492
56,981
2,005
206,478
6,710
6,710
213,188
$
$
F-18
Table of Contents
Cash equivalents, short-term investments and long-term investments as of December 31, 2019 were comprised as follows (in thousands):
Cash equivalents and short-term investments:
Money market funds, included in cash equivalents
Corporate debt securities
U.S. Treasuries
Government agency securities
Total cash equivalents and short-term investments
Long-term investments:
Corporate debt securities
Total long-term investments
Total cash equivalents and investments
Amortized Cost
December 31, 2019
Unrealized Gains Unrealized Losses
Fair Value
$
$
50,242 $
46,695
59,058
12,796
168,791
1,599
1,599
170,390 $
— $
8
26
24
58
2
2
60 $
— $
(4)
(2)
—
(6)
—
—
(6) $
50,242
46,699
59,082
12,820
168,843
1,601
1,601
170,444
As of December 31, 2020 and 2019, the aggregate fair value of securities that were in an unrealized loss position for less than twelve months was $28.3
million and $28.3 million, respectively. As of December 31, 2020 there were no securities that were in an unrealized loss position for more than twelve
months. As of December 31, 2019, the aggregate fair value of securities that were in an unrealized loss position for more than twelve months was
$2.0 million. As of December 31, 2020, the Company did not intend to sell, and would not be more likely than not required to sell, the securities in an
unrealized loss position before recovery of their amortized cost bases. Furthermore, the Company determined that there was no material change in the
credit risk of these securities. As a result, the Company determined it did not hold any securities with any other-than-temporary impairment as of
December 31, 2020.
There were no realized gains and losses on available-for-sale securities during the year ended December 31, 2020 and 2019,
6. Restricted Cash
As of both December 31, 2020 and 2019, the Company maintained non-current restricted cash of $1.3 million. This amount is included within “Other non-
current assets” in the accompanying consolidated balance sheets and is comprised solely of a letter of credit required pursuant to the lease for the
Company’s corporate headquarters.
The following table provides a reconciliation of cash, cash equivalents and restricted cash that sums to the total of the same such amounts shown in the
consolidated statements of cash flows (in thousands):
Year Ended
December 31, 2020
Year Ended
December 31, 2019
Beginning of Period
End of Period
Beginning of Period
End of Period
Cash and cash equivalents
Restricted cash
Cash, cash equivalents and restricted cash
$
$
53,241 $
1,270
54,511 $
147,493 $
1,270
148,763 $
47,906 $
1,270
49,176 $
53,241
1,270
54,511
F-19
Table of Contents
7. Property and Equipment, Net
Property and equipment, net as of December 31, 2020 and 2019 was comprised as follows (in thousands):
Laboratory equipment
Furniture and office equipment
Computer equipment
Leasehold improvements
Total property and equipment, gross
Less: accumulated depreciation
Total property and equipment, net
Estimated Useful Life (in
Years)
5
4
3
Shorter of useful life or
remaining lease term
December 31,
2020
2019
$
$
11,408 $
1,071
1,528
8,572
22,579
(15,243)
7,336 $
11,374
1,071
1,505
8,572
22,522
(11,850)
10,672
Depreciation expense for the years ended December 31, 2020 and 2019 was $3.4 million and $3.9 million, respectively.
8. Accrued Expenses
Accrued expenses as of December 31, 2020 and 2019 were comprised as follows (in thousands):
Employee compensation and benefits
External research and professional services
Lab consumables and other
Total accrued expenses
9. Common Stock and Preferred Stock
Common Stock
December 31,
2020
2019
$
$
6,825 $
4,855
364
12,044 $
5,147
3,639
121
8,907
The Company is authorized to issue 160,000,000 shares of common stock. Holders of common stock are entitled to one vote per share. Holders of common
stock are entitled to receive dividends, if and when declared by the Board of Directors.
On December 17, 2019, the Company entered into a Sales Agreement with Cowen and Company, LLC (“Cowen”) pursuant to which the Company may
offer and sell shares of its common stock with an aggregate offering price of up to $50.0 million under an “at the market” offering program (the “ATM
Offering”). The Sales Agreement provides that Cowen will be entitled to a sales commission equal to 3.0% of the gross sales price per share of all shares
sold under the ATM Offering.
The following table summarizes sales under the ATM Offering (net proceeds shown in thousands):
For the year ended December 31,
2019
2020
Total sales under the ATM Offering
Shares Sold
Net Proceeds
Average Selling Price
447,847 $
2,074,274
2,522,121 $
3,510 $
14,513 $
18,023
8.57
7.23
In January 2021, 3,156,200 shares were sold for net proceeds of $30.2 million. Consequently, the Company completed the sale of all available amounts
under the ATM Offering (Note 16).
Preferred Stock
The Company is authorized to issue 5,000,000 shares of undesignated preferred stock in one or more series. As of December 31, 2020, no shares of
preferred stock were issued or outstanding.
F-20
Table of Contents
Shares Reserved for Future Issuance
As of December 31, 2020 and 2019, the Company had reserved for future issuance the following number of shares of common stock (in thousands):
Shares reserved for vesting of restricted stock awards
Shares reserved for vesting of restricted stock units
Shares reserved for exercises of outstanding stock options
Shares reserved for future issuances under the 2017 Stock Option and Incentive Plan
Total shares reserved for future issuance
10. Stock-based Compensation
2013 Stock Option and Grant Plan
December 31,
2020
2019
—
588
6,586
1,284
8,458
—
460
5,735
1,288
7,483
In February 2013, the board of directors adopted and the Company’s stockholders approved the 2013 Stock Option and Grant Plan (the “2013 Plan”), as
amended and restated, under which it could grant incentive stock options (“ISOs”), non-qualified stock options, RSAs and RSUs to eligible employees,
officers, directors, and consultants. The 2013 Plan was subsequently amended in January 2015, April 2015, July 2015, March 2016 and October 2016 to
allow for the issuance of additional shares of common stock.
2017 Stock Option and Incentive Plan
In January 2017, the board of directors adopted and the Company’s stockholders approved the 2017 Stock Option and Incentive Plan (the “2017 Plan”),
which became effective immediately prior to the effectiveness of the Company’s IPO. Upon the adoption of the 2017 Plan, no further awards will be
granted under the 2013 Plan.
The 2017 Plan provides for the grant of ISOs, non-qualified stock options, RSAs, RSUs, stock appreciation rights and other stock-based awards. The
Company’s employees, officers, directors and consultants and advisors are eligible to receive awards under the 2017 Plan. The terms of awards, including
vesting requirements, are determined by the Board of Directors, subject to the provisions of the 2017 Plan.
The Company initially registered 1,753,758 shares of common stock under the 2017 Plan, which was comprised of (i) 1,510,000 shares of common stock
reserved for issuance under the 2017 Plan, plus (ii) 243,758 shares of common stock originally reserved for issuance under the 2013 Plan that became
available for issuance under the 2017 Plan upon the completion of the Company’s IPO. The 2017 Plan also provides that an additional number of shares
will automatically be added to the shares authorized for issuance under the 2017 Plan on January 1, 2018 and each January 1 thereafter. The number of
shares added each year will be equal to the lesser of (i) 4% of the outstanding shares on the immediately preceding December 31 or (ii) such amount as
determined by the compensation committee of the board of directors. Effective January 1, 2019 and 2020, 1,317,935 and 1,349,526 additional shares,
respectively, were automatically added to the shares authorized for issuance under the 2017 Plan.
st
st
As of December 31, 2020, there were 1,283,871 shares available for future issuance under the 2017 Plan.
2017 Employee Stock Purchase Plan
In January 2017, the board of directors adopted and the Company’s stockholders approved the 2017 Employee Stock Purchase Plan (the “2017 ESPP”),
which became effective upon the closing of the Company’s IPO. The Company initially reserved 302,000 shares of common stock for future issuance under
the 2017 ESPP. The 2017 ESPP also provides that an additional number of shares will automatically be added to the shares authorized for issuance under
the 2017 ESPP on January 1, 2018 and each January 1 thereafter through January 1, 2027. The number of shares added each year will be equal to the
lesser of (i) 1% of the outstanding shares on the immediately preceding December 31 , (ii) 603,000 shares or (iii) such amount as determined by the
Compensation Committee of the Board of Directors. Effective January 1, 2019 and 2020, 329,483 and 337,381 additional shares, respectively, were
automatically added to the shares authorized for issuance under the 2017 ESPP. No offering periods under the 2017 ESPP had been initiated as of
December 31, 2020.
st
st
F-21
Table of Contents
Stock-based Compensation Expense
Total stock-based compensation expense recognized in the consolidated statements of operations and comprehensive (loss) income for the years ended
December 31, 2020 and 2019 was as follows (in thousands):
Research and development
General and administrative
Total stock-based compensation expense
RSU Activity
Year Ended December 31,
2020
2019
$
$
4,242 $
5,529
9,771 $
4,353
5,256
9,609
The Company has also granted RSUs to its employees under the 2017 Plan. The following table summarizes RSU activity for the year ended December 31,
2020 (in thousands, except per share amounts):
Unvested as of December 31, 2019
Issued
Vested
Cancelled
Unvested as of December 31, 2020
RSUs
Weighted-Average Grant
Date Fair Value per
Share
460 $
420 $
(248) $
(44) $
588 $
5.61
6.50
6.54
6.14
5.82
The aggregate fair value of RSUs vested during the year ended December 31, 2020, based upon the fair values of the stock underlying the RSUs on the day
of vesting, was $1.5 million. The aggregate fair value of RSUs vested during the year ended December 31, 2019, based upon the fair values of the stock
underlying the RSUs on the day of vesting, was $0.7 million.
As of December 31, 2020, there was unrecognized stock-based compensation expense related to unvested RSUs of $2.2 million, which the Company
expects to recognize over a weighted-average period of approximately 1.7 years.
Stock Option Activity
The fair value of stock options granted to employees and directors during the years ended December 31, 2020 and 2019 was calculated on the date of grant
using the following weighted-average assumptions:
Risk-free interest rate
Expected dividend yield
Expected term (in years)
Expected volatility
F-22
Year Ended December 31,
2020
2019
1.2 %
— %
6.0
72.3 %
2.2 %
— %
6.0
69.4 %
Table of Contents
Using the Black-Scholes option pricing model, the weighted-average grant date fair value of stock options granted to employees and directors during the
years ended December 31, 2020 and 2019 was $4.25 and $2.76 per share, respectively.
The following table summarizes changes in stock option activity during the year ended December 31, 2020 (in thousands, except per share amounts):
Outstanding at December 31, 2019
Granted
Exercised
Cancelled
Outstanding at December 31, 2020
Exercisable at December 31, 2020
Options
Weighted-Average
Exercise Price
5,735 $
1,230 $
(128) $
(251) $
6,586 $
4,586 $
8.76
6.68
4.67
12.69
8.30
8.15
Weighted-Average
Remaining Contractual
Term (in years)
Aggregate Intrinsic
Value
7.2 $
18,959
6.5 $
5.8 $
13,110
10,832
The aggregate intrinsic value of stock options exercised during the years ended December 31, 2020 and 2019 was $0.5 million and $0.6 million,
respectively.
As of December 31, 2020, there was unrecognized stock-based compensation expense related to unvested stock options of $9.4 million, which the
Company expects to recognize over a weighted-average period of approximately 2.2 years.
11. Income Taxes
The provision for income taxes for the years ended December 31, 2020 and 2019 was comprised as follows (in thousands):
Current taxes:
Federal
State
Total current taxes
Deferred taxes:
Federal
State
Total deferred taxes
Total provision for income taxes
Year Ended December 31,
2020
2019
$
$
— $
14
14
—
—
—
14 $
—
46
46
—
—
—
46
F-23
Table of Contents
As part of Congress’s response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), was signed into
United States law on March 27, 2020 and modifies certain provisions of the Tax Cuts and Jobs Act, enacted in 2017, with respect to net operating losses.
Under the CARES Act, the limitation on the deduction of net operating losses to 80% of annual taxable income is suspended for taxable years beginning
before January 1, 2021. The CARES Act did not have a material impact on the condensed consolidated financial statements.
A reconciliation of the federal statutory income tax rate to the Company’s effective tax rate is as follows:
Income tax computed at federal statutory tax rate
State taxes, net of federal benefit
Tax credit carryforwards
Permanent items
Change in valuation allowance
Other
Effective tax rate
Year Ended December 31,
2020
2019
21.0 %
4.2 %
7.8 %
(12.4)%
(20.4)%
(0.2)%
— %
21.0 %
4.8 %
(5.4)%
1.1 %
(21.4)%
— %
0.1 %
The principal components of the Company’s deferred tax assets and liabilities as of December 31, 2020 and 2019 were comprised as follows (in
thousands):
Deferred tax assets:
Net operating loss carryforwards
Tax credit carryforwards
Deferred revenue
Operating lease liability
Intangibles
Accrued expenses and other
Unrealized loss on available-for-sale securities
Depreciation
Stock-based compensation
Total deferred tax assets
Less: valuation allowance
Net deferred tax assets
Deferred tax liabilities:
Section 481(a) method change
Operating lease right-of-use asset
Depreciation
Total deferred tax liabilities
Net deferred taxes
December 31,
2020
2019
$
22,717 $
21,387
528
4,614
785
1,838
17
314
4,031
56,231
(52,172)
4,059
—
(4,059)
—
(4,059)
$
— $
33,008
17,185
—
5,407
519
1,358
17
—
3,376
60,870
(43,219)
17,651
(12,827)
(4,812)
(12)
(17,651)
—
As of December 31, 2020, the Company had federal and state net operating loss (“NOL”) carryforwards of $82.2 million and $86.3 million, respectively.
Federal NOLs generated through the year ended December 31, 2017 expire at various dates from 2032 through 2037, and federal NOLs generated in years
beginning after December 31, 2017 may be carried forward indefinitely. State NOLs expire at various dates from 2035 through 2038. As of December 31,
2020, the Company had federal research and development tax credit carryforwards of $16.1 million which expire at various dates from 2032 through 2040.
In addition, as of December 31, 2020, the Company had state research and development and investment tax credit carryforwards of $6.6 million and $0.1
million, respectively. The state research and development tax credit carryforwards expire at various dates from 2029 through 2035 and the state investment
tax credit carryforwards expire at various dates from 2021 through 2023.
Management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which primarily pertain to NOL
carryforwards, tax credit carryforwards, the Company’s operating lease liability and stock-based
F-24
Table of Contents
compensation. Management has determined that it is more likely than not that the Company will not realize the benefits of its deferred tax assets, and as a
result, a valuation allowance of $52.2 million has been established at December 31, 2020. The increase in the valuation allowance of $9.0 million during
the year ended December 31, 2020 was primarily due to the reduction in the deferred tax liability that was recorded as of December 31, 2019 related to the
Company’s Internal Revenue Code Section 481(a) method change for revenue recognition under the Celgene Collaboration Agreement. The deferred tax
liability reversed during the year ended December 31, 2020 and is no longer available as a source of future income.
NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (“IRS”) and may become subject to an
annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%
as defined under Sections 382 and 383 in the IRC. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income
or tax liabilities. The amount of the annual limitation is determined based on the Company’s value immediately prior to the ownership change. An IRC
Section 382 study, completed in August 2016, identified three previous ownership changes for purposes of IRC Section 382. As a result of these ownership
changes, the Company’s NOL and tax credit carryforwards allocable to the periods preceding each such ownership change are subject to limitations under
IRC Section 382. No additional ownership changes were identified in a study completed in May 2020. Subsequent ownership changes may further affect
the limitation in future years.
The Company had no unrecognized tax benefits as of either December 31, 2020 or 2019. During the year ended December 31, 2017, the Company
completed a study of its research and development credit carryforwards generated during the years ended December 31, 2016 and 2015. The Company has
not conducted a study of its research and development credit carryforwards generated during any subsequent years. This study may result in an adjustment
to the Company’s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being
presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development credit carryforwards,
and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the
consolidated statements of operations and comprehensive (loss) income if an adjustment were required.
Interest and penalty charges, if any, related to income taxes would be classified as a component of the provision for income taxes in the consolidated
statements of operations and comprehensive (loss) income. As of December 31, 2020, the Company has not incurred any material interest or penalty
charges.
The Company files income tax returns in the United States federal tax jurisdiction and the Massachusetts state tax jurisdiction. Since the Company is in a
loss carryforward position, it is generally subject to examination by federal and state tax authorities for all tax years in which a loss carryforward is
available.
12. Related-party Transactions
In July 2019, the Company entered into the Celgene License Agreement under which it received a non-refundable upfront payment of $50.0 million from
Celgene. Previously, in July 2016, the Company entered into the Celgene Collaboration Agreement and a Series B-1 Preferred Stock Purchase Agreement
with Celgene. Under the Celgene Collaboration Agreement, the Company received a non-refundable upfront payment of $225.0 million. Under the Series
B-1 Preferred Stock Purchase Agreement, Celgene purchased 10,448,100 shares of Series B-1 Preferred Stock for $36.1 million. These shares of Series B-1
Preferred Stock converted into 2,831,463 shares of common stock upon the completion of the Company’s IPO. In addition, an affiliate of Celgene
purchased 625,000 shares of the Company’s common stock in the IPO at the public offering price of $16.00 per share for a total of $10.0 million. As of
December 31, 2020, the Company had recorded no reimbursable expenses due to or from Celgene. As of December 31, 2019, the Company had recorded
$0.7 million of reimbursement expenses due from Celgene within prepaid expenses and other current assets in the accompanying consolidated balance
sheets.
As discussed within Note 3, “License and Collaboration Revenue”, BMS completed its acquisition of Celgene in November 2019, and Celgene is now a
wholly-owned subsidiary of BMS.
In August 2020, the Company entered into the Gilead License Agreement and Stock Purchase Agreement under which it received a non-refundable upfront
payment of $85.0 million and cash consideration of $35.0 million for Gilead’s purchase of 5,539,727 shares of the Company’s common stock. As of
December 31, 2020, the Company has recognized $62.3 million in revenue under these arrangements and has recorded deferred revenue of $1.9 million in
the accompanying consolidated balance sheets. As of December 31, 2020, the Company had recorded $0.1 million of reimbursement expenses due from
Gilead within prepaid expenses and other current assets in the accompanying consolidated balance sheets.
F-25
Table of Contents
13. Commitments and Contingencies
Corporate Headquarters Lease
In November 2016, the Company entered into an operating lease agreement (the “Corporate Headquarters Lease”) to occupy 51,000 square feet of
laboratory and office space in Cambridge, Massachusetts. This facility serves as the Company’s corporate headquarters. The lease term began on
November 1, 2016 and extends to March 31, 2025. The Company has the option to extend the lease term for one consecutive five-year period, at the market
rate, by giving the landlord written notice of its election to exercise the extension at least twelve months prior to the original expiration of the lease term.
The Company provided the landlord with a security deposit in the form of a letter of credit in the amount of $1.3 million, which is recorded as restricted
cash and included within “Other non-current assets” in the consolidated balance sheets. The Corporate Headquarters Lease also provided the Company
with a tenant improvement allowance of $0.5 million. Leasehold improvements related to this facility are being amortized over the shorter of their useful
life or the lease term.
Accounting under ASC 842
As a result of the adoption of ASC 842 on January 1, 2019, the Company recorded a right-of-use asset and a corresponding lease liability on the
consolidated balance sheets as of December 31, 2020 and 2019. As there is no rate implicit in the Corporate Headquarters Lease, the Company estimated
its incremental borrowing rate based upon a synthetic credit rating and yield curve analysis. Based upon this analysis, the Company calculated a discount
rate of 8.0% for the Corporate Headquarters Lease.
As of December 31, 2020, the future minimum lease payments due under the operating lease for the Company’s corporate headquarters are as follows (in
thousands):
2021
2022
2023
2024
2025 and thereafter
Total remaining minimum rental payments
Less: effect of discounting
Total lease liability
$
$
Amount
4,505
4,633
4,764
4,900
1,242
20,044
(3,155)
16,889
The Company recorded operating lease expense for the Corporate Headquarters Lease of $4.2 million for the years ended December 31, 2020 and 2019. As
of December 31, 2020, the remaining lease term of the Corporate Headquarters Lease was 4.3 years. The Company presents changes in its right-of-use
asset and lease liability on a combined net basis within “Other liabilities” in the consolidated statements of cash flows.
License and Collaboration Agreements
The Company has entered into various license agreements for certain technology. The Company could be required to make aggregate technical, clinical
development and regulatory milestone payments of up to $9.0 million and low single-digit royalty payments based on a percentage of net sales of licensed
products. As of December 31, 2020, the Company had made $0.7 million in aggregate milestone payments under these license agreements. The Company
may cancel these agreements at any time by providing 30 to 90 days’ notice to the licensors, and all payments not previously due would no longer be owed.
The Company has also entered into collaboration agreements with various third parties for research services and access to proprietary technology
platforms. Under these collaboration agreements, the Company could be required to make aggregate technical, clinical development and regulatory
milestones payments ranging from $12.5 million to $12.9 million per product candidate and low single-digit royalty payments based on a percentage of net
sales on a product-by-product basis. As of December 31, 2020, the Company had made $1.8 million in aggregate milestone payments under these
collaboration agreements.
F-26
Table of Contents
14. 401(k) Savings Plan
The Company has a defined-contribution savings plan under Section 401(k) of the IRC (the “401(k) Plan”). The 401(k) Plan covers all employees who
meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Beginning
on January 1, 2018, the Company matches 50% of an employee’s 401(k) contributions up to a maximum of 6% of the participant’s salary, subject to
employer match limitations under the IRC. As such, the Company made $0.6 million and $0.6 million in contributions to the 401(k) Plan for the years
ended December 31, 2020 and 2019, respectively.
15. Net (Loss) Income per Share
The following table summarizes the calculation of basic and diluted net (loss) income per share (in thousands, except per share amounts):
Net (loss) income
Weighted-average common shares outstanding, basic
Dilutive effect of outstanding stock options
Dilutive effect of unvested RSAs
Dilutive effect of unvested RSUs
Weighted-average common shares outstanding, diluted
Net (loss) income per share, basic
Net (loss) income per share, diluted
Years Ended December 31,
2020
2019
(43,842) $
35,426
—
—
—
35,426
(1.24) $
(1.24) $
56,823
33,080
1,121
1
92
34,294
1.72
1.66
$
$
$
The following weighted-average amounts were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-
dilutive (in thousands):
Outstanding stock options
Unvested RSUs
Total
16. Subsequent Events
Year Ended December 31,
2020
2019
6,594
660
7,254
3,727
24
3,751
Subsequent to December 31, 2020 and through the filing date of this Annual Report on Form 10-K, the Company sold an aggregate of 3,156,200 shares at
an average price of $9.87 per share for net proceeds of $30.2 million. Consequently, the Company has completed the sale of all available amounts under the
ATM Offering.
F-27
Table of Contents
Exhibit No.
3.1
3.2
4.1
4.2
4.3
10.1#
10.2#
10.3#
10.4#
10.5*#
10.6#
10.7#
10.8#
10.9#
10.10#
10.11#
10.12#
10.13
10.14†
10.15‡
10.16‡
10.17‡
21.1*
23.1*
31.1*
31.2*
32.1+
101*
*
+
#
†
‡
EXHIBIT INDEX
Description of Exhibit
Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Annual Report on Form 10-K
(File No. 001-37998) filed March 8, 2018)
Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant’s Annual Report on Form 10-K (File No. 001-37998) filed
March 8, 2018)
Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-215372) filed
December 30, 2016)
Amended and Restated Investors’ Rights Agreement by and among the Registrant and certain of its stockholders, dated April 17, 2015 as amended (incorporated by
reference to Exhibit 4.2 of the Registrant’s Registration Statement on Form S-1 (File No. 333-215372) filed December 30, 2016)
Description of Securities (incorporated by reference to Exhibit 4.3 of the Registrant’s Annual Report on Form 10-K (File No. 001-37998) filed February 27, 2020)
Jounce Therapeutics, Inc. 2017 Stock Option and Grant Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.1 of the Registrant’s
Registration Statement on Form S-1/A (File No. 333-215372) filed January 17, 2017)
Form of Restricted Stock Unit Award Agreement under 2017 Stock Option and Incentive Plan (for employees) (incorporated by reference to Exhibit 10.1 of the
Registrant’s Quarterly Report on Form 10-Q (File No. 001-37998) filed August 9, 2018)
Jounce Therapeutics, Inc. 2013 Stock Option and Grant Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 of the Registrant’s
Annual Report on Form 10-K (File No. 001-37998) filed March 8, 2018)
Jounce Therapeutics, Inc. 2017 Employee Stock Purchase Plan, As Amended (incorporated by reference to Exhibit 10.1 of the Registrant’s Quarterly Report on Form 10-
Q (File No. 001-37998) filed November 13, 2017)
Amended and Restated Non-Employee Director Compensation Policy
Amended and Restated Employment Agreement between Richard Murray and the Registrant, dated January 6, 2017 (incorporated by reference to Exhibit 10.4 of the
Registrant’s Registration Statement on Form S-1/A (File No. 333-215372) filed January 17, 2017)
Amended and Restated Employment Agreement between Kim Drapkin and the Registrant, dated January 6, 2017 (incorporated by reference to Exhibit 10.5 of the
Registrant’s Registration Statement on Form S-1/A (File No. 333-215372) filed January 17, 2017)
Amended and Restated Employment Agreement between Elizabeth Trehu and the Registrant, dated January 6, 2017 (incorporated by reference to Exhibit 10.6 of the
Registrant’s Registration Statement on Form S-1/A (File No. 333-215372) filed January 17, 2017)
Employment Agreement between Hugh Cole and the Registrant, dated August 14, 2017 (incorporated by reference to Exhibit 10.8 of the Registrant’s Annual Report on
Form 10-K (File No. 001-37998) filed March 8, 2018)
Form of Director Indemnification Agreement (incorporated by reference to Exhibit 10.12 of the Registrant’s Registration Statement on Form S-1 (File No. 333-215372)
filed December 30, 2016)
Form of Officer Indemnification Agreement (incorporated by reference to Exhibit 10.13 of the Registrant’s Registration Statement on Form S-1/A (File No. 333-215372)
filed January 17, 2017)
Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.14 of the Registrant’s Registration Statement on Form S-1/A (File No. 333-215372)
filed January 17, 2017)
Lease Agreement between ARE-770/784/790 Memorial Drive, LLC and the Registrant, dated November 1, 2016 (incorporated by reference to Exhibit 10.11 of the
Registrant’s Registration Statement on Form S-1 (File No. 333-215372) filed December 30, 2016)
Amended and Restated Exclusive License Agreement between Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center and Memorial
Hospital for Cancer and the Registrant, dated September 28, 2015 (incorporated by reference to Exhibit 10.9 of the Registrant’s Registration Statement on Form S-1 (File
No. 333-215372) filed December 30, 2016)
License Agreement by and between the Registrant and Gilead Sciences, Inc., dated August 31, 2020 (incorporated by reference to Exhibit 10.1 of the Registrant’s
Quarterly Report on Form 10-Q (File No. 001-37998) filed on November 6, 2020)
Stock Purchase Agreement by and between the Registrant and Gilead Sciences, Inc., dated August 31, 2020 (incorporated by reference to Exhibit 10.2 of the Registrant’s
Quarterly Report on Form 10-Q (File No. 001-37998) filed on November 6, 2020)
Registration Rights Agreement by and between the Registrant and Gilead Sciences, Inc., dated August 31, 2020 (incorporated by reference to Exhibit 10.3 of the
Registrant’s Quarterly Report on Form 10-Q (File No. 001-37998) filed on November 6, 2020)
List of Subsidiaries of the Registrant
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002
Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002
Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002
The following materials from the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, formatted in eXtensible Business Reporting Language
(XBRL): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations and Comprehensive Income (Loss), (iii) Consolidated Statements of Stockholders’
Equity, (iv) Consolidated Statements of Cash Flows and (v) Notes to Consolidated Financial Statements
Filed herewith
Furnished herewith
Indicates a management contract or any compensatory plan, contract or arrangement
Confidential treatment granted as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended
Portions of this Exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K
Table of Contents
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Date: February 25, 2021
JOUNCE THERAPEUTICS, INC.
By:
/s/ Richard Murray
Richard Murray, Ph.D.
President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.
Signature
/s/ Richard Murray
Richard Murray, Ph.D.
/s/ Kim C. Drapkin
Kim C. Drapkin
/s/ Perry A. Karsen
Perry A. Karsen
/s/ Luis A. Diaz, Jr.
Luis A. Diaz, Jr., M.D.
/s/ Barbara Duncan
Barbara Duncan
/s/ J. Duncan Higgons
J. Duncan Higgons
/s/ Robert Iannone
Robert Iannone, M.D., M.S.C.E.
/s/ Robert Kamen
Robert Kamen, Ph.D.
/s/ Cary G. Pfeffer
Cary G. Pfeffer, M.D.
/s/ Luisa Salter-Cid
Luisa Salter-Cid, Ph.D.
Title
President, Chief Executive Officer and Director (Principal
Executive Officer)
Treasurer and Chief Financial Officer
(Principal Financial and Accounting Officer)
Date
February 25, 2021
February 25, 2021
Chairman of the Board of Directors
February 25, 2021
Director
Director
Director
Director
Director
Director
Director
February 25, 2021
February 25, 2021
February 25, 2021
February 25, 2021
February 25, 2021
February 25, 2021
February 25, 2021
Exhibit 10.5
Jounce Therapeutics, Inc.
Amended and Restated Non-Employee Director Compensation Policy
The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Jounce Therapeutics, Inc., a Delaware
corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a
long-term basis, high-caliber directors who are not employees or officers of the Company. This Policy will become effective (the
“Effective Date”) upon approval by the Company’s Board of Directors (the “Board”). In furtherance of this purpose, all non-
employee directors shall be paid compensation for services provided to the Company as set forth below:
Cash Retainers
Annual Retainer for Board Membership: $35,000 for general availability and participation in meetings and conference calls of
our Board. No additional compensation for attending individual Board meetings.
Additional Annual Retainer for Non-Executive Chairperson of the Board: $30,000 to acknowledge the additional responsibilities
and time commitment of the Chairperson role.
Additional Annual Retainers for Committee Membership:
Audit Committee Chairperson: $15,000
Audit Committee member: $7,500
Compensation Committee Chairperson: $12,500
Compensation Committee member: $6,000
Nominating and Corporate Governance Committee Chairperson: $8,000
Nominating and Corporate Governance Committee member: $4,000
Science and Technology Committee Chairperson: $12,500
Science and Technology Committee member: $6,000
No additional compensation for attending individual committee meetings.
All cash retainers will be paid quarterly, in arrears, or upon the earlier of resignation or removal of the non-employee director.
Cash retainers owing to non-employee directors shall be annualized, meaning that with respect to non-employee directors who
join the Board during the calendar year, such amounts shall be pro-rated based on the number of calendar days served by such
director following such director’s appointment or election.
Equity Retainers
Initial Option Grant: One-time option grant to each new non-employee director upon his/her election to the Board after the
Effective Date to purchase 31,400 shares of common stock, par value $0.001 per share (the Common Stock”). Such initial option
grant shall be made upon the director first becoming a director. Such initial option grant shall vest in equal quarterly installments
during the 12 quarters following the grant date, subject to the director’s continued service on the Board.
On the date of each Annual Meeting of Stockholders: Annual option grant to each non-employee director serving on the Board
immediately following the Company’s annual meeting of stockholders to purchase 15,700 shares of Common Stock, provided
that if at such time a director has served on the Board for less than 270 days, the number of shares subject to such option shall be
reduced to the applicable amount set forth below based on such director’s length of service on the Board as of such time:
Length of Service on Board as of
Annual Meeting Date
180 days or more, but less than 270
days
90 days or more, but less than 180
days
Less than 90 days
Number of Option Shares
11,776
7,850
0
Such annual option grant shall vest in equal quarterly installments during the 4 quarters following the grant date, subject to the
director’s continued service on the Board, provided that if the Company’s next annual meeting of stockholders is held prior to the
first anniversary of the grant date, the vesting of such annual option will accelerate in full as of the date of such next annual
meeting of stockholders, subject to the director’s continued service on the Board as of immediately prior to such next annual
meeting.
All of the foregoing option grants will become immediately exercisable upon the death, disability of a director or upon a Sale
Event (as defined in the Company’s 2017 Stock Option and Incentive Plan). In addition, if the option grants described above are
in the form of options to purchase the Company’s common stock, par value $0.001 per share (the “Common Stock”), the
directors will have until the earlier of one year following cessation of service as a director or the original expiration date of the
option to exercise the option (to the extent vested at the date of such cessation), provided that the director has not been removed
for cause.
Any stock option granted to a non-employee director pursuant to this Policy will be granted at an exercise price equal to the fair
market value of a share of Common Stock on the date of grant.
Expenses
The Company shall reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending Board and
committee meetings.
ADOPTED AND EFFECTIVE: December 4, 2020.
Subsidiaries of the Registrant
Exhibit 21.1
Name
Jounce Mass Securities, Inc.
Jurisdiction of Organization
Massachusetts
Percentage Ownership
100%
We consent to the incorporation by reference in the following Registration Statements:
Consent of Independent Registered Public Accounting Firm
(1) Registration Statement (Form S-3 No. 333-223518) of Jounce Therapeutics, Inc.,
(2) Registration Statement (Form S-8 No. 333-215794) pertaining to the Jounce Therapeutics, Inc. 2013 Stock Option and Grant Plan, the Jounce
Therapeutics, Inc. 2017 Stock Option and Incentive Plan and the Jounce Therapeutics, Inc. 2017 Employee Stock Purchase Plan, and
(3) Registration Statements (Form S-8 Nos. 333-223519, 333-230088, and 333-236687) pertaining to the Jounce Therapeutics, Inc. 2017 Stock
Option and Incentive Plan and the Jounce Therapeutics, Inc. 2017 Employee Stock Purchase Plan;
of our report dated February 25, 2021, with respect to the consolidated financial statements of Jounce Therapeutics, Inc. included in this Annual Report
(Form 10-K) for the year ended December 31, 2020.
Exhibit 23.1
/s/ Ernst & Young LLP
Boston, Massachusetts
February 25, 2021
Exhibit 31.1
I, Richard Murray, certify that:
1. I have reviewed this Annual Report on Form 10-K of Jounce Therapeutics, Inc.;
CERTIFICATIONS
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: February 25, 2021
By:
/s/ Richard Murray
Richard Murray, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
Exhibit 31.2
I, Kim C. Drapkin, certify that:
1. I have reviewed this Annual Report on Form 10-K of Jounce Therapeutics, Inc.;
CERTIFICATIONS
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: February 25, 2021
By:
/s/ Kim C. Drapkin
Kim C. Drapkin
Treasurer and Chief Financial Officer
(Principal Financial and Accounting Officer)
CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32.1
In connection with this Annual Report on Form 10-K of Jounce Therapeutics, Inc. (the “Company”) for the year ended December 31, 2020, as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her or his knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
Date: February 25, 2021
Date: February 25, 2021
By:
By:
/s/ Richard Murray
Richard Murray, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
/s/ Kim C. Drapkin
Kim C. Drapkin
Treasurer and Chief Financial Officer
(Principal Financial and Accounting Officer)